ࡱ> HKABCDEFG[ &bjbjmm bb)tt $ P!"4 afH#%(%%%K:I<<L$ǂ}i >W9K:>>tt%%[TTT>t% %T>TTjv H T{%P3EN z2x10az#P#d{{n# |x)=Lu=6T=,=)=)=)=2R)=)=)=a>>>>#)=)=)=)=)=)=)=)=)=B ::    ABSTRACT The problem that this essay addresses is that electronic platforms currently implemented across Allegheny Health Network (AHN) are not being optimized for clinical research subject identification and retention. The goals of my summer residency with the Allegheny Health Network Research Institute (AHN Research Institute) directed my masters essay work. National best practices were a guideline to catalog existing subject recruitment practices and utilize new technologies to more efficiently identify and retain enrollees in clinical trials. The objectives of my work are three-pronged: 1) gauge the effectiveness of Epic as a screening tool before and after implementation of an out of the box clinical trials feasibility tool - SlicerDicer; 2) assess areas to improve subject/volunteer identification for recruitment within the EHR; and 3) analyze clinical research coordinator attitudes about Epic and CTMS as a whole. The study design is a pilot study, a pre-/post-interventional quantitative survey to measure research study coordinator perceptions of the observed interventions aimed to optimize electronic screening and other clinical research capabilities. Secondarily, qualitative responses were collected to help guide my recommendations and next steps to interventions post-implementation. The method of analysis was primarily quantitative with average scores calculated for each pre- and post-survey question with sporadic qualitative responses utilized when appropriate to supplement quantitative responses. Opinions concerning ease of screening, accurate identification of applicable study patients, and perception of Epic improved after introduction to SlicerDicer, while perception of time spent screening patients improved as well. Conclusions from the study are that SlicerDicer was effective in significantly positively shifting the attitudes of Allegheny Health Network clinical research coordinators regarding ease of screening and identifying applicable patients for research studies, while solidifying Epics standing as an effective electronic health record. This issue is of public health significance because optimizing recruitment methods to clinical trials will ultimately forge new medical frontiers: new interventions to surgery, investigational pharmaceuticals, implantable and wearable devices, biospecimen collection, and diagnostic technologies. While increasing patient accruals to these therapeutic areas will have a direct and largely positive impact on the future delivery of health care, resources remain scarce. Physician investigators time needs to be efficiently managed and the dedicated team of public health trained staff will be charged with developing and deploying the very resources and optimization methods outlined in this analysis. TABLE OF CONTENTS  TOC \o "2-4" \h \z \t "Heading 1,1,Appendix,1,Heading,1"  HYPERLINK \l "_Toc478981714" preface  PAGEREF _Toc478981714 \h viii  HYPERLINK \l "_Toc478981715" 1.0 Introduction  PAGEREF _Toc478981715 \h 1  HYPERLINK \l "_Toc478981716" 2.0 Literature review  PAGEREF _Toc478981716 \h 4  HYPERLINK \l "_Toc478981717" 3.0 Interventions  PAGEREF _Toc478981717 \h 16  HYPERLINK \l "_Toc478981718" 4.0 Study Design and methods  PAGEREF _Toc478981718 \h 19  HYPERLINK \l "_Toc478981719" 5.0 FINDINGS AND ANALYSIS  PAGEREF _Toc478981719 \h 21  HYPERLINK \l "_Toc478981720" 6.0 DISCUSSION  PAGEREF _Toc478981720 \h 26  HYPERLINK \l "_Toc478981721" 7.0 Conclusions AND Recommendations  PAGEREF _Toc478981721 \h 28  HYPERLINK \l "_Toc478981722" 8.0 Public Health Implications  PAGEREF _Toc478981722 \h 30  HYPERLINK \l "_Toc478981723" AppEndix A: AHN IRB NO PURVIEW LETTER  PAGEREF _Toc478981723 \h 31  HYPERLINK \l "_Toc478981724" APPENDIX B: BLANK PRE- AND POST-INTERVENTION SURVEYS  PAGEREF _Toc478981724 \h 32  HYPERLINK \l "_Toc478981725" Appendix C: stata output from power analysis  PAGEREF _Toc478981725 \h 34  HYPERLINK \l "_Toc478981726" bibliography  PAGEREF _Toc478981726 \h 37 List of tables  TOC \h \z \c "Table"  HYPERLINK \l "_Toc478981737" Table 1. Results of Pre- and Post-Epic Implementation Surveys  PAGEREF _Toc478981737 \h 21  HYPERLINK \l "_Toc478981738" Table 2. Estimated Sample Sizes Required for Statistical Significance of Survey Questions  PAGEREF _Toc478981738 \h 22 preface I would like to thank the three members of my essay committee, Dr. Mark Roberts, Dr. Gary Fischer, and Kyle Bird, for their commitment and revisions towards my essay. I have learned so much from the three of you throughout this process. Introduction In my administrative residency with Allegheny Health Networks (AHN) Research Institute, I was afforded the opportunity to witness the deployment of two electronic platforms for patient management: Epic, the electronic health record (EHR) implemented across the Allegheny Health Network and Clinical Conductor, a clinical trial management system (CTMS) used to manage patient recruitment and clinical trials financials. I was trained on the basic capabilities of Epic over a two day period for a total of sixteen hours. As I progressed through my residency I noticed that there were several opportunities to optimize the use of Epic for clinical research purposes. Epic training provided a general overview of the EHR. It did not give a more specific demonstration and/or use case of the systems capabilities, E.g. using the system to register and schedule patients in the Esophageal and Lung Institute, reconciling patient billing questions with invoices dropped from the back office, rescheduling patients because they presented to their specialists office without a prior authorization for diagnostic imaging. The problem presented to me during my residency was that electronic platforms currently implemented across Allegheny Health Network (AHN) are not being optimized for clinical research subject identification and retention The following are objectives of my essay: 1) gauge the effectiveness of Epic as a screening tool before and after implementation of an out of the box clinical trials feasibility tool - SlicerDicer; 2) assess areas to improve subject/volunteer identification for recruitment within the EHR; and 3) analyze clinical research coordinator attitudes about Epic and CTMS as a whole. Assessment of these objectives will help to determine whether the interventions implemented by AHN increased the effectiveness of Epic and where improvement is needed. CRC attitudes are important because these individuals are utilizing Epic on a daily basis for clinical trial operations and their feedback must be taken into consideration. The AHN Research Institute is at the forefront of research on a local, regional, and national level. The institute offers new drug therapies, revolutionizes surgical procedures, and offers innovative devices and wearable technology that reduces the impact of chronic disease. Through partnerships with industry, government, academia, and health systems across the Pittsburgh region, best practices in medicine are developed. By creating new methodologies in treating disease, the AHN Research Institute improves the health of its patient base while advancing the science of medicine. Clinical trials are the foundation of sound decision making in health care. Within the AHN Research Institute, clinical trials activities are operationalized in three sub-disciplines. The first sub-discipline, laboratory science, is when principal investigators and scientists work in hospital laboratories to discover new molecules and methods for treating disease. The second sub-discipline, translational science, is when new therapies, proven to be safe in the laboratory, are offered to a small sample of patients to determine dosing levels and first-in-human safety. The third sub-discipline, clinical research, is when the intervention, proven to be safe in a small group of patients, is offered as part of a larger and controlled, nation-wide study. Allegheny Health Network offers hundreds of these types of clinical trials. Once the safety and effectiveness of a medication, treatment or therapy is proven, it becomes the new standard of care and best-practice for treating a particular disease. All of these steps are necessary in the advancement of science and precision medicine, helping to improve patient care and promote better patient outcomes. Literature review Before an in-depth overview of electronic health records and their importance within clinical research, it is important to differentiate between basic science, translational, and clinical research. Basic science research often called fundamental or bench research provides the foundation of knowledge for the applied science that follows. This type of research encompasses familiar scientific disciplines such as biochemistry, microbiology, physiology, and pharmacology, and their interplay, and involves laboratory studies with cell cultures, animal studies or physiological experiments. Basic science also increasingly extends to behavioral and social sciences as well, which have no less profound relevance for medicine and health.1 For many, translational research refers to the bench-to-bedside enterprise of harnessing knowledge from basic science to produce new drugs, devices, and treatment options for patients. For this area of research the interface between basic science and clinical medicine the end point is the production of a promising new treatment that can be used clinically or commercialized. Meanwhile, for others especially health services researchers and public health investigators whose studies focus on health care and health as the primary outcome translational research refers to translating research into practice; ie, ensuring that new treatments and research knowledge actually reach the patients or populations for whom they are intended and are implemented correctly. The production of a new drug, an end point for bench-to-bedside translational research, is only the starting point for this second area of research.2 This leads into clinical research, which is research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Clinical research includes mechanisms of human disease, therapeutic interventions, clinical trials, development of new technologies, epidemiologic and behavioral studies, and outcomes and health services research.3 Now that clear distinctions have been made between basic science, translational research, and clinical research, the focus can be shifted to EHRs and how they have become essential within clinical research. Electronic health records (EHRs) are becoming increasingly important within clinical research. Clinical research requires collaboration between clinicians and researchers, but often the collaborations are poorly supported. The Institute of Medicine has called for a learning healthcare system to accelerate cost-effective generation of new evidence directly from and applicable to patient care processes. The model envisions conducting clinical research as a result of patient care.4 The increasing adoption of EHRs offers the opportunity to permit rich data collection and longitudinal analysis of patients and to increase coordination between patient care and patient-oriented activities, while reducing the burden placed on physicians, patients, and healthcare delivery.4 In 2014, seventy-six percent of U.S. non-Federal acute care hospitals, had adopted at least a basic EHR system, which represents an increase of twenty-seven percent from 2013 and an eight-fold increase since 2008. Nearly all of those hospitals, ninety-seven percent, possessed a certified EHR technology in 2014, increasing by thirty-five percent since 2011. Non-federal acute care hospitals include acute care general medical and surgical, general childrens, and cancer hospitals owned by private/not-for-profit, investor-owned/for-profit, or state/local government and located within the fifty states and District of Columbia. Basic EHR adoption requires that each function be implemented in at least one unit in the hospital. Possession of certified EHR is considered to be either the physical possession of the medium on which a certified EHR system resides or a legally enforceable right by a health care provider to access and use, at its discretion, the capabilities of a certified EHR system.5 EHRs can be used to automate prescreening and can significantly improve recruitment efficiency and costs. However, for all of the improvements EHRs can provide for research, barriers still exist in perfecting the optimization. Several barriers are present that can be improved in achieving optimization of EHRs for research. Inaccurate diagnosis codes and problem list can cause errors in electronic prescreening of patients. The notion of data analytics and informatics intervention in clinical documentation, while unorthodox, is a needed intervention post-EHR implementation. Institutional privacy rules can limit use of EHRs to prescreen patients for research and access can be granted to medical records to collaborating researchers, called preparatory to research. Given the sorted history of research practice, patient privacy protections have been outlined in the Federal Register and strictly enforced by regulatory bodies both internally through local internal review boards (IRBs), and externally through governmental agencies (FDA, HRSA, etc.) and central IRBs. While human subjects protections take precedence over the practice of clinical research at-large, it is critical that a balance be stuck between regulatory oversight, and the societal benefits achieved through clinical research.4 Current research practices require informed consent and EHRs have the potential to enhance the process. Another issue that is highly controversial with EHRs and research is that of patient privacy and consent. Privacy can be defined as the ability to control the collection, use, and disclosure of ones personal information.6 Traditionally, policies to protect privacy in research have relied upon anonymization of the data, and in the case of research using identifiable information, seeking the prior consent or authorization of the individual.6 However, there is a large gap between the ideal of informed consent and the practice of obtaining consent or authorization in practice.7 Consent forms are often too lengthy or opaque for people to understand, people are unlikely to read the forms in any case, and people may not have (or feel they have a reasonable alternative to consenting.8 The consent model and the trust model are two possible approaches to address some of the challenges for a research network based on federated EHRs. A federated EHR model consists of a collection of clinical data repositories which are located remotely. In this model, patient data is not stored in a centralized, accessible location and continues to be stored locally.9 It is debatable whether explicit consent is required for reuse of key-coded EHR data for research and statistical purposes. In some countries, special legislation may require primary EHR data to be submitted for public health purposes to national or regional registries without the need for consent of the data subject.9 The trust model approach reduces the information content of the data so that individuals can no longer be identified. However, the uncertainties of the legal position of nearly anonymized data make it difficult for researchers to know when they are being compliant with the law while using EHRs for research.9 The issues of biospecimens, consenting and genetics in clinical research were clearly illustrated by the case of Moore v. Regents of the University of California. John Moore, a patient who underwent treatment for leukemia at UCLA Medical Center filed an action against his physician Dr. Golde and others, because they used cells extracted from him in lucrative medical research which eventually yielded a patented cell line without his permission. Moore alleged thirteen claims, including a breach of physicians duty to disclose competing interests that may affect medical judgment, lack of informed consent, and conversion. The court held that a physician who is seeking a patient's consent for a medical procedure must, in order to satisfy his fiduciary duty and to obtain the patient's informed consent, disclose personal interests unrelated to the patient's health that may affect his medical judgment. The court ruled Moore had no cause of action for conversion because once the cells were extracted from Moores body; he no longer had any claims of ownership over them.10 In 2013, several changes were made to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule to streamline informed consent. The changes to the HIPAA Privacy Rule include permission to obtain a single authorization to use protected health information (PHI) in both conditioned research activities (such as clinical trials, in which individuals cannot receive a particular treatment unless they agree to the use of their PHI) and unconditioned research activities (such as optional tissue and data banking); permission to simultaneously obtain authorization to use PHI in both current research and future research, provided the future use of PHI is described with enough specificity that a reasonable person would expect that it would be used for that purpose; and clarification that, for the purposes of HIPAA, genetic information is health information, though, not on its own, identifiable.11 In theory, the new HIPAA rules allow researchers to obtain, in a single authorization document, permission to use a participants data for a clinical trial, permission to bank the participants tissue/data for future research, and permission to use the participants data for future research, provided that the document includes a description of the research that has a degree of specificity that is acceptable to the institutional review board (IRB) and gives the participants a reasonable idea about the nature of the research.11 Preparatory research is one of the areas where HIPAA has impacted subject recruitment and retention. The purpose of preparatory research is to review PHI to prepare a research protocol or to facilitate subject recruitment by identifying prospective research subjects for purposes of seeking their authorization to use or disclose PHI for a research study.12 Prior to performing preparatory research, the researcher completes a Preparatory to Research form and submits it to their IRB or Privacy Board. On the form, the researcher outlines the purpose of the review, what specific PHI will be used and/or disclosed, why the PHI is necessary for the research, where the information is located, and how and by whom the information will be accessed. The researcher agrees not to remove any PHI from the covered entity and to follow the minimum necessary standard.12 A covered entity may require the individual who accesses medical records for preparatory research or recruitment to be an employee of the covered entity.12 Pre-screening of potential subjects is another area where HIPAA has reached. A researcher can pre-screen potential subjects over the telephone with the use of a HIPAA Waiver of Authorization. The researcher needs to demonstrate that the research could not practicably be done without a waiver, the research could not practicably be done without PHI, the subjects rights and welfare will not be adversely affected, there is a reasonable risk to benefit ratio, the use or disclosure plan involves no more than minimal risk to privacy, and a plan to protect identifiers and destroy identifiers at the earliest opportunity.12 Due to preparatory to research requirements, screening in academic medical centers is especially difficult. It is quite possible that a primary investigator would not be the patients attending of record, and that the patient would be seeing multiple providers at one point in time. Having multiple providers increases the probability of a patient meeting an exclusion criteria and thus, harms subject recruitment and retention. To address these issues, case-based reasoning using EHRs can also be used to identify eligible patients for clinical trials. EHRs have been proven to be useful for efficiently identifying eligible patients for clinical trials to reduce potential delays due to recruitment difficulties. Due to differences in semantic representations for key eligibility concepts between EHRs and eligibility criteria, the case-based reasoning (CBR) paradigm is useful. The purpose of CBR is to use previous knowledge and experiences to solve a new problem. In this case, the new problem refers to discovering patients eligible for a trial, whereas the previous knowledge can be seen as the set of enrolled clinical trial patients.13 Case-based reasoning represents a novel combinatory reuse of clinical and research data and research data from clinical trial management systems, specifically the information about trial participants, to improve clinical trial recruitment and screening. In particular, the feasibility of using EHR data of clinical trial participants to recommend potentially eligible patients to a trial without processing its free-text eligibility criteria or requiring identifying controls for designing classifiers has been demonstrated. The CBR approach can be applied in several capacities. It can be used as a self-standing tool, which constantly monitors a clinical data warehouse and alerts investigators when a new potentially eligible patient is identified.14 Additionally, an investigator can use CBR to rake all the patients in a data warehouse. And finally, depending on the data types included in the EHR patient representation, the framework may allow for a high-degree of interoperability.11 While the CBR approach can be considered a successful one, many barriers still remain when utilizing automated clinical trial screening. The barriers to efficient use of automated eligibility screening systems are three-fold. First, although automated eligibility screening systems should ideally be evaluated on real-world data, the goal is hindered by the lack of access to production EHRs. Second, not all automated eligibility screening algorithms proposed in the literature improve performance. Third, few studies explicitly report trial screening efficiency with and without automated eligibility screening.15 Another issue is that inclusion/exclusion criteria are becoming increasingly stringent and specific, and the result is the recruitment of exceedingly homogenous subject pools. The homogenous subject pools are important for efficacy studies, but they are atypical for real practice settings and therein lies the problem.16 Automated screening will keep subject pools homogenous as long as the screening system is able to analyze all subject recruitment criteria. Another issue with subject recruitment is the amount of time needed to identify eligible patients. EHRs are a much more efficient way to identify patients for clinical trials. Hand-searching paper medical records of varying quality and legibility is an inefficient use of time. Organization of paper medical records can vary between practices or even between providers within the same practice. Often, information in the paper medical records is not accurate with conflicting information such as contact information, age, and chronic medical problems.17 Because EHRs have become more commonplace in primary care offices, more investigators have been able to take advantage of databases to identify possible participants for clinical studies. The content within an EHR is crucial to determining study eligibility criteria. Studies that have more complicated eligibility criteria might have more difficulties finding potentially eligible patients. Also, EHRs may not routinely capture race and ethnicity in all patients, which can be a problem, considering that disparities exist in clinical trial participation among medically underserved populations.18 To address disparities in clinical trial participation, patient navigation can be utilized. Simply, patient navigation is a strategy for increasing patients access to care by helping them overcome barriers in their communities, and within the health system.18 Navigators provide a bridge between the patient and the healthcare system. Specifically, in cancer trials, navigation has been a success. Studies reported clinical trial enrollment that ranged 61% to 86% among study eligible minority patients, demonstrating patients willingness to participate in clinical trials.19 However, there are challenges that still exist. There is a low number of available clinical trials for minority patients, who may be deemed ineligible due to presentation at higher cancer stages and increased co-morbidities.20 Exclusion of potentially clinical trial eligible patients due to co-morbidities has also been documented among African-American cancer patients and is a persistent challenge for minority patients accrual into clinical trials.18 Along with the previous methods of subject recruitment for clinical trials, data can also be used as a recruitment tool. Eligibility criteria not only specify the population for a study; they drive recruitment, selecting subjects for observational studies and generalizability of results. Eligibility criteria are usually expressed as descriptive text rather than combinations of discrete clinical data elements, but formally structured representation of eligibility criteria is increasingly useful in the era of EHRs, to facilitate various research functions including evaluating feasibility, cohort identification, and trial recruitment.21 If eligibility criteria are broken down into criteria elemental statements (CES), they can potentially be addressable in a typical integrated EHR. EHR data, on its own can be useful for identifying patient cohorts for trials, but EHR data alone is often insufficient to identify an individual patient as a suitable trial subject.21 Use of structured data elements can frequently expedite the screening process for enrolling patients and in a small proportion of trials be entirely sufficient.21 Integrated data capture can increase efficiency by streamlining data collection. Research systems, often known as data capture systems or clinical trials management systems (CTMS), work alongside EHRs to track the additional clinical and financial information required by law. To ensure appropriate reimbursement for the services provided to a patient in a clinical trial, research sites must develop a budget for each trial and must conduct a Medicare Coverage Analysis (MCA). This identifies the services for which Medicare will pay under the Medicare Clinical Trial Policy. Non-compliant billing is subject to severe penalties, as well as civil and criminal actions. The first step is to determine whether the trial qualifies for coverage.22 To qualify, a trial should meet the following criteria. The purpose of the trial must be to evaluate an item or service that falls within a Medicare benefit category. The trial must have a therapeutic intent, in that it could potentially improve the participants health outcomes. The trial must also enroll patients with a diagnosed disease rather than healthy volunteers. Some trials are deemed to have the desirable characteristics and automatically qualify. Trials that would automatically quality are trials funded by a federal agency, such as the National Institutes of Health or the Centers for Diseases Control and Prevention, trials supported by a center or cooperative group that is funded by a federal agency, trials conducted under an investigational new drug application reviewed by the Food and Drug Administration, and drug trials that are IND-exempt.22 Integrated data capture can provide many benefits for EHR systems. Integrated data capture streamlines the research data capture process by allowing a user to bypass the typical steps required in completing electronic case report forms. Integrated data capture also reduces the risk of a transcription error because data are entered directly into the electronic case report form, as opposed to manually. The electronic case report form data contain details about the capture of the information in the EHR. These values are synchronized with the EHR, and the details of changes are recorded, providing a complete, clear sequence of events, thus providing support for audits and monitoring visits. Finally, while working in a study participants EHR record, a care provider can submit the data to the electronic case report form in real time. This capability prevents a time lag between EHR capture and transcription of data, allowing for participants data to be captured and finalized more quickly.23 Integrated data capture provides many benefits to users, but there is also room for improvement. This was done by adding additional data categories to the electronic case report form, limiting overrides of data, creating more flexibility for inputting data values, indicating when data collection mode is active, providing more specific information for audit purposes, condensing repeating data, and by grouping related data elements together.23 Another important element in data capture is remote monitoring. Monitoring is an FDA- mandated process whereby the integrity of the clinical trial process is validated. The validation process includes site visits to inspect personnel, facilities, equipment, processes, and source and regulatory documentation. Monitoring, specifically, is estimated to be about one-third of any prospective clinical trial operating budget. Remote monitoring allows pharmaceutical companies and contract research organizations (CROs) to remotely conduct monitoring activities that were previously conducted on-site. This includes delivering documents to a clinical research associate (CRA) via email, fax, or snail mail to satisfy monitors queries and conduct source document verification. Remote monitoring has been challenging to date because the industry lacks accessible infrastructure to allow HIPAA and 21 CFR Part 11 compliant access to patient records, regulatory documents, and trial master file content for monitoring. Perhaps, a remote monitoring system would be beneficial in the future to better assist CROs, pharmaceutical companies, and research centers.24 Research as a field is extremely complex. Not only are there different methods of research, from basic science to translational and clinical research, but there are many regulations and laws that aim to protect the privacy and well-being of research subjects. With the advent of electronic health records, research has become inherently more complex and with the ease with which information can be accessed, this has put research and those who work in the field in a precarious position. Ultimately, though, the trends of medicine have dictated this path and those who chose research as a career will have to navigate the landscape with trepidation. Interventions AHN has implemented four innovative tools and has customized them to increase efficiencies within the Research Institute. Coordinators now have access to pend orders, labs, and scans and can also document visit notes and telephone encounters. A custom tool called the emergency department (ED) visit report was created. SlicerDicer allows providers to look at deidentified patient data and run database queries to identify those patient populations with clinical criteria for particular research studies. They can use the information to potentially develop targeted interventions for patients or to place them in relevant clinical trials post-consent. Clinical Conductor, a clinical trial management system (CTMS) has been used to manage patient recruitment and clinical trials financials. These interventions have a clear utility for the Research Institute and are why AHN is leading the way in clinical research. The ability of coordinators to pend orders, labs, and scans and the ability to document visit notes and telephone encounters is of great importance. It allows for continuity of care in that primary investigators are able to keep tabs on study patients at all times. Information is able to be disseminated much more efficiently and patient safety improves because those involved with the study are informed at all times. Other institutions allow coordinators read-only access and AHN is leading the way in this respect. The ED visit report is an important intervention for several reasons. If patients on study present to the ED, it is essential that their primary investigators be informed so that it can be determined if the episode is related to the study drug. If that is the case, the patient must be unblended. This is also an efficient way to track adverse events of study participants. Prior to Epics implementation, there was not a standard process for addressing the concern. There are two phases to AHNs rollout of SlicerDicer. Phase I, which ties into the pre-/post-intervention survey, is feasibility completion, and Phase II is screening while avoiding preparatory to research issues. The fourth intervention is Clinical Conductor, a CTMS used to manage patient recruitment and clinical trials financials. Clinical Conductor has many features that AHN utilizes to efficiently run its research operations. With Clinical Conductor, AHN can achieve the following financial objectives: set and track budgets and payments, ensure billing compliance for single and multi-arm studies, leverage unparalleled financial granularity, and easily set multiple budgets for the same study. Clinical Conductor also assists with patient recruitment. Study coordinators can sync and search the patient database for patients, track campaign effectiveness and increase return on investment (ROI), utilize CMTS web recruitment, and analyze the patient database to determine trial feasibility. AHN can also track trial visits and resources and check patients in and out for visits in real time, schedule patient visits within a required window, store patients in the CTMS database, and quickly pay patients with easy-to-use debit payment systems. Though all of these interventions have aimed to increase efficiencies within the Research Institute, barriers still exist within Epic. Not every individual is granted the same access to patient information within Epic. This keeps patient PHI from being spread to ill-equipped personnel, but it inhibits lines of communication between healthcare personnel. Epic also had a great amount of downtime and seemed to always be going through systemic updates. Training for use was also far too simplistic and did not give an accurate portrayal of day-to-day functionality. The barriers that exist show that Epic, though a strong EHR system, can still be improved. Study Design and methods The study design is a pre-/post-interventional quantitative survey to measure research study coordinator perceptions of the observed interventions aimed to optimize electronic screening and other clinical research capabilities. The pre-/post-interventional survey was sent to thirty-nine and thirty-one CRCs and administrative directors respectively. The surveys asked questions of the CRC experience with Epic regarding the following criteria: the ease of screening, the accuracy of applicable patients and how well they are identified, the individual CRC perception of time spent screening, the individual CRC perception of Epic, and effectiveness of adverse event reporting. Approval was gained from the Allegheny Health Network IRB stating that my study was a quality assurance/quality improvement initiative. This will assist in deciding whether to pursue different strategies for optimizing electronic screening or whether long-term solutions have been discovered. The data was collected using survey questions answered on a 1 to 10 scale, 1 being the most negatively associated response choice, 5 being a fair response choice, and 10 being the most positively associated response choice. The method of analysis was mostly quantitative with average scores calculated for each pre- and post-survey question with sporadic qualitative responses utilized when appropriate to supplement quantitative responses. Limitations of the data are numerous. This project was specific to Allegheny Health Network and thus only included clinical research coordinators employed in the network. This made the sample size smaller and the findings less generalizable than if CRCs from other health systems were surveyed as well. In addition, participation in the pre-modification survey was less than expected, with nineteen to twenty-three out of the thirty-nine study coordinators and fifteen out of the thirty-one study coordinators tasked to complete the pre- and post-surveys submitting responses. Key sources of information that will inform key objectives of the study are the qualitative responses by CRCs. This information will give direct insight into daily struggles with Epic and will provide valuable feedback for potential solutions for optimization. The quantitative scores will also be important because the closer the average scores are to 1 for a certain area, the more attention that area should be paid. If an area has a score closer to 10, the less attention that area should be paid. The findings of the pre-/post intervention survey are broken down by number of responses and average score. The number of responses varied because coordinators decided not to answer the question or simply were unaware of Epics capability to perform a function. The average score for each question was calculated by dividing the total score by the number of responses for each question. In order to see if I could extrapolate my findings to the entire population, I performed a power calculation. Given my sample size, I would need to have a large effect size that could account the effect of my test variable despite the random variation within my sample. Findings are presented in table format on the following pages. FINDINGS AND ANALYSIS Table  SEQ Table \* ARABIC 1. Results of Pre- and Post-Epic Implementation Surveys TopicNumber of ResponsesAverage ScoreTopicNumber of ResponsesAverage ScoreEase of Screening based on diagnosis only using Epic 23 4.26Ease of Screening based on search criteria available in SlicerDicer 14 7.57Ability of Epic to identify applicable patients accurately 22 4.95Ability of Epic to identify applicable patients accurately 15 7.37Perception of time spent on screening patients 23 6.80Perception of time spent on screening patients 15 3.93Perception of Epic as an EHR system as a whole 23 6.83Perception of Epic as an EHR system as a whole 15 7.87Usefulness of Epic in generating adverse event reports 19 4.50 Usefulness of Epic in generating adverse event reports 9 5.44  Table  SEQ Table \* ARABIC 2. Estimated Sample Sizes Required for Statistical Significance of Survey Questions TopicRequired Sample Size (n)Power ()Ease of Screening based on diagnosis only using Epic/SlicerDicer 5 0.02Ability of Epic to identify applicable patients accurately 56 0.02Perception of time spent on screening patients 8 0.02Perception of Epic as an EHR system as a whole 29 0.02Usefulness of Epic in generating adverse event reports 121 0.02 * = 0.05 Based on the results of the pre-/post-intervention survey, key findings were discovered. Based on opinions of ease of screening, pre- and post-SlicerDicer, there was an improvement from 4.26 out of 10 to 7.57 out of 10. Coordinators believed that the search criteria available in SlicerDicer would be an asset towards optimizing screening. Coordinators believed that SlicerDicer would help them achieve a more accurate estimate of the target populations in study protocols and that familiarity with the tool will assist in navigation. Based on opinions of the ability of Epic to identify applicable patients accurately, pre- and post-SlicerDicer, there was an improvement from 4.95 out of 10 to 7.37 out of 10. Coordinators believed that if appropriate criteria are selected to narrow the search, then identifying applicable patients will be easier. Others believed that they will be able to identify most populations searched for, but if information is missing within a patient chart, that individual may be omitted from a search that is conducted. Based on opinions of the perception of time spent screening patients, pre- and post SlicerDicer, there was an improvement from 6.80 out of 10 to 3.93 out of 10, albeit with mixed reactions from individual coordinators. Now, additional time will be needed to properly identify needed populations due to inclusion and exclusion, and current procedural terminology (CPT) codes. Based on opinions of Epic as a whole, pre- and post SlicerDicer, there was a slight improvement from 6.83 out of 10 to 7.87 out of 10. Coordinators generally believed that Epic was a useful tool, and that it will continue to be enhanced in the future. There were noteworthy themes from the findings of these surveys. A theme with ease of screening was accuracy, in that if International Classification of Disease (ICD) codes are used for more accurate diagnoses for specific study protocols, then stress from screening will be lessened. Amount and quality of information at admission, communication among patients and providers, variance in the electronic and written records, coder training and experience, and both unintentional and intentional errors, can contribute to inaccurate diagnosis for study protocols. These sources of error along the patient trajectory and along the paper trail can help evaluate situations where ICD codes can be used effectively for screening.25 A theme with accuracy of applicable patients for studies was missing information in patient charts. Oftentimes, patient information that satisfies eligibility criteria can be scattered in multiple information systems, databases, and patient documents. Automatic database queries that assemble pertinent clinical information for review by clinical research staff could be a solution for this issue.26 A theme regarding the hesitance that SlicerDicer will definitively decrease time spent screening is, again, CPT and ICD codes. Integrated data capture would be a way to ease the concerns of study coordinators who were surveyed. As stated previously, integrated data capture streamlines the data capture process by allowing a user to more easily fill out case report forms while reducing the risk of transcription error because data are entered directly into the electronic case report form. The electronic case report form data contain details about the capture of the information in the EHR. These values are synchronized with the EHR, and the details of changes are recorded, providing a complete, clear sequence of events, thus providing support for audits and monitoring visits.23 Automated data capture could decrease the amount of time coordinators spend looking up codes for the specific diagnoses of their patients. There are several implications from the pre-/post-survey results. As this project is site-specific to AHN, SlicerDicer could be a boon for the research operation of the network. Improved accuracy of identifying target populations will ultimately aid subject recruitment if coordinators are search the correct demographics. It would also be useful to see if adding criteria-specific classes to SlicerDicer would assist coordinators in saving time on screening. Many coordinators were apprehensive still about the time they will have to spend screening. Some coordinators believed that SlicerDicer could increase the amount of time spent on feasibility because of its ability to actually allow identification of a population with statistical merit. Additionally, time spent screening may be sacrificed for accuracy, so competing goals need to be addressed. One coordinator believed there would be no change in time spent screening because generating data on patient details was not time consuming prior to SlicerDicer. Again, significant improvements would be in accuracy of the report, not time saved to generate the report. AHN needs to align its goals appropriately because not all goals may be achievable using SlicerDicer. The perceptions of Epic as an EHR system were positive after exposure to SlicerDicer. Many coordinators thought that the system is very functional if they are allowed access to all capabilities. As well, coordinators believed that Epic has many beneficial tools that can help AHN become a more efficient hospital system. There has been a great amount of congruence between major findings of the pre-/post-intervention survey and expected results. It was a goal to have SlicerDicer improve opinions regarding the ease of screening, the ability to accurately identify patients for research studies, and the overall functionality of Epic, while improving opinions regarding the perception of time spent screening. However, there was one area with unexpected and ambiguous findings: the usefulness of Epic in generating adverse event reports. Many coordinators did not answer the question on both pre- and post-implementation surveys. Many coordinators were not familiar with the adverse event report or said that it was not covered in the SlicerDicer training session. Responses to the specific question were very limited on the pre- and post-intervention survey. Work needs to be done to familiarize coordinators with the capabilities of the adverse event report within Epic. There were limitations that affect the generalizability of the study findings for practice. A power analysis was conducted to determine the statistical significance of each of the five survey questions (Table 2). The findings from questions one and three were statistically significant with required sample sizes of five and eight, respectively. However, the findings from questions two, four, and five were not statistically significant with required sample sizes of fifty-six, twenty-nine, and 132. This is a pilot study, thus the effect size must be large. The results of my survey were also impacted by non-response bias. Coordinators chosen for the sample were unwilling or unable to participate in the survey. Non-response bias occurred because the responses that were received may have differed in meaningful ways from non-respondents. The study has low power and is more likely to provide a wide range of estimates of the magnitude of an effect. The definition of the variables of interest in the study could have been more clearly defined, but since this is a pilot study, all findings can be viewed as preliminary and can lead into future studies. DISCUSSION There are action steps that need to be taken to address the unexpected findings and major limitations of the study. As the ED visit report is a custom tool that is essential for tracking adverse events in study patients, it was surprising to see that many coordinators were unfamiliar with the tool. The major limitation of the pilot study was the lack of survey responses for both the pre-implementation and post-implementation surveys. However, because this is a very preliminary endeavor and that the survey and interventions are specific to AHN, this limitation can be a guide for future studies that the Research Institute undertakes. It was positive to see that opinions regarding ease of screening, pre- and post-SlicerDicer, improved from 4.26 out of 10 to 7.57 out of 10. Because certain cohorts of patients can be selected, specific information can be found to identify potential exclusion criteria for patients being screened for studies. This may make the screening process for study coordinators much more efficient in the future. Also encouraging was that opinions regarding the ability of Epic to identify applicable patients accurately, pre- and post-SlicerDicer, improved from 4.95 out of 10 to 7.37 out of 10. There is oftentimes an abundance of data within a patient chart, and SlicerDicer can hopefully start to subdivide pertinent data in more meaningful ways. SlicerDicer also allows for data to be collected based on specific patient populations. Instead of evidence-based practice, it is practice-based evidence. This tool will not only assist CRCs in identifying patients for suitable clinical trials, but will give providers with AHN more autonomy within Epic. An important development is that SlicerDicer, as a standalone database, is updated nightly with patient information from Epic so study coordinators will always have the most recent medical information to make informed decisions about patient recruitment. However, this is in the infant stages as deep dives into patient records are limited to physicians, quality, research, and administrative leadership. SlicerDicer will also reduce time spent screening patients which improved from 6.80 out of 10 to 3.93 out of 10. SlicerDicer, because of its many capabilities, can allow coordinators to conduct preliminary research within patient files to more efficiently determine whether patients are eligible for studies. This will not only increase accuracy of patient identification for studies but will allow patient recruitment to be more efficient. With the advent of SlicerDicer as a component of Epic, the perception of Epic as a whole slightly improved from 6.83 out of 10 to 7.87 out of 10. Epic is a useful EHR tool, and the slightest of enhancements have created a more functional product. However, one practical issue regarding Epic is that it takes years to fully integrate the technology into a large health network such as AHN. Based on the further analysis of the study results, conclusions can be drawn and recommendations for AHN-specific action and opportunities for further research can be discussed. Conclusions AND Recommendations Conclusions can be drawn from this study based on CRCs surveyed. One conclusion is that SlicerDicer was effective in significantly positively shifting the attitudes of AHN CRCs regarding ease of screening and identifying applicable patients for research studies. Another conclusion is that SlicerDicer solidified Epics standing as an effective EHR system. I am confident that Epic will continually be improved and that its capability and efficiency will only increase over time. A more lukewarm conclusion is that SlicerDicer will dramatically decrease the amount of time that AHN CRCs spend on screening. Though this cannot be adequately measured until coordinators are enabled the time to become deeply familiar with SlicerDicer, feasibility will be able to be measured. Though the results of this pilot study were promising, I have several recommendations for AHN and for opportunities of further research. This pilot study, seeing as it was solely focused on CRCs employed by AHN, is very preliminary and will give AHN an opportunity in the future to more actively engage the foundation of its research operation. CRCs do much of the grunt work of research studies and their opinions are extremely valuable. One objective should be kept in mind: Accuracy should not be sacrificed for speed. With constant accrual of the most recent patient data made possible by SlicerDicer, the appropriate patients will be placed into appropriate studies. This information can be used as a tool for AHN research leadership as to how best attack the conundrum of electronic screening for clinical research. Opportunities for further research are numerous after the results of this study. A six-month or year-long follow-up study of SlicerDicer and its impact on physician/primary investigator efficiency would be very beneficial as it would truly gauge its effectiveness and compatibility with Epic. It would also give CRCs the opportunity for in-depth, hands-on practice with the technology. Data would be more readily available and similar surveys could be completed at the quarter, half-way, and final checkpoints of the follow-up study. AHN cannot assume that based on the sporadic responses of the coordinators surveyed for this pilot study that SlicerDicer is a panacea for their clinical research needs. Further follow-up efforts are needed to fully optimize electronic screening within the AHN Research Institute. Public Health Implications This issue is of public health significance because optimizing recruitment methods to clinical trials will ultimately forge new medical frontiers: new interventions to surgery, investigational pharmaceuticals, implantable and wearable devices, biospecimen collection, and diagnostic technologies. While increasing patient accruals to these therapeutic areas will have a direct and largely positive impact on the future delivery of health care, resources will remain scarce. That is the nature of the field. Physician investigators need to manage their time efficiently and public health trained staff will be at the forefront of developing and deploying new interventions like those detailed in this essay. Additionally, electronic platforms currently implemented across AHN are not being optimized for clinical research subject identification and retention. The use of EHRs in concert with clinical trials management systems and SlicerDicer. Optimization of clinical research may never be fully realized because of the inherent complexities of the field, but it is of public health significance that innovative interventions like these pursued by AHN are leading the way towards progress. AppEndix A: AHN IRB NO PURVIEW LETTER  APPENDIX B: BLANK PRE- AND POST-INTERVENTION SURVEYS Masters Essay Study Coordinator Survey (Pre-Epic Modification) Name: Service Line/Department: On a scale of 1-10 (1 = not easy at all, 5 = fairly easy, 10 = very easy) how easy is screening based on diagnosis only using Epic? On a scale from 1-10 (1 = not accurate, 5 = fairly accurate, 10 = very accurate) how would you rate Epics ability to identify applicable patients? On a scale of 1-10 (1 = not much time, 5 = fair amount of time, 10 = long amount of time) what is your perception of the time you spend screening? On a scale of 1-10 (1 = not a useful system, 5 = fair system, 10 = excellent system) what is your perception of Epic as an EHR system as a whole? On a scale of 1-10 (1 = not useful, 5 = fairly useful, 10 = extremely useful) how useful do you believe Epic is in generating adverse event reports? Masters Essay Study Coordinator Survey (Post-Epic Implementation) Name: Service Line/Department: Following the group training and introduction to new EPIC search tools, on a scale of 1-10 (1 = not easy at all, 5 = fairly easy, 10 = very easy) how easy do you feel feasibility completion will be based on the search criteria available in SlicerDicer? Following the group training and introduction to new EPIC search tools, on a scale from 1-10 (1 = not accurate, 5 = fairly accurate, 10 = very accurate) how would you rate Epics ability to identify eligible patient populations? Following the group training and introduction to new EPIC search tools, on a scale of 1-10 (1 = less time than prior to SlicerDicer implementation 5 = the same amount of time, 10 = more time) how much time do you feel you will spend completing feasibility? Following the group training and introduction to new EPIC tools, on a scale of 1-10 (1 = not a useful system, 5 = fair system, 10 = excellent system) what is your perception of Epic as an EHR system as a whole? Following the group training and introduction to new EPIC search tools, on a scale of 1-10 (1 = not useful, 5 = fairly useful, 10 = extremely useful) how useful do you believe Epic is in generating adverse event reports (E.g. the ED utilization report)? Appendix C: stata output from power analysis Question 1: sampsi 4.26 7.57, sd1(1.96) sd2(1.40) power(0.8) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 4.26 m2 = 7.57 sd1 = 1.96 sd2 = 1.4 n2/n1 =1.00 Estimated required sample sizes: n1 = 5 n2 = 5 Question 2: sampsi 6.8 7.4, sd1(1.3) sd2(2) power(0.8) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 6.8 m2 = 7.4 sd1 = 1.3 sd2 = 2 n2/n1 = 1.00 Estimated required sample sizes: n1 = 56 n2 = 56 Question 3: sampsi 6.83 3.93, sd1(1.34) sd2(2.41) power(0.8) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 6.83 m2 = 3.93 sd1 = 1.34 sd2 = 2.41 n2/n1 =1.00 Estimated required sample sizes: n1 = 8 n2 = 8 Question 4: sampsi 6.83 7.87, sd1(1.34) sd2(1.44) power(0.8) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 6.83 m2 = 7.87 sd1 = 1.34 sd2 = 1.44 n2/n1 = 1.00 Estimated required sample sizes: n1 = 29 n2 = 29 Question 5: sampsi 4.5 5.44 , sd1(2.54) sd2(2.67) power(0.8) Estimated sample size for two-sample comparison of means Test Ho: m1 = m2, where m1 is the mean in population 1 and m2 is the mean in population 2 Assumptions: alpha = 0.0500 (two-sided) power = 0.8000 m1 = 4.5 m2 = 5.44 sd1 = 2.54 sd2 = 2.67 n2/n1 =1.00 Estimated required sample sizes: n1 = 121 n2 = 121 bibliography Association of American Medical Colleges. Basic Science. Modified in 2017. Date Accessed January 7 2017. Woolf SH. The meaning of translational research and why it matters.Jama. 2008.299(2), 211-213. Michigan State University Clinical and Translational Sciences Institute. Clinical Research, Trial, and Investigation Defined. Date Accessed January 7 2017. Weng C, Appelbaum P, Hripcsak G, Kronish I, Busacca L, Davidson KW, Bigger JT.Using EHRs to integrate research with patient care: promises and challenges.J Am Med Inform Assoc. 2012 Sep-Oct;19(5):684-7. doi: 10.1136/amiajnl-2012-000878. Epub 2012 Apr 29. PubMed PMID: 22542813; PubMed Central PMCID: PMC3422845. Charles, GD, M, Searcy T. Adoption of Electronic Health Record Systems among U.S. Non-Federal Acute Care Hospitals: 2008-2014. 2015. ONC Data Brief, no.23. Office of the National Coordinator for Health Information Technology: Washington DC. McGraw D, Greene SM, Miner CS, Staman KL, Welch MJ, Rubel A.Privacy and confidentiality in pragmatic clinical trials.Clin Trials. 2015 Oct;12(5):520-9. doi: 10.1177/1740774515597677. Epub 2015 Sep 15. PubMed PMID: 26374682; PubMed Central PMCID: PMC4702499. Henderson GE.Is informed consent broken?Am J Med Sci. 2011 Oct;342(4):267-72. doi: 10.1097/MAJ.0b013e31822a6c47. Review. PubMed PMID: 21817873. Paasche-Orlow MK, Taylor HA, Brancati FL.Readability standards for informed-consent forms as compared with actual readability. N Engl J Med. 2003 Feb 20;348(8):721-6. PubMed PMID: 12594317. Coorevits P, Sundgren M, Klein GO, Bahr A, Claerhout B, Daniel C, Dugas M, Dupont D, Schmidt A, Singleton P, De Moor G, Kalra D.Electronic health records: new opportunities for clinical research.J Intern Med. 2013 Dec;274(6):547-60. doi: 10.1111/joim.12119. Epub 2013 Oct 18. Review. PubMed PMID: 23952476. Stone J. (2010). Conducting clinical research : a practical guide for physicians, nurses, study co-ordinators & investigators. Cumberland, Md.: Lancaster:Mountainside MD Press. Freedman RS, Cantor SB, Merriman KW, Edgerton ME. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26832744" 2013 HIPAA Changes Provide Opportunities and Challenges for Researchers: Perspectives from a Cancer Center.Clin Cancer Res. 2016 Feb 1;22(3):533-9. doi: 10.1158/1078-0432.CCR-15-2155. PubMed PMID: 26832744. 104th Congress. Health Insurance Portability and Accountability Act of 1996. https://www.gpo.gov/fdsys/pkg/PLAW-104publ191/pdf/PLAW-104publ191.pdf. Accessed 3 July 2016. Miotto R, Weng C.Case-based reasoning using electronic health records efficiently identifies eligible patients for clinical trials.J Am Med Inform Assoc. 2015 Apr;22(e1):e141-50. doi: 10.1093/jamia/ocu050. Epub 2015 Mar 13. PubMed PMID: 25769682; PubMed Central PMCID: PMC4428438. Weng C, Batres C, Borda T, Weiskopf NG, Wilcox AB, Bigger JT, Davidson KW.A real-time screening alert improves patient recruitment efficiency.AMIA Annu Symp Proc. 2011;2011:1489-98. Epub 2011 Oct 22. PubMed PMID: 22195213; PubMed Central PMCID: PMC3243166. Ni Y, Kennebeck S, Dexheimer JW, McAneney CM, Tang H, Lingren T, Li Q, Zhai H, Solti I.Automated clinical trial eligibility prescreening: increasing the efficiency of patient identification for clinical trials in the emergency department.J Am Med Inform Assoc. 2015 Jan;22(1):166-78. doi: 10.1136/amiajnl-2014-002887. Epub 2014 Jul 16. PubMed PMID: 25030032; PubMed Central PMCID: PMC4433376. Richesson RL, Hammond WE, Nahm M, Wixted D, Simon GE, Robinson JG, Bauck AE, Cifelli D, Smerek MM, Dickerson J, Laws RL, Madigan RA, Rusincovitch SA, Kluchar C, Califf RM.Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory.J Am Med Inform Assoc. 2013 Dec;20(e2):e226-31. doi: 10.1136/amiajnl-2013-001926. Epub 2013 Aug 16. PubMed PMID: 23956018; PubMed Central PMCID: PMC3861929. Ruffin MT 4th, Nease DE Jr. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/21900440" Using patient monetary incentives and electronically derived patient lists to recruit patients to a clinical trial.J Am Board Fam Med. 2011 Sep-Oct;24(5):569-75. doi: 10.3122/jabfm.2011.05.100169. PubMed PMID: 21900440; PubMed Central PMCID: PMC4224283. Ghebre RG, Jones LA, Wenzel JA, Martin MY, Durant RW, Ford JG. State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual. Cancer. 2014 Apr 1;120 Suppl 7:1122-30. doi: 10.1002/cncr.28570. Review. PubMed PMID: 24643650; PubMed Central PMCID: PMC4039342. Holmes DR, Major J, Lyonga DE, Alleyne RS, Clayton SM.Increasing minority patient participation in cancer clinical trials using oncology nurse navigation.Am J Surg. 2012 Apr;203(4):415-22. doi: 10.1016/j.amjsurg.2011.02.005. Epub 2011 Oct 13. PubMed PMID: 21996347. Moffitt K, Brogan F, Brown C, Kasper M, Rosenblatt J, Smallridge R, Sullivan D, Kromrey J.Statewide cancer clinical trial navigation service.J Oncol Pract. 2010 May;6(3):127-32. doi: 10.1200/JOP.200006. PubMed PMID: 20808555; PubMed Central PMCID: PMC2868637. Ateya MB, Delaney BC, Speedie SM. The value of structured data elements from electronic health records for identifying subjects for primary care clinical trials. BMC Med Inform Decis Mak. 2016 Jan 11;16:1. doi: 10.1186/s12911-016-0239-x. PubMed PMID: 26754574; PubMed Central PMCID: PMC4709934. Morillo A. Understanding Medicare Coverage Analysis for Clinical Trials. Beckers Hospital Review. Published November 1 2012. Date Accessed January 8 2017. Laird-Maddox M, Mitchell SB, Hoffman M. Integrating research data capture into the electronic health record workflow: real-world experience to advance innovation. Perspect Health Inf Manag. 2014 Oct 1;11:1e. eCollection 2014. PubMed PMID: 25593571; PubMed Central PMCID: PMC4272439. Jones R. Risk Based, Remote, and Centralized Monitoring in Clinical Trials: Whats What? Florence Healthcare. Date Accessed January 8 2017. OMalley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring Diagnoses: ICD Code Accuracy.Health Services Research. 2005;40(5 Pt 2):1620-1639. doi:10.1111/j.1475-6773.2005.00444.x. Thadani SR, Weng C, Bigger JT, Ennever JF, Wajngurt D. Electronic Screening Improves Efficiency in Clinical Trial Recruitment.Journal of the American Medical Informatics Association/ : JAMIA. 2009;16(6):869-873. doi:10.1197/jamia.M3119.      PAGE ii  PAGE 13 OPTIMIZATION OF ELECTRONIC SCREENING IN CLINICAL RESEARCH PRACTICE by Jared Lee Garfield BS, Quinnipiac University, 2014 Submitted to the Graduate Faculty of the Department of Health Policy and Management Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Public Health University of Pittsburgh 2017 UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH This essay is submitted by Jared Garfield on March 23, 2017 and approved by Essay Advisor: Mark S. Roberts, MD, MPP ______________________________________ Professor and Chair Department of Health Policy and Management Graduate School of Public Health University of Pittsburgh Essay Reader: Gary Fischer, MD ______________________________________ Associate Professor Department of Medicine, Division of General Internal Medicine School of Medicine University of Pittsburgh Essay Reader: Kyle Bird, MHA ______________________________________ Director, Allegheny Health Network Research Institute Pittsburgh, Pennsylvania Copyright by Jared Lee Garfield 2017 Mark S. Roberts, MD, MPP OPTIMIZATION OF ELECTRONIC SCREENING IN CLINICAL RESEARCH PRACTICE Jared Garfield, MPH University of Pittsburgh, 2017 Legend Ease of screening: 1 = not easy at all, 5 = fairly easy, 10 = very easy Applicable patient ID accuracy: 1 = not accurate, 5 = fairly accurate, 10 = very accurate  S T s t u v 3 E L ` c     I N P U X ^ a  »h86?h'kh/Vhk7hh[h/jh_UmHnHu h3T^hTahTa hvhh;vh;v5h-jh-UmHnHuhAjh@mUmHnHuhY;NjhAUmHnHu4J\wXgd%gd*gdvgdv`gd)+ ) 5 D * G Q } C 89mbc LQQRS˿˿˿˹|$jhQ1h%0JUmHnHuhvt6jhvt6U h%h h%hh*hTaPJ h5PJ hPJ h#PJ h-$PJ hI*PJhH h/VPJ hPJ h/VPJ h)FAPJh)FAh[hwh/VhI*/STpqrsz{|ҿ񴥴|f|񴥴T#jwh%UmHnHu*jhQ1h%0JUmHnHu-h8&h%5;CJOJQJaJmHnHu#j}h%UmHnHujh%UmHnHuh%mHnHu$jhQ1h%0JUmHnHu*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu ()*DEFGHIJKLhijkno|}~ǾǨǝ|ǾfǝT#jkh%UmHnHu*jhQ1h%0JUmHnHu#jqh%UmHnHujh%UmHnHuh%mHnHu*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu$jhQ1h%0JUmHnHu-h8&h%5;CJOJQJaJmHnHu  #$9:;Uһҭҭ|һҭfҭ*jhQ1h%0JUmHnHu#jeh%UmHnHu*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu-h8&h%5;CJOJQJaJmHnHu$jhQ1h%0JUmHnHuh%mHnHujh%UmHnHu#UVWYZ[\]^z{|}|llZ#jYh%UmHnHuhQ1h%0JPJmHnHu*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu-h8&h%5;CJOJQJaJmHnHu$jhQ1h%0JUmHnHuh%mHnHujh%UmHnHu#j_h%UmHnHu34569:TUVpǰǥװvmvWǰǥ*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu#jSh%UmHnHujh%UmHnHuh%mHnHu-h8&h%5;CJOJQJaJmHnHuhQ1h%0JPJmHnHu$jhQ1h%0JUmHnHu*jhQ1h%0JUmHnHupqrtuvwxy567Q|jT*j hQ1h%0JUmHnHu#jG h%UmHnHu*jhQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu-h8&h%5;CJOJQJaJmHnHu$jhQ1h%0JUmHnHuh%mHnHujh%UmHnHu#jMh%UmHnHu QRSUVWXYZvwxy|jT*j hQ1h%0JUmHnHu#j; h%UmHnHu*j hQ1h%0JUmHnHuh%mHnHuhQ1h%0JmHnHu-h8&h%5;CJOJQJaJmHnHu$jhQ1h%0JUmHnHuh%mHnHujh%UmHnHu#jA h%UmHnHu ()?@AB^_`a{mdmN{m<#j/ h%UmHnHu*j h*Uh%0JUmHnHuh%mHnHuh*Uh%0JmHnHu$jh*Uh%0JUmHnHuhjhU hU4Dhjhvt6U-h8&h%5;CJOJQJaJmHnHu$jhQ1h%0JUmHnHuh%mHnHujh%UmHnHu#j5 h%UmHnHu(^gTUVWXet"$H)Z)2:c?gd3T^gdgdgd)`gd3T^gd$k`gdj,gdj,gdsgdU4D $ gdU4D;<=WXY[\]^_fgSUVWXekz*ӿӱӱӿxtplteteaZVZVh$x h3T^h3T^h$k hj,hj,hsh$hj,jhU#j)h%UmHnHu*j h*Uh%0JUmHnHuh%mHnHuh*Uh%0JmHnHu'h8&h%CJOJQJaJmHnHu$jh*Uh%0JUmHnHujh%UmHnHuh%mHnHu!*+ST`fgk^e015Fsl~k n !!!t"<%G%]%d%s%y%%5&E&&&&''/'?'(() )H)Y)Z)ȼȴȴȴȴȰh3T^hOhtghn]h%,ohahh h3T^hTahTahhM h3T^h h3T^h$xh$x h3T^h3T^hEZ)a)y)*+<,=,//224455566666:7M7B8G8H899>>b?c?@@A@AAAAvBwBCCC-E.EgFhFiFJJ7N9NKPMPQQQSSETGTVVVVX3[4[5[%^&^ܱh3T^h3T^CJOJQJaJ h3H* hL)H* h*h3T^h+; h3T^h'Th3T^h3T^H*!h3T^h3T^@fHq h'T h3T^h3T^Fc?xBiFJNPHTVX_cgRlp4svA|ŀPQ_Ίgdv`gdvgd3T^gd3T^ "d`gdNk#gd*gd3T^&^'^___|a~aa.b/bbbuewexeggghhhjjjjjkkkXnYnZnoooGpHpIp1s2s3svvvvvzzz>|?|@|€ÀPQgsw׃ڃOQRSDŽԄ h3T^h?9dh?9dhp h:0h%,ohh3T^ h3T^hL) hL)H* h3T^h3h3T^h3T^H* h3T^h3T^ h3H*I $%6܅(46ՐِGH`a ,-7;DK{ϖؖ |mvy⸴⸝hyvFhA[h hhh-hh+Fhh3T^ h6hp h h;h6hlyhp h6h%,oh h3T^h:0h:0 h3T^h?9dh?9d>Ha-( `fz$d$If`a$gd*$d$If`a$gd'T $$`a$gd*gd+Fgd+Fgd gd+F`gdgd3T^gdvƙљ (3Jwx$&C &'()+:DJX^_`|r|rhpth?9d5PJh3`h?9d5PJ hhaS hh?9d hh hhuvhNk#mHnHujhaSUhaS h hW6mh h VCJaJ hhh Vhh hvh Vh^h?9dh~hW6mhA[h h+Fh%,ohyvF,3478=>? àȠɠʠ1256;<=PRVXdfhlnprtx⺱jhNk#UhNk#h^5;CJPJ\^JaJ h^5PJ h'T5PJ huvPJhuvhuvPJjh'TUmHnHuhwh?9dCJPJaJhvh?9dCJPJaJh3`h?9dPJhpth?9d5PJh3`h?9d5PJ1#kd$$Ifl.ֈ0`  "000000 t0 644 lalpyt*4589>$d$If`a$gd'T$d$If`a$gdw >?#kdJ$$Iflֈ0`  "000000 t0 644 lalpyt*?z{~àĠɠ$d$If`a$gd'T ɠʠ#kd$$Iflֈ0`  "000000 t0 644 lalpyt*ʠ2367<$d$If`a$gd'T <=#kd$$Iflֈ0`  "000000 t0 644 lalpyt*=lmpqv$d$If`a$gd'T #kd6$$Iflֈ0`  "000000 t0 644 lalpyt*RTXZdf$d$If`a$gd'T$d$If`a$gd'T fh#kd$$Iflֈ0`  "000000 t0 644 lalpyt*hnptvx\h$d$If`a$gd6R$d$If`a$gd86?$gdNk#gdv $`a$gduv$d`a$gduv \h !_acegҤԤ֤ؤڤ XZb|̸¸¸¸¸̩}w h86?PJ hngPJ hPJ h V5PJhvh^PJhvh VPJ h^h^h^h^CJOJQJaJh VCJPJaJh^CJPJaJh9Rh^CJPJaJ h^5PJh3`h^5PJhNk#jhNk#UhNk#mHnHu.\I66$d$If`a$gd6R$d$If`a$gd86?kd~$$Ifl.F v!   t06    44 laXpytv"#^I6$d$If`a$gd86?kd0$$Ifl2F v!   t06    44 laXpytv$d$If`a$gdh^_bchi6kd$$IflF v!   t06    44 laXpytv$d$If`a$gdh$d$If`a$gd6Ri$d$If`a$gdh$d$If`a$gd6R$d$If`a$gd86?ѤҤդ\I66$d$If`a$gd6R$d$If`a$gd86?kd$$IfllF v!   t06    44 laXpytvդ֤ۤܤI6$d$If`a$gd86?kdF$$IflZF v!   t06    44 laXpytv$d$If`a$gdh6kd$$IflF v!   t06    44 laXpytv$d$If`a$gdh$d$If`a$gd6R!ۭ)}*=|gdH ^gd# $a$gdU$a$gdzgdhgdvgdv $`a$gd$^`a$gdNk#$d`a$gd^ڦlը+7Wx 'x#&>SlLSkq`aڭۭ=@Asuru}߾ʷʫʫ hZnPJ h3PJ h3H*PJ h:PJ h86?PJ h@PJ h%,oPJhhd0PJ hd0PJhhPJ hPJ h)FAPJ hLPJBSghѳ-ϵѵյֵ ͷ8joN[_dQkپ¹¹¹¹³­¡¡¡› h-PJ hMPJ hPJ h%,oPJ h86?PJhh rPJ h rPJhhZnPJ hZnPJh rhhhhZnhA[ h3H* h@H*h@ h3T^h@=پ޾34ſ;<|_top)EK|} 4?]~G)*Gdks^_(FMu|ĺĺĴ hvPJ h\RPJ h3PJ hLPJ h)FAPJ hUPJhh hhPJ hyvFPJ h7?kPJ h .xPJ hrPJ h PJ h86?PJ h VPJ h-PJ h]L PJ=h',<=osruAEzN@./TU!2uvwmnʾʾʸʲʲhM h3T^hvhv hMPJ hEPJ hmCPJ hA[PJ hhPJ hH PJ hngPJhH hH PJh#h#PJ hUPJ h#PJ hLPJ hvPJ>nopqr.$hd^h`a$gduv$ & F-da$gduvm$$d`a$gduv & Fgdvgd & Fgdv $`a$gduv`gdyvFgdEgdvgdEgdEnopr| @NolmnRSTTUV()*pppaUhuvCJOJQJaJhU )hU )CJOJQJaJhU )huvCJOJQJaJhU )huvPJhU )CJOJQJaJ hU )PJ huvhuvhuvhuvhuvPJhvh5 hki5 hv5hjhkiUmHnHujh%UmHnHuhzhv hPJhyvFhyvFPJhEhEPJ!GHIopq PVol ' & F0dgdU )gduv$d`a$gduv$d^`a$gduvm$$ & F-da$gduvm$lmSTUV)*)*+,YZ$d`a$gdgd[gduv$d^`a$gdU )m$$d`a$gduv$d`a$gdw~m$ ' & F0dgdU )$hd^h`a$gdU )m$*[),6XYZf ABNOPQwx5678QRklmnopz|QR^_`a h86?hhhki hvhhuvhU )hU )CJOJQJaJhU )huvCJOJQJaJO BOQx68RlnpR_a$d`a$gd $&GIb|~0gtv8$d`a$gd #$%&FGHIab{|}~/0fgstuv789:Z[\]vw DE{|34h h6Rh hvh h86?h[8:[]w E|4MOpr$d`a$gd4LMNOopqr!"#$Z[/0IJbcde6yzվ1huvhuv0J&CJOJQJaJfHq -huvhuvCJOJQJaJfHq huvhuvCJOJQJaJ hkih[ h6Rh h86?h hvh>"$[0Jce6 ' & F/h^hgdw"gd[gdv$d`a$gdz~56oaders !w67z{εΦΦεΦεΦεΦεΦεwh*huvCJOJQJaJ>huvhuvCJOJQJaJeh@fHq r@huvhuvCJOJQJaJ1huvhuv0J&CJOJQJaJfHq -huvhuvCJOJQJaJfHq 3huvhuv6CJOJQJ]aJfHq %6pae/]^y  v x |  h^h`gdw" ' & F/h^hgdw" uv 0./·l]D]]]]0huvhuvCJH*OJQJaJfHq huvhuvCJOJQJaJGjhuvhuvCJOJQJUaJeh@fHq r@>huvhuvCJOJQJaJeh@fHq r@ huvhuvjhuvhuvU-huvhuvCJOJQJaJfHq hkihL)CJOJQJaJ-hkihL)CJOJQJaJfHq /Zh"#\]\!  "  ȧ荆bRRFhuvCJOJQJaJhuvhuv6CJOJQJaJGjhuvhuvCJOJQJUaJeh@fHq r@ huvhuvjhuvhuvUhuvhuvCJOJQJaJAhuvhuv>*CJOJQJaJeh@fHq r@>huvhuvCJOJQJaJeh@fHq r@-huvhuvCJOJQJaJfHq  q      r t v x z ~                     ( 1 4 IJĦ{{r{{{r{hc\ hU4Dh h5h8Bh5PJh$)mHnHujhUhh2jh2Uh[huvh@CJOJQJaJh@CJOJQJaJ"h@h@6CJOJQJ]aJh@h@CJOJQJaJh:CJOJQJaJ"h:h:6CJOJQJ]aJh:h:CJOJQJaJ#| ~            ( ) * + , - . / 0 1 $d`a$gdaS$d`a$gd8B H`gd$k1 4 G g h i j k l m n o p    # ; < = > ? @ A B $d`a$gd~$d`a$gdaS $`a$gd~4 G f g h p   D [ \ ] a b c        ,FIJ HJQԽحԨԜԕԇzxzjhNk#h>*CJPJaJUhWehCJPJaJhWeh>*CJPJaJ h_h h@mh hU4D5 h5h8Bh5hY;Nh5hhmHnHu hhhU4Dh h5hAhmHnHu hU4Dh hU4DhU4DhU4Dh5)B C D ] b c d }            $d`a$gdWj $`a$gdWj$d`a$gdaS $`a$gd$k $`a$gd~ $`a$gd|3$d`a$gd~     CW(fy-FGHI d`gd;  $`a$gdWj$d`a$gdWjIJKmrs UH$d`a$gd;$d`a$gd6$d`a$gdw$d`a$gd9W $`a$gd_ $`a$gd$kTime spent screening patients: 1 = less time than prior to SlicerDicer implementation, 5 = same amount of time, 10 = more time Perception of Epic as EHR system: 1 = not a useful system, 5 = fair system, 10 = excellent system Usefulness of Epic in generating AE reports: 1 = not useful, 5 = fairly useful, 10 = extremely useful Legend Ease of screening: 1 = not easy at all, 5 = fairly easy, 10 = very easy Applicable patient ID accuracy: 1 = not accurate, 5 = fairly accurate, 10 = very accurate Time spent screening patients: 1 = not much time, 5 = fair amount of time, 10 = long amount of time Perception of Epic as EHR system: 1 = not a useful system, 5 = fair system, 10 = excellent system Usefulness of Epic in generating AE reports: 1 = not useful, 5 = fairly useful, 10 = extremely useful HIJQW !"#$%& h^h`gdw"$d`a$gdv`gdvQ "#$%&h[h2h"1<h%hhNk#hCJPJaJE 000P1h:pvt6/ =!"#$% Dp?0P1h:p$k/ =!"#$% Dpnc~.7ߌ>PNG  IHDR9sRGBgAMA a pHYs&?IDATx^eU/wu}vV[ (""DAQQ*bE `("HD ,FWmvUUg}ַ֚a1Øc uƯn&Sen|gsmu7oO[onww/;Sy'?5;ofַݏ~FOG91&7|s~o|oM8FCxp{ůqb柛_-| G:$o|;a^Yrˢկ~վghtAݳ~W{+_=w}n;ۛC=}U<n ^Cup@>t{E3kn|?9itM~-|{/níZ{sG[3hg=k]t?| ]|+{K_x?{Ah 07;t_5 Oz#ʳ(B{ۿr/"1 #x ƌWՍH?e 3?I|4a'AG0O}j3c/n'fY?4O`x?aƿoUX\$\a]H+ )|p~\]J'%H(i/qks==jYv((HaR8g&,܊7M?D E}Bqd&xpw.I^+?]04 Ӊ23Θ5.L+*te?Y´bdW,[O~;;묳SO= |#vqV }3鮺.뮹%[,,h]wu?cXl}CK.uu{>-õrEno͏a& q@W$/ +F3swG . bwy.km|+-a 7lo2CPhFl*c ?餓ZMe0pK3??y]}M Ğ{9KeX) ,eH%c0%X n8ДAo~Ӫi~_3 K/mպt{޳yғԤ>DR5Q}B7SwlLX8H?U`*tUa _V:04Œksx@p ۜoa4Yk\#d2|BD#V2=o*Ke 6ht ^kSmlI/~կv[mUSg2T;@(s.n֖< ']|ŭpXN'mtցEe*1 p-pRK*d1}ZX,kV,0T/0ԊmiQk*je2|a _H3\-Vuݐf >GVnZ0a[弅UKY6,\4ci  d@IՃ*p0X,kC2|a6 "{v#'>/G?vm[>On'#YiGYug.4Ã.p[VlMiغ:`ϑe;JWlYul/L7*F6(g6lF9泟l73]5g: ~_~u;a;WhC чcFp`kIb:|#mv@. A t9`M׽ZF9A]H{GSApFN;ܙg5Nc}ȟsU҆O.'nkNҗԎ:~RXlVפcl3jX/錖`N\Jw4ֺ4E 4GG: AjجZa`ӏj/04m*+g +^ N\6bl!_Rhzȡ}8% iAO6'?NRBY}hY/wJ8Gi32mZK]0tFlR0tN24IpsVsX.=w߽sA7mN/ӎcgK'<%)<-bm.>f 7jIZh:cUa6(>Sw>(1 t ܜܕ1 W8XXmG`$#s°č;t:έm#Y2i 2GwOc,ɅYkR1i.S|ha#ܒlްJMiS|_ofV4JUשn8XkZU /7IhUY=oW984^Uzͺ"9tjS&(ߩBlGasLp R;m:?pԵ8QgN!j(_*<.ƑD8o0 /?;8M?*F>97 -{i KCC?"˜ϪW](Gc;:tt a% ܞTb|5ƍnVkJ x -QN&}km$U/~Teʞx}&vXd@$>U"3RPd Y]P5$0s5ְקr\R*c 9ZJVZN>v7%htI|PP`iP PNxȬס7۝@(Dx U2[ _x)Lbn $$ {Ykۗ\vYXV bU*4SBS6 q>I +œ/ņVW654vL1i!$ tMg0&?ӝJsԪmjtem TϤHQc*ᄮpA#ŭCTsUz\1ōIͦv4t lr%ӿj'qAbL@:4WF+z0՜D15 V{t{Tܠ=K寧Зgh U𵤳E}~^gP.h7ak3}Ut6s[ ҆;#ξ*%]bBXXs5ÒzJmiHQH=Y@֑eF[/5#NSFnLsפHAHV9:$ă>9o E+O44$R';k !aFf 5JVXX,uI Ӎ2|T#mH3<t蒐0%Vzռ,%XIF`DZTK+mQ>FiDi]@K'Hs^95>nF匨YftH:&Uu543nMk_^LN]cQRZ5 MnK.~Y[gxX_xThc-r9hDjf_TQ`nUZ(h2|e/QJ-:0`̈ԓK.UIէEF0b4JlJQb7LpI4ƜƜ Xy;12"HpCRerRgdF1rRc}lb:_gȜ1tK FsԈ*[4ʘ;)|]wuQaQ-M@ PIhj6C@2 -qUF6 O[B+jUenl[&%K _%;5!VJ 3|Uuk钂e"F_b[EQhe7„*\ψQa^T/0T/0,&Wt?tJ:ElUXikg֮ƎJ#t2DVV1%%fFUZ֤%eZzJm& *L Ma dF^5V\szXl>|e5dyilɬퟑ ,M 6hE}fL2dtMV0w,t\cah"FݖgYa4 v6]`c1nb~e`[ [_,íݲ>DCHSm&VfU ՇJ8hDYf.2=5ݶX;peAҵĭ/p-0iZh-öqj7_>.Q.$x2|aF۪8M0^Xl˪X,k2|a1^M?[R>XLkdQXfGeCU exML?*G]siz~3Ϡ<_ӧY^:>Az AZs;HR[Owy'n釛'c ;E=Sϙ_fc&I?g S|bLSj9Lwy;޷~{{u]&1q nޛ-4|ouaݏ#7Dۤ>{[om'|;4{ŭأ%H8'&3CKx/\1 Y ?~h }-^2a盙3R 1٫uWU534 ;oC't{g=8r/- <)7x'.a损a=:1OXGzr!|}i|qw}67xF_82C [A8;:4Fqc ?3b[O`{a}[fr7dp=Bs/7%p/fq/lD↹o/=W:gxf&&z#I[q_&-Ń=䗧e6f$K^WsLݥ4n7p7 vIsA~q?pG}bƽǷ‹Os^󙖹2SDd 7И_җڠnmGz8%Xa0nQ~mq~2[鴂BJ7`R .w'YMl6yV դH 6rY`$WB]L%^wuTFl0sy5Ia~z_UVV8AzH2AIڦ뮹a{XEP輇>mnt&Lf <5L]jKhJe6/1EK~UW-'T_j"0wha4X̆Qv #d2{ 0k7b X26ڨ+r9~MZ@o<^E(;[[E?o[ײ?ƠPF`;ϯph݊Q`A$"zzdvfonE+@ _B[}҇Օ(nz0>S`'K^ٝ9U@($ U٬d/1̶Ú+k|HFd]})) #`.;eWBH3ۺf;/J<0Ifov[o̶spva1.L**FَAv  {2 ;3Pnd>̭Cv+{}{L=z21l* x#N7Ѝ R&8@{̝FdMڼ{>l<΂1mCO~r3/vƩӃ~eJԉs;mAQAihX|{F,iy]0$g9! n*h7oZ%#' 0BW2k0@q֖<_FEubI 3f qƣBh]f?e5:ݛvƨgvjX9IKpʼn٦n\8Ãkktp]vrfoϨ1̞T8Tn˳>.ѯe#lR6T& r°jOlnSof3~!'Cf!%ޕ#7L. 7ܰn/EjϡHu!3d /@jᘸig9LQsZM̌F٪bkգLmݚ 3Gs=`ʌcU v\ $Us}wVKPeqU肓e U={G0#U /V,2 '[S =նLTCN;a8nX1_If&  #lPz 1W ihW 6 #]*7:F'qEǦ59.]kf@'kh¡wuja5Ru'AA/؃>6 e9`aEyH2;jMlEGf[-ZMJRA ETb'd("Ѥ p>7h=Om]/e YGx%FF  ojD%u]Dԥ)J$ (cIm4ňL!jUH3t)؛pяEӰS ]LŲ2T?akx8h^&D@/DD> 9h$uY| 6hoנI'Fd?=IIfgKwoZI*tŌL**ktSJuk&LH1 1z5nn'6cjfdfGWC"5]iZɷ[د0Fsd)It)M莒VVӥ4f\Taj'ꇿQw G٪ݭ z iC)M“rk[ S؛䐡BXPS`xVGn @GVU(&;a=+Ky . 0!;Xܷ‡q9K (1.L**FOƜM8hhf/H2 sZZZOkac$] Tf/ Tf/ Tf/ 6qdÚF $ +`0 9fK #lVoՇ}\dS֩e偱dƗ3^;F f0o ,f0q_iɼI*gb1Ϊ=\l߹evK4KUXIfCʃy];+VjŠc$Z Ud'tn핵]s fB-uz1̎8h/+3ఢg>5 #llf J+JA6vS$ղ:lSut\ms"Aaa$<a$MmjJ#YZ}iͪ}kd9ĨYvLt:-D+0kˊc$--Uesa[wMVک.ݶ[ݱP4ji[~lymDa1.L**Fh,/Fِs9 ㉑dva2PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPNSf3=fg2,ygY8IBfEjB0pΌ<4ɞ,.&­tu]ۙ.r̰ㄝ/lO}j4{WUa~Gҗ1~}mvȭ]-̗e`g5z ~>Wa1hǯ0'~7st4Aqg>+q-܉N|sf [ܻxҌV“>@K:;4kED /}ʿ|f' os'r!\ ,O{|^Ƌs^{8S>G,㗹8' GeCs+'e42t=C;{q-o(y[҇{|&/7~OnRTb* nUIw1TO;YBCfDVMpI@c; d[4R0/" J ~EFB~EO5#QGC]hķFǿ=Ғ{e[[vefF{; |G>I'm6`fmŦnl-u]ӟԭZmĖ[n٦Oo{Ї>)zd|4+o)[n{~_i"oۛ;~⊦h|[?7ff﮻jve7U½4Tzr矖4-<~ z[b`ݪƬp;ú0YḀ4wa@slӕNM}\t0*^x4-mΔBPvKP, =P|I,”PR sp :fPRp S.%܅”PR }X ,_8|!k }X/N6; 05p֠Ba1v25'`]7vusyc9[MrȝBa0{x|on BwPX> X(&CqBaQ](L) G w06|v7n6oڡss@w9kSbrvX)4G# ^4+ c'Nt=0!t& "]#N<Ķ8r^tiQGrKk\4NeYV(L#Rs Ƿ w58_>TMqGVm-PX:N!ew\c/p+ w=3<>](F./ jC]z1Y>m裏nSb.{Q025 ykڅԧm˿˶3cmS_(|efmڿo͝?O>n[QZkukv7M=otAzPC.{;lt ?S}g}Zx}>:.3i쭷.{ض\s5[.sI-rH"K]w6&{ ǥ= nzxƢ{o馭 m.bp 5B(YXbQ\pW=ۄ24OE'tRd`]K)T~駷`07fFP`-p~q=lWO=6 {no}}^ziS,^~F7hxG;V:g:_⢴`&}cNw= } W ,$Bۀ_.Cki0(.CrB0;m `0Cm}#8 ;>YZlQe] k7ЄQ_jĶ`0v½;`; I5Rl6#F ZQ`b ~ы^hPX܅䣄PRhy0O^A?{VV>;UXDP4ҿg\,[جLӧ7@_{ի^VVwk6x> b+^2bzo~ 7ܰ  DD8VYHrYgu~xssGAM+ׅ y-oi c4|[}h4ӟE$ J1[g'/ςHS jga(qmEUNq 7-ѳRMBloj(ٲHWA=s(FCl^*,C3Mgmv[lіl }{ۓPHymm#7xcV~#87Fp4+BR؟4!T~I!~F:H#"Py{* OiSd(c"HxSzoN ͔K#PR^:Z^-X+;*]eJ3&7S#8W\qE;K^AfgO8:*A@Ąd4.m0.f>?Pi hYBga记~svuKiQ[$djO;C nMnh![BoZCWӑ&C0jZF򐇴&g_H5nZ OZ$׭:˦ f7~GH0O~;t|8 M]d4iEф1 ixE9+4ߚr7nYuܠEsJK'& ڝY*l4^_F5EW0Y_p( -/pX;ΖMq!Ӧ (ҌW%Rsg1_c25 8 n2tH @"˭#G9t8`-Ƈp N0d)9ZgG_~saI, "MfSVR0ÿḩC9LSm{`Bh**;S: 9E8AFbp-iJҀg?M :M3 Ӝ3#kLA\NX҇{a@]C,̜M5ʍ0M4a`R^;|HgP& *f 5qPNA/Vզ2-vi5n0ÂAeA1A:A]{d>A^Ko7ݒP1\.4n}/`X㈱n5,2 i˸aOӱ7wxL<ootZe% hVMh9Z=5g4+-j!)Z4f&b"4 kFui&ܢ+l2Pc2=j-x3c& 4hfbGdp֦hiK9LՊf;mD(IZAF{ C&jJk0d噖 e3E8|AY[ =Д]iOZL J3%\- +IZX<-tmr}s'kP,izDyʐG Yd@ ݒT@KI@ eQ'?W7 wꆂ Ve' )dlL_~%~T d ̠=2`BX xw@ >^-aS~!ħQ^MX?CxwO̠O7a&'!@+$Ma'$,( ⦏4;y ~`z.?kÛwlŜ~NXFٌ4ӧ K_d_ s e apBc:N3?j͸~\mh=A2ŕBJ&}ڶGc'A7s- (ߦ!o擀nh Bɭfl.ל,%"M_J9h>S\ 2e4 SDM= oZhnP<It&R r:tLC_XeBh>n2BmQ6t6h M"0n;(A1]m dе1ģ.0GC+oJG23!wJv5sT`%V.y:y+NW<]' یM]X3McNW i\iZ iJfԂ Цh4 أūV!^J))?ѮihjhJ-,}ҴQa; >f(R08sٚPr fM_h5i5릿z /i"-xM~U\i0#铪0};-L3~1Os;a?}ahy5 PE,䣄PRp+뀭m #|9"ʰm}OijĚn_VYlՕ~Ɲycn5]\Z̓ꗚVчu@?Ler+=a }}-+ìu6P§0nY(7cJ>SHHc|D48i;S2!0wy5~GSz nc@Z17hQxOX.k:xsZӏCfZ'ʃ2dP446` `4!:o'T/) 0U0Vs=&eicpL&7He:gу9mm5ӄBN VVXǿ9z<(d n ~J=o Zm*(* d!AU[m}z(ʩT2: s |f9y<|FvoeJelA3X.J𳦂?oeR&*2eBE4*ɜIDVAF@2L hInV'- *>SusZ0KC4l倍aP8 VVF0r>e8;Ę24m09&U;k[Eh5)WJjes4kնVHYu@ieΠUZkb MM^7M5+2{.֤AsU@SҖMqPPMjcV xZ!&n-( hLMX7ief\Ue'Z27Flɚa=K@!n0pj&~|kxkNPX w6p[=ꨣ'VmI mHMj·z3G03v-lBk|,Z5G_XY =a>-k`Ǐ~u.";Z6[ *+m˒@{G{_(c%/NlE*5w6jwGiF[ֿ9ք/*6385_ A8s#&kĖB8Ni7޸G8 Y@ñ@4cltjpzJN"e5)2sR 8)$wK.~srYV(L#ƲY^(VÄ~|.BLY9,OJi7whgwI7\,{gr9{nioBaZ1TsϧpZU2wv0E'bM7nMxg;3~;{+c+܃ 1<88f ,7i. U^,IeBauc;r4a lKGH#!\ksAA8:ׂGв7 ״7 gQytn5cnpwKw%yurĭQtR9XO-j)np `p/ BaJ1v­omǔ+zCGPXp&5rEjPX1 =% P ŠPR sp 'VY(&%܅”bhs BaJQ](L)J )E w0*y{f ¤bpa 䣄PRp S=  PRp SBaJ1TkWX0zK w0*ܮ) Ba1$SO=uֺP(L*J )fy +&%܅”bp-䣄PRTPR ](L> wm)&%܅”bp_gGb_n'.O8=l!Ҟ׽uK^/~q׿{+^K_C//ߥIKC~?aq6>=Gܓ—>_9ogpmKz8ALbЃ!l"(`c;yE)rG{АhxmvD/Ipn%fo p#x4a'c/,q~.>w)!^qN 77衏6w :A+z)h/$DŽ , /0R I<Ơo|cX|e=FK̸_Jl=E[<ҲOӛ?t7jhѐxŃd> ]U-x|8E /̒37^c?*=|)N2=0iTyzXi)a1+I޻іf4pOyN:勞 ?Ŀ䏼O/S2'Zґ?nȍohqFt$?-WxJy7s#?iig/I?4%ȋoE8HI~Ia/DN°C=߉K0K&A~n=?̹枽0$? sq}3_d=iZI_or>{a̍ xGhK[ICtR(Y[NX_ Ϸ0͝ʯx#O^roɏ4o_ ?e%xopю@/ <zp?Ɵoc?}G<| [i 嗝N+T; ;otOڡ7yVJ9 gјiZ 0$+&!0I"/ZI0WK4K8BKB!0Pǟ0'7 iʅ'|Kw;^aat;IL$A_ h3^s C\om R5og.!ΜG$qzsLkhO0S;ޱN'tRɝ:<)=Ō{~oۛ;fh熙x#=9vhK/ ^ ]r-㏝89Ŀ?ʍ [+^N8޿DžhN%l|_ <'UcOĕtE7" nMvap>f^\`oh;4}k4`|I3qFݤK_|_h,sёIV ēWܡ>%cǜ{vE/'ni$υzd4UA, sB0y(.(BaP](L)J )P^6B0(.%܅”bl 8!P(wʡ-T/smY̸QNO?!6PN6\Ifmmw 7|huUb^I2 /"/kim@'O. }Cۯ}{:XoZ6Ŭ.rCed OxB;dCI؃׷gK m_܎;䓛B6O]h68ۀK3i~ >\6lm{&A$vuVJvWۊ(AjEGJPGpl%>G>nAd,o'%V[mjp5o7p|e馛cgհ2H "6~WLVT©4m럝|-9??*gM{@7"旝GX+|fy n{U_۵Z[N9唶VbfծЇTzjJ[஻Va̲ NS1yL3ХYNۮm` Zs T 詙նN kF;'Z}cۛJ~_//" " im3z[ISpLD]s欳j]vi9 G.kfrA3a ㆱnQˬT(VrgyhB0p ѡPRp Sy]( 4i[džxfӟ$ 3bY!Xiᑙo~ #-fn ̎X;afx,?fyA<1m5^(.Ll2|{-R"OzғڦVsS;S?YBm ,\C;֦R,lSOm~LZccvN0pS`6c T cT0q $+eFcLs1$keԙV%8+T47fF ¶hsV3#7ZV] dskT ˳cEQ](L)J ہРҤV5j.kZ[eHSҾ95n|Q]8XӯImӑ1[68Tӆ­ Bj2Pp SBaJ16G hQ](L)J )E w0(.%܅”bN, BaJQ](L)J )E w0(.%܅”bjvqP;J )E~Z(L)J )E w0(.n?.ٯ]>9K/]t|[?]Ppo6onqp{[nis1GӺ _6۬~`5/\uGyd;Ba0v½뮻ǹ.nsK.N{ΪvEM(]onmN>v'`>V0M+ ۛ?߄/xAkp?mq=h7NDs}0m+ hA-&'܅Ban;ᶓNkZUzU;3vmךқni;P(,c'/~񋻧>۱IGw+.nK܎V2ߔ  c׿ןO2gB0C.&柑BaP](L)J )E w0(.c%ܦ9xmE,~g] l~N:nvj<;оPLLY'uv:x5p ;F7yԅװ)-ܲmݺ|+&K|SZ?ٯpiny!>$ؽ'?l9#fM]X 4ixv)zЃ..;g]|i˽}fv׶v}n]viVڪo>6WխoA{#{bvT7uUgyfez.#TmE}#`R؝vv묳N'lV񫢳__|`(owwqM8]wn7n?4!f7~!چnstDx@PwV)Z`yJWG{YVFnڇ\OSJ׼5]߻;wx+Z}݄b!`+ᣱ.j]'p@ (BT ;|pSoo<^-? [Mw_}Ǎn7պ_Gت ܈FS S38<?N_I|GpAch[Ҝ?* |h '4^ !! ƝoY`A%(4wvZ)Q ] >iPLv++!LJ*!'zZѤҒo~-)PN;ZZ DeW]uUK _y QX- |-?gU>Mtir@Fa~Q](L)J )E w0(.CJ X i׿K_Ye|\`*PXH 3<mNcJ1L-Ї0ĢRg}vg<čdUa+ V buEVlYiv`5@ 4Z[ַ" n+h[+@}=hK+$B- j)W4^{H[L[F=m( J P](L)J )E w0(.%܅”bR8cixB A 9<_b{"n͹hxC#1 *pg tL- wyg{_|ōk‚J?qu\wT'D{S܉_W9|aE`}\Շtvaep%aؙpLJ-^!dҦ9é%E {<)P8^HdſFrm{+9- {#΢BsR>vtG4r Qv̏?^|%Fm4B 8 /N\QX ~Ł8u[omzW{9r3Τ- Er[@ΣU̠s/NqfcqPA?Gc[pTAϑ>LU8V)`G#t4BKX$G=\Th : ADZB9LEB`5hRQzTӎ*~V)T*'ZK)2tBBQI0 >^~96)rS[G8[E% K4S/T܊CŅP6y[TtHCq!d!&T~,R- timsv(IXAQ,SVT *y>gpk2C% 2J"zKOe jnZ]鞁?* P+ 教 ʇ>Ms* s^p VFC((JT9$h_Z p:L IpU R{k AG擞4 ¢MFn/ ;!'VžGфW<;XH[qnt@_x?fCUؔFu*][X2&RKBAgs d}:iA2H^-"%X٠{Є%堏2gY_c%qi Qc,D`54Ҭ2Xi'IPMC~M_M? 0> ?e@O[[QSO5gf54ğzt)߫\@%&n&gH3 R:]4ťu`Q%1ՌM_45qM@=.O=q%4Ƨ]+7 *Jc~O.B(5gy<裾|> L7Cki4H@ܸO zeǙ~.TYmaASpZ~( ш6AOO ߦJNտK8T.~>Os 1tJ ~*A$W0T3 n 1ˠ_4Ax ?捗sqOQc0-%9.08#!曭1LoPIda*'i܂4NVy*SeX 7$$D" 'v8Y bĢnVm[ i-dQF+6۬-Ql)^A=U7- Yguڢ+m^LBYb8YBU? ^TLX|.YU'^;㊠ ۜE/Yz&VɪH-±B0,}lPt1/DSK\ )j)!CdR1YpYE$-F(d c ZxUqc&=,.k;4WBϟFڍ 7 Y;Mm}Vvm3pO{)<W@,CU,UJ\l\a&*R!4* K%-!~*rVe+*k[HiK 0O-ğm Ӳzxi>AE@,+f[s IOSXiz+Œ *?T ZF*t@A"\Z6ZS^d)wGj@\pdᏕHq[E%Zq U{i-y> $N9p _e#oo8b{)Sxx.na9;y.8 ]|+a4<[ MGMGohOB%2V6}YBC(@PBF2#L&fYat,@S_8!o n /CǠ ¤OD90ZR1®f0?t҇6 M2H+d/̄kG8}REjWJ`M6i[WUPG 6'=[JopT* r3a^鋣+q}J&l/a Ht[[x.3#. ~e, @9FAPA%ǏԈ6!Vh, d*e dQ Z:cF 7 $h@!BS )tH{ !S7UA`5h>_u'4J.* ]il# P3sL@OګKX*$TA |R) -Aݖw?owaK#鬬hIH䉁1FU@I~W>/eˠʞ@g wi3 Qz1v=طKS rAP0?>5*^WΠ>Zp}̅$4Wc?Z,H('& m_|0M7Dʠ 4$h;X/ )yk"lP?}UlH+yhf|N8@[sZ}Nk Ƀg5kAJ:iO߾-0$Mh},Ch*`Z1]0iq/mg0}v鞅6w9oOCYs0f>0V­0Z٥/ipHOGW%ЄDߓK3ࢿ?O/ [vy23ЕK;ss|QUpa.4cD A Pge0"EOtBF䋃S` #&r`(8 B\D;(AGMh,Af\+t2p&VTPo^,WeV`/HS']<2MM` ƒCnPx@?”BP ͧrRh4f`맍8NÇ%-,42$-EU)hx3!5.T@"eTr]8Y.sOBR 24,%Լ*Sƅ~KqWUs_+Vho5a(n<ߏˤ@oFC w7*8`LGuP{^mK!!чB 5Uv@,P +J郣e@.!c Bt1_'Lq2 k<2BmA`YVVS~P}kt}B#a`k , ]}Fq5N@M,7dW(zVS8P"4Rsb"ONͪ1`nђt2!ma\AȍQz"FʒeNNuenF  -s à#jr5+6RLK `0zinKH# Z41%& +$z5jO/(x6ҪVI#m :L$HL - F *?}zSh[V@ 4%TJ]E_qUYI3iܿi0Q 6l/V᫈ +3@OO8> RNZV*eSE5_8TP~ [(%97*:өI;I;VK`& |+ͿUh$5-5AR0Pf0 p3T da.l4HZ!樰ZWsII$Y#VGiAqV[_ !G|hiW -a?7-=iπ,MZ_hetnO$a섻P(c'cjY[xgP_>wNpN 5“ }K>=/ Բ@iAhgn9Z(nhb> AL X?9k%=y϶8A )5} X23Xb\?}yomV܂~X445dGO?DH/~G<m@JUPW\Tpx3mJVsJ]Qሏ>(ƧhJ3X i@P,)L'JL'6HbѸ'#E 8ˀ6nYPx@T21u~. ƲN#) h|}`ZV_b̀Quvb}J+`#mRQi 7V_ft]Z\ D.L'J3p Gih eg,)3C҄&=&)mE@{hk d7<@*-@t  #vL(Njof xǾ0}HҐ B07p S f乄P6p SBaJ1TkW7Ly9XZ^d% Y[5/{l,R ,DN,D6߹`XZO.;tt+mWky rƨ zaaӅ;Ns^c5Z+(Ve՚yk+S- .᳐N1c%3 9]QVYf9lw 0 D"0 |Z byj+<svedVL[Ef[a_Z`ъqܣΕË 3rS\zY\#l#͑N`oCj@ /dB+j7 , u ?v`Is VϞ δ&>,8R[koVمgqsxS.MBpIPH1 |+)VvB2(cT.M o\[c'TPB,!jx V)d@KVF[t@ath Fg+e)?JN Nxsg֥7yb 3iJA,QYi?8&  !(| ^4O訤RyѬ 1!%2TဵQ# r@OHts`OSV~)/iӮxLkCZ AOM =e<ybŠVI<9iVwy% |)^yRX (c'WOq\AKBgaKV1͘hCD[2Ȇ܆ 4\1 FDʰ% 40b}A1nu1Wh9BxK mAh}71`w;:Jg w.+V 1b#5q ,a5CjjN"A1PO!3@Ǐp55  _ _4O5륓n~JÞp;ټ7wQ0WMF~5AMe APP MXO\cGN f7A/45K$nɴ|4os{K#}`YiJk@ na@8?8L4'&Ȏ;l3i>4c*seIP&&|t͟8PoA僾|¯1g sϗpg@TQV0 0`:2A( !4Re-GA*FTi @BfDs~nUNҖfUWq0w̋A-K(ng] F!(L݈Jep>;(PO *< +Evd ܉F*QtH O*C/ׅ7*ZJ!R_'x}nLğtV`A[~7ePW/LyVaQ KN抡=_{|eB-e4hr* KBFW`0~ K3<>](FBaJQ](L)J )E w008##ܦ#zyGM) c(V]e)KWWܱM;}g7;ͷryBab5_Lp-<(B K)䲌2!lɴ0Nl'ªin{0Z:ck*$,0-/ )[1fUQBaa{eIeYX(,DLp ?PR/BaY{v~Si_%^羯9w![F5wm*؏nnbl;Mܐ-߇~[Comt}?Nh?LSuT&.)znP-ҍ+C 1fyt>t@rC[BMs=}> ;a n 7l-s ~i^Mh7NbP)sO@*1v@jB@@4a%Nfi_B@\nkiqEno4@@ ;j_(c%ܚ}# 'v\sm[S4.>hOm*c%ܹ1gNY?Z}5}p;d1}np*X`Ycj퐅Baq ^bɠXsG5;4 pp2(E#_ yvC򐶚tT@$,7 %8ꨣf\ ӎn#FO8nhȄ\Sȷ9c;, n?Z\s^:㟙cvY~0 ᶬPF7DZ߭om9f܁tdw|([H,Uey ӈjCՙ:p<Ќ7wMŶD J4BOo7]Cޅ4b섻P(c'n׶CmS_o/n2RI 1vm gkj[ifw`ۥ,/| ^-ܲz[xF4;Z_ wܱ{cxܮ}#ٚ´blRTBZ^gb`=}hrH0 n]> L V˺0;v޾uӲ4p|3cm-jR Uf*(<ͭ9oPf,54BìpE̻pXj洶A8S^ndaq4985kH3f)0&x,6r)8vGkBaub섻P(N BaP](L)J )y.. %܅”b۱9ZyEn(  an Bb;tM<)mY w;Pl@B0wzFk@P6p SBaJQ](L)J )P#cTX w0(.%܅”PRp S-BarXy.. C BaJQ](L)J )E w0(.%܅”PRp SBaJQ](L)J )QGU](L#J )Šp癧P.%܅”PRTX08#J iD w0(.%܅”PR”PRp SBaJwPFp SBaJ1TӟZ IE w0(.%܅”bp'?. BaJQ+ )E w0(.%܅”PRo..%܅”PRp SBaJQ](L)wp ӈBaJQ](L)J )0s9?Zay>,uYЇ>t7}s}wENlIO?yoXz >}ws}גxݠ}aa{sgK8gߥ=;#x${i3ϣꩧ}֛y;3"<QO=L9N)B>jzꩧzg>KD=snks51ꪫvۜoyNM7ݴn3,syvyײo}[|\gXgXz׾ύ7xw<~J=z ?I}Q;/~q/\a[F=q`/۷z/l-::r -aha|[ƯWZr/<3:0Ap7y=9i|]j4s]8p+ci1x?ᇝ?-:hK vܠ#xbsmo{[aEƛLϭGtg=Yw{:UE~w$W\%=%>E_߿s䋲Z97x0̥C6zVX-n`/27?G<|𫜢 ?xJW" [>_9,˞~+q |qrfp͟2|ó(ݔ%aot!,?rǟe.,wh+C>%MZwEW+ą[p0))[h' | =Kx~1gM>0fPa,*b6ƿ}n<Ɍ;3ƏHsIRr+skz=>{4vs{0ÛF/|9h(̒ჽC?՛}<aqIhIft,o>lO6~&hw˜߄oO> ݔ?n~Ϳ4V8މ7;nWß7'a{%ÇoO0O:ܷ7>4a.ξ+FU~0 s=sgǜʗ? ;;~B?IStC{qD[|x矝t+3c7{itO:zM|?ʛ-Z0óp?C̙h_{Żtf7'h  40gWWɡ?ܣ/MZWWnБ{-vۭ }BaH3 ᛟy/a'єZ= [Y(McC"a2×|Ov}>~ ׿0=y#I9<)/Nx/l郎U~cTDy# =¯.%ZGr}4bMOd1aGN;2ijpz' ǯ)ݸG'o/3='i>}N8g;wޑa~7 4~6.H;~<I)s +%z8'a#7IOn a GO(3okxi!ǟ4.u0wgt/@9Na^{ܮ6!$1,qd|N$80)"/I!#cD7ΞDW8А̹- 7?rtGhlc7~2G aGXI0/ҍGś7b9q/lCxxP!~y7GOo{I\5#4p'Gyǝ?7%}6OKgm옣#~N0OܣJzCTB hYXVf xכ;|%#7BGNǫ4TPa%߷׃?2"M<ŭo ʂY1<<'Lb.ߓx;o~_43~ƃ;?rǍH).p#|EvSF0 3OO*ߙ5u7z舻7c?4FGȬ@ӓgmxΛ ʱF%x :)4 hpa^<<ʱ㎛qZ a2HVk*.!R$0 3P {If* OK=)!)z~ [:fMa`K|^z? M _A7[nW:MíV &>Gi*#]~J7#w&stL\27x0>J~GҀ?<ˎ?z{qg/=ar 4S^zC[(?,}ܢĭtg&LxEO7wC!7;?$_-ŏ8{Kڣ+MşG=z)x{n-34()OaI{>#NxIDOG&EƸg-~p/ę5Z6; h/]Ж}q.gF%QF'?^-\|U{K&±GX%q^< WyW2r+:ޗnͽ2-OIq#~ex#zDMnEfb'nܢ;6Ń欸O;e*O-hLIHy +)0"&"e.!EЛsVf /*IȐd f.ZR[qͭ0ƌ;h7,g$/;!HaALxqrAC8G#!F-LMXi(%OCo)' y#M-q?{s<_qt77)sqˌ_t•x?{2'.3GÞ(031OCK g]xeϜ[vm߉a.b&l;eE IC_L{4اLЃNx?qCS3wv 7LZ)f.K{5OxAW-z}AϿoax=4 >i}褬%xT7;|0KF}^S>ŇYҒߤZo4ĕ[{4]d7h #^0qnQ07d5r#^KÛaxe{&+w3ZŭR`:J΃AҾ&fъ>{N?4Vujxs7mUqkSNiI'.wWǯzjk0;{f.Z>Fm;-~ S\p]x 燽p< Zh ?O>yQZs~g)3tea>q$mnOYB9?q憝 7^Ҥ~K~(pqK&q SOH#ላ<`$|KMz_x3kN` 3v&I[|ywIMK%nt`>ͽ5ڞM:t=RōW_ݞ~KBK}sݕW^]|׾\wu\;V﮹f7= 㦛nj﫮}_onfw h~h;/yx+bQKys-}tţϓN,b-Zh ܆wŝ}_nvM\BǓ;q{!˯|+V IX4%ip>c_aۧ%ln8%'~vs?|A=5sϼÜ۸}xotaq-|s6ĩ77n/o<|]2/}a|_lIȞp- xJ}on`)BP( BP . Ba09,]5;6/ .BP(sV܎O~2mz?ɹΔe[ܥ.SP( Ս9_22m7M;oֹ71y˦6@v;&ϱzwVYF/6;?  }?OxMu;ڑ|̜oX>]~2t@+@:u]RӰs 0x;p 1GP9<~mmn78,$OV K'uoq;s9hx<6p?*8Tя~t, hq7?\` l48UqLpg a(yRn[mUiO~r MЇڈ 7:ԧܻ9n'>.И Y9쳛BfnR _~t&lho^t{օ^hճlA;7\]r xsWF-C:E_#7.6&3o7>>ϴ4t>tvQTl+3%gS=6۬u& FqhBS%Fh}&Wvmw2^$ls <<[s4n5X5NA^{uY;̭2@pAK`;K9zЃZs-hWzF!ث@CZ}ƭL*BctCE9ORtaR(L z)>я )\DYQx. E dQ}B 4\vAQIA?#s>(GG}&9'" 3*d@_h\ԡ4VRh{755(pfp5J0u4&G>񓨸 Sz2OAwdZ1Wj+ ¨0h*ҀbhkuY& *!eA]wu[Kb#뭷^G=jѐ?PAKrCWZx7{ܧ _)Z%Oj Ё8jer%Nh `".*J1yLKOFÃř6U(,9r"UdyG]c#_WUwSҊ QȆŵھ6UHRH5we'NSZOkA33EyӘVV@izДޯ!}c۰?7EGAVnچ ykkh=U〢@(n|_enDzzibֻ.JA[ou% R( E Yr[o^s4SaH568և69V S]Ͻ0P8QZzєER h(qC2EуęQZ7BluaOI0͙/Kyp>zƷa4Jk6d'qZ-t砃j*m٦ c}]4G ":fO|? f^BaA>G[ FZehQ/>JW RqrS i+Z(JbBcQ3V¥YHsCyk'W!6|u* ^ .MBPX2Cˑйlk;zwr5-wjWZzZjki5<5e'M S2d(c& p H9z Xio 7eXJO3=~Wb3n@.L+1Bipg?ʝ { .*Q ahPH[9(F<yzkNޅ´ošґ8ș5,lʕylG[j9ٲ) eR5ɥf5V[\:;7*i;N`w | Z'*OFaSb`Uޔ؇N,Pnx@Sb~"׽Z2v-h h19}t,SQҾU,T2R eaqdx#b6f!58,S)YX7PȔhc(hBc(>,u6Xc0; |DXDO{l)7wMpn>1/{,Pס!8zroªG)(5A1 -d]a! #`M}*O\ʝ{ۿ[3[AA )yl̟8xAV-zBJS GnE|»>En6hVhht-t UVЏQT(L;T;Gaa`Ί[n!$#jG2 BPOS:3wq. Ba\P{)mJBP7. BaPP( mΌn.]( }ڙ,ʕK@lI#[;nvҚ-_;@~le+˂mc./J73b7ʊv8HgKxӲwP(bjJ:|ŶL;W`KCTT&bL&mVmko.e?NrZܸaPӪ`'rd3&ER^~vNeE 쬡T)fnv-x]$*i8B\clt`s&KCv8Pƽ.HC2װ׹x/UhhdH5Ŷj Ky{5ID  *Lw, *`' :tZ})q"8-qn3u ?>2LI;2DA ]kN@x /j0j4+w?(`Ǧ:u8;X NxOqr :v*$^tiDW!3$4n:8\=qB)BPSD. +k =nu4. U =b=Q=hg;o6 _5wdAنAеyh9XJ/LJq *9lvlokJP0vkpdw)Pye'<:T@mO;Q8sVJq uO=yb^{ 5LOsR-]( wP( R܅BP(LJq B0A(]( rWe+ϵP( ŜR܅BP(3Kq,BP(/Jq B0A(]( wP( =yϲ{R܅BP(3Jqo{ۺ޻ M/?E_}g?}w]wu7OSs ̸>u_p /N;}֋_SN..nnw>tp@wW6~.nv^7̞gvguV{(>BP/^(C9)=ܳ׿S_rssI'uǻ?>ֶͽ]:蠦pַ6whnG?K_Rwp~6ƁӞ֝xM/ {nv?߾;|a5¸Zx ^)O>{sXP( RKm^ݏ~;wmv>u?-آ)׽u9zx;Z_bw7ůg};r_4N7 o}[ݖ[n2LOı۽e/kto./|awM_W#<} gmih\|mvBP/^ g)0cs3LΜ"k ]S@q~^4<PCm4 ыկ~ y(s?%@ G*K Ba~QP( B)BP(& BP . Ba0gmt)BP(n^~_P( yF)BP(& BP PswP( u. BaB,gtYF)BP(sq/tWW2rxK^.'sL DXusܻdk UW]n#n?+ d'>7Ѯu]rul6jaZwǷ;_u~E$M_믿}.q̀\rWKI8F ` `ycW.(mg=Yݫ^vCve MP( RK4?Ϸ7߼[՜~>ꨣ-_/PfO:ӽ{Ǣ);7nBmbF-t'PoۛM6٤w{:pmݶ;]ޮ[Ͻ ۯ} BaAq3 \-sŦچ?6En :aRk^n [#7Mܕ}8(+u'pFO̓+?]) ZO2){^Ixo|Rw'xP(& BP Yqy Vq{ks枃ܳycn|߆ٽn=r0O|} B"0Y{)0 v۵!ڪІ>mo{[7~~m曻-آ)w]t, BaEQ{2ۊ'=Ifm-& /|-H3WmN\ۂ=i-6/^( Šn)%r>S-:-=;m;wuW+Mz}Sj l + BaE\?鬷BP( R܅BP(LljF7/]q'\P( E)BP(& BP . BaP{) ̩gn馛;g;oeaKǡ.?& /(   7wܱ7hN]h/O5Na7J>.ǮM,iEp _*ɳ%A_Q.!zx+*g1 )P(RKAܜEYLUj.pvcKeBvFº۝|Mi>hK)g'9RSp)t}n'wG=Qbߵ;/v+n眽Bq{8]wu͟ȸ?ry}iP2n@sW\o$?㬳\sv^{ܫkO/%/|GIc}#}vɭu޺qի\sM{ d@~uxm/3(cfa$_>򑏴q_ܮUv4ʜ@G1҈` vء]+ty0zx袋_N;–wmFSXn4Fse4|rLN.?w'̕G?jq/w^STǮL\xEw5h%GqDKqx!]_/:I =3~oūP7,&D z;@*k(pʕQ[׊"~S RhZFWSġ(vU`kݔ8 Tj*߾2U\na7qNbqJ[Mˉq'0zqoֽm_Uq^vœ` g EApO!򣄹yCҝ~͏%BRIKƶ<)M<lJ>̄!~/2 ΜGPv}6qڞ#4Vʕ[l"B/h ~pk0H3ʫ-Kji@?CS:s|sYϕƣngN}Gp(gW@:+W3QV#zK!eOSȏ{ZCTV4V n{ҡyD KWBS*BgLe2ѫR)kS$=#%5!U8)Hʊ"7EA=яnz}C[eC뭷^kx0Ud*t0n| Gi UTzz6*Zi~ы^*:{ߔT(jJ;RHc!FO=#!zЃZ/Q>^иАۿۖ7?oRWS ) 0<<뮻6s$}ZϕqM8xӟޔ?%-6۴ b2v&zҕ@(&V IZkV4V>@?Ss/]t1G>eN˿˦H ŬQ_Y[guZ#Eh*'9i`9P( ӃRKE贲n)U-9tSQ*IISNr2Ә/' é]qҕ2A-t-z N<ӫvR[u2Ӽ(qdYP( F\Kq/^{̆)TO:_ps?e_P( ӃR܅BP(LJq B0A(]( 87_^=f0#"Y@$ؒ,9%g,I *T@ HQz){w`{~XcUa֬YUsVZ CڜV(  wP( C_0. BaH0n}wGqDw{?s-L> cN:{>d4tpij;}v5 .{t[lE;/kF# 7ОW_WZ\ߣ/4onʔ)>-sB[opgv'p[=J+6ڨ}w[o$Ӹ_}&m~ /nݓO>9߁jV?}?9OF+~z Lܷzvb^?WrLWEI/a49w_:nV^|og !CwƀÅKD0=% aힼ$_z; i뀳?}i ϯ p'O7~tot]vY{?ȣ UgOOЧ y˨0sសv7G~#t^zi馛oW]uv 8v[{7˷#LU`ᦄftd š}٧5F!4_(eSN^L}Ygu3hyͷuNi'0s16 Yt #qvwygummO<;uYɌv '}c- / ׏ dsg7#,[dEp<o%zN#ot>:* w߽ks9|ne_W=w\3r .h.=s$|(р 2 Gq@n#lF m42Ȍ3N8S[np(7T@EW0!0Y㥠ES6zw^S:6@ֈP^^q/bv(( fBʩn*Q@QP* P@B!FΐQ.l3NûFo(Qkf\utp2. Qʍ1PnRD:>2 K,1Ͱ( )-P`8)JFMGSf*(~Ew6kFcJuHHJTyzꩭ>MI2Z ^0(9v wYJ#I<<㗁HduF ,%BS_@]D=`rӞE٫/s 7ly'2;7m [f(3)3S=m^O'GGmN9:eĎojf9)⇬+ߏ~~!KzBpG7ÍH瑜k̬Dra￿Ɇv$mJ{ѱ~]{I 8ḧꍫ c6PH}% 6%r*FcՇ5x*Q/(MQFSҠtilΟnu)X~7zq~RGVhq $L #1d.N= F }P#Px&KqChxg) n^됴(iLK&i#<)1G<|Qˆ/N=YHEߕcx䓡#:/J~Qfȇ RF< ?u{:$ÄEڐ;9IKxr̀|[}LɆ7.n:?zu0H0NrP/#/¥M3i~y骻!Ou01. eǬ!&<;ABaA.=Q`ߛ Ѡ4M66Yr%tV0#>q4P2F]u<6@SDzͬb[WLzl zֈMLAno|#AN쏚&"߫-^\#L&_x~},(3?3N^]ݱt`zhM. ( 2ӣm)1uBaFv,M5_od~3ܦ장8³Nk'2`6X&Pmh*z(Q,E.enjq҈)U]t>k|LQY˳Lk1l·;LJ1RK1k֮Uk6\"|kx(gMɏ$ӽ`3g2Nj-SmHdh}OgF:lQ>jݏt.1#/mJΚUL˿K^>JF_k6,䣮3:<:ڏ}䥓E&{6[E[\_p E2ݻ-#BI,]7yD#o*+:bw4E>uPrG>V_Sd (h|S8)>KJM.(~}r (Vy =SFʛR4U..lc,Q NΏ:(mtb)x4#`-dژ,V騫#>UJʄqV&z-<RAY||eI~ß*[/ rI|4AO&A\yyF?yP2(E %dPsȚ܍ ÁH07g_?6VP( mYtm wP( 2܅BP( p B0D(]( v6T\{>}=9Ɂ ٌok' ktg zp0`p0OZL~(ϳCP9g[ψdؑS;([7cAy |b;g g`>JI>'F C]rbh)7OF2|䓪gxvn+' |>|3gx@= CN}UAEYGq2éq3C-z3Norx> =C$|cKq9jd})M !97Hr䔏ӝ*Ds~(?8(qSNbhU3}.9"Ϸ9KXbu~%M>~;Ѿ; O}S|ʃ{Rb@x!&{^rubщ1px>З&E#S^Zz:}wAY80D}[m߬\EgNt4BWdI&oS_V:XozӛA9MdD|mNSjWN';E,/G&.uǩ0i2Oe#=4| ʷ0ţև_YQ'AYhhKC_goNP 6Mʻ rj:*"ҋGuC/ IN=y8L 2ė䋌Iã~[^uʹE7cB{z#yupSDq3NBsssԣG4}MP*6(Dj(zÔM$&#GH8J4RE#ȃ(Cnԡ$b8. aa95n(B:2:5d@R^\J\{ޖE*nO<rȗ0x9Ԃq|CHt:<,)+ƊxW6T~ Ϝ< כ򁮃B,QʖAbќ:v鈁^cLбqX1 !9ЇZ({CfF!Y!g }Jn:N>CS^9 (ڤt/FS@#@oqpNvS.@;:\.R&3BǏ:(v>cCcȑ1ŸIוvB(QglpɁ11?y9Fy3:Ph-yj_3:KNDuHAx舸k:ǁ4M'S-1níίxhh*=nD1 4Dax(aO7)(*=eFQ0Q-e4g#.h ȫ1̞G;vR ^ʊQ"uGaxSO4(#2%sr|Sd@2fLS@voh+51:/ht*:Q}0: G^r* lE8@|W^t 213"^)m`(sS⪿Q.ãsӫ΂yёO F:B3I2R5C#n|1uP8<: >!e Z_xOt1̸'ǍOf@w3 _,P៱UWcqCEFt_f6 8D ltO?B&2܅BaBa^D1`M]3=Ww.qΨG[{SJ/ܴה)S441-ݴ)fLi а#/Ay [r04ZѳѠѕhe07m h0R-y F3eFf4f6h8"u`n3+:n:lm.=Tҙ-z@2eg 2k{d )+2@ED8 PLC|Ч|u`tiH,M%^MrxLo]%%oWxfxmCS+KNy6i]ko{ c)z3% )Cw OxJ5w7җor܄%c=k:K8D~cSmY&Ode[]9+KSwySO S:w[2X`܁kZ4oZU}fLaCQ_6˛#oچ;N23=Ed.?'D~ Mcª[cVߤ7qvL O6}&ֈW:ڎvҴAnݲLjIKtZvÕ|ÂyQ׳LS`LbNMhQx|XSNdbOBwi?:6ꚺˋ" _:2)="h븑00O/p Ť}RO6q` _*֍RƚB m\c5ʒ2QEˇ10 jAx׻z6|% Y9h)]<~1A6X8FRN(pɁ!>e͔¦t22$ tVD(HR#ʼ/o ?o}[]9SYk13:xcDޔ!Pz MJʝ#?i';27ƀE[d~ȃƃ a2!z]}'p? 17wu]FI>XUD=$tR9țM#W;tht7.GG [~e_7#L wR@:MFUu1WꢻeFN֒s`~A; ']A/efvW:Qh[yϸP۬dÛK7HБȌߺ+k)v fdL%#:,ғ.w򥰤ŘvI2'33,Y7xː(g2[C>ꇸ]]?>&S3RV^Hfum/gxc$1:3 F앺MǫQz FFltSߨf fF_1璳Fݮ5r122 f1̜ l@Yp,NHjglMe͏[5h JeL7dڋNcL'R (a)EQQ)0Ӕd*"ֽ(S\lj̔t):Szݔ3]9< %CP4:9,Q>ixb4 4J:ƴL>)n^8w|γ6l4im_S~ھS ]~)^LC"?K 葫4zg1XN@)  ?W@Y G8&`Mz$K ]Nb]tV.&fP'(2V|?<L7/61v2efȖᔆ.CRg[f;X' uS-:O꣺7]Q0⛮%;KRGJLی/Fͺ'?Q;#G~G!mMG̨ H-=dGҞAl*/y7=ՇN)o2^a)f?rSj?<2T׵;nQ}x;xA4=yPM`ޡJښ,+/Z\v_u|jK^0+7íi* 7)Zv4a(@UCRV%FY_FKDGC.Rc}P4: 0 &4lX$8 Gո4I.)Cm_Ao0K v\DyQ>llRؤaCW::*>ԛnFKKrVtTyGyҒbSz2;#'-J4J398墜)ZA1rB%s#yr[G3fK0M33F*aEQN WY˯BY8t(-h20#B(e me7^ 7+#`PzS7#dJW'E}ur4bŸv1J:EYjW#2m/e3X-rf6'eȇMF*;"sWACmE}W,jKtFG/NcImmi ؇97uF;mF2>(c\4cj+tMotgwpe<(Kmo Y-WT_Lau^Rr+=$x5^=i ot s(];x~R*ƠoDYBanĄ ^=q҈hpB #g=OgF0`Qg@Ẋ(4:ԣ/̚hAF*:eixϷ kĬ=9Ќsv(^{ ڐԫ3 :fGcAֱ:(=XO^gtkȦ#(S֨U~S*#SMLSaԐi&w ԏiP=~F0@XzmlNnciLG7'qczaSBŏ<>Cq7m%)+ R372pdim5S呟qy6i*L˙*}Bgx<@f!X.?vGϒr1hz9`-3>7@)UyM>䁌ݱ9k٦kJ4LSep:a:FT=5iZ탑YxᅛCc~NsSǦO7@ ֚Oa@:\4+,ŵGġxk[ޭmR~: ?ANGP< .dm2B~-lMz_G֯l O@&}]IR>KKx"Wuкqܔe톜Rǥ]Ywi>2Rwq\XNST:cxFAש{Mvm r.^h2ܣAT)KMGnh܉_i?[AcX)9^c44*Ћgd4nR@0N-0 mzx@b(/ Cc(nkNbh)>yjԔE.FH RDBOyRTxx^l]V3VE_2E|b4}-Jlh\`=~hX10(iH5Ёǟ44r?:@@y8.T"aڟ:) CN+g&H2{Iz( +ȟ2fS&:*`䜀z[VʃHGM߃O=ڑzP#uLKWOK}VtFO0@U6.rUothmFO}PV:: :r9xfW> Ϙ.i#:u:|c<.y+bwH{GdzXЎ!c=Ĕ *3Fҡ𡝋20gQ{ 3 **DQF㔟aQJqai*)'F@ɇ%cǻ:)y( LXF2JAEᣍ'堌 6z2BaA/Pd?FC=8s\:ѳx "2Pb|uHU1ʀcФC( eȓr`/a K#HO'Oݐ!NԆ6c>; :44~1򦭑YꐺO: #+ƋY*| 7Y,z:KSg Sܻ d𪇃 /e—z K 0F]d\m 2:z :YēwuGP_&.YTL'F]%ku\38&MyЁA}zD0@egJ##C9ļ`0AIZwyEv KGV^ f|Wí}X ϔxlZ(xxI=H N!ea| <=3f4={^zcCBędQ((=#ӢLM^)>Lc,с-7~&YbH)*7e+Ԙ0SָMzFߺo@[5KYYbMuaPڵL_ˏ)K<_uBߙ3"1*On_ӄV8S2*dY8g4- g偟75gehr率ZO=@t8蘲`tM_UF6? '1l^}͊५XjW\ӦA#BaP{ 0.֐(XZ$8IDATPĔh ]6iz*jc܁RۉX'6iM:K) !}勞8c="G}ȚQhFB8ҭsꔠo3K`lpYcL 9wtf-zw69/Z'0蒽VG:-: GiIC1: )H''Y.PYSFʃ!(D4]hQuLu̞y҉Q2w8e]\F^ ^(#B0|(=PF*Q1 6lfËюM^ id@1T0ESnٽMagѬg#!ʜȂ x|]`l)z#F^>F3Q`>(X\#=;'r`7@FѤ , b4C0Jxfԍ]Fo#J` U^5*g#Z5c%x%F1w|ppV| 8$3#Zj#Od2xB74"W\ʧf3BӷԔ40`r |t1{朶hҖD|g7}F$/}0c,8!0UWѼdP Qo|IG&^9hA>3(Cj>ws SzݺpmWS/t<ȣb4=POD }tISs6U꘶)H%)>}3?])7_r#!ɋ0\<(/ !=u?~ʡ=MP_G;xv #ɂ}yt%u$P{ 8X!҇@ Jq~)?(?p 9j@B)b:es  NNآ5vhL}8AIl(C!e;@DwX<8ʉnҐGIeP"i:\oX(IGO:~ŠQ! F>3h(Oe-}~Nlʢ(|P.dKQʑ:FJ!t`b6M9 (L()3PI粯@]]GILi2o=шg7d)-d(WXav?P Q/#Wq8z: hGkxRT`iqy7RRMwʐ\3';yRa@9aJɂ#:]amIGHL(#uN]eK6nD6XL#z:183CN(V :G)(@\hcu(,uN#EFğwwWn(ku hedڨ 8IOYPhaHPB x|ra9#J }Ј)|f'9-g׃szN~e({/4KO&1:>ڋgFAJaV'zm36qi bQdtcF6xtjCi.ut21VRut>UW3 6#2T;'e}3M]1PP_ cm"guNUɅnڅjkF1N92w W GfV& JPmU2ܯ "fƸь(9aPԟe̢D1cvf4uñdy *#oFؔpv ^ 'p њee3FHC3%FFk PM}ecP~LQ›:ʚi9aM?662% Sv2gZ%2dj;kʔ`t~wq֟Z,ݤE LWhZEߴbޟ2 ig]ǔ+cɧp'Bh(Oe瑌,o:M]_^1٬$<^&kȸkX2a-Gz᧟wӫ䭾pBc2>xCJꋻ0V՗ΩphΕjn¡N&qcJ۴-I9Y75-#it{@dz݇kebyֈtk7]oď^ O-wW%n~a_~_.r 뻥.rCHJ /3^RSC[}(2)[{:0hPYdZNcm5ZP7[Ci֒li:)5"V50!xv gǃuPu&bgԚ%eo mq?޺2rR,#}]) [ȭ(Q,N-u}(@ E])bJ, i,䑂StȒ"tcUYZǯ}xZďkoQ d (ceH;NX#n?ce[L¦*uC;J6D.Hn)w7ى#.Cɸ3K6Cޭ[GO]@Yљʆ-&4ѳI$kyup۷W/b- <+޴r/SoykW6rgauo%@m4[i M'GT/}<85٫[% ~t.l'I]/qmNc<EYQxngaS7(y1rf|(n B@SCc( ^\4.xoJ&JWcPS<4L Ȧ+Ƌe@5"F  y ~ѴR2qA[x+@Sv#S8 `tD܆JK-TݮoFo|)GԱ Q4)U^9G6vUfۆ=2d3z)0(c2ièvYv< o$sM) rӉ۩xQ.6ة0ݣí/_ڒ: _iK꺼ɣB~z<&g:<-:'o^}7MMG6, G@CTd. (@7A_z4njŽ7-^? -ߨK#>(#t2>3/:װavOgViҲHzhu~97D 7]( ܆2܅BP( p B0D(](  wP( CܩyƆg(e BP\Uͮi <6;^ LF:=p3BP(̿(=;Hġ/@4-\u7P v0 9Am# w'9 `P(C(A:9nЩ^qP rBa:b8Ngr˜*b(sNbhC9I&pGP(/j!͟bLm#BU#gG 2ি72w#7Firq,># a, 2C˅BPQP( !¸ w}]( ^:P( !ABP(e BP"0'x؆O/]( $ \ߑV+ߢn1 -PwǏ Ba0n]S )SSN;n-.첑s~qo܎iu.ҝ#! B0(=Ipolݢ.ڎJ^:v[6^'C=tRFBPe_!8ngyXTǦ݃> 套^Iwnt tj (#hܿ뿎. YCtT\{`ES_aM^  3l<9hP hwЇ.p޻GB;o}[xGKΛጊMk'>Zn6};nr mny(/3 &n8gnTs=mP(&6܌AzS'o*1iP>=ں6y~h#މ4b-ֽ5]w6gx1Շꫯ 3q}ݷm3`m|F+heW\\& hYxچ;dnɂ5wmYI`{^߳DQ( n{Smst7@ћ0GqD lFmv}6"ԧ>5Mg~+_ly嗷џ:c +`]qeĀq?ܦg0cZg8Qd_2lF9:ӭ?2O҄kuNc- y eg: h`,M33n(BLZ ^zrqΥN2,3m݈ QQg:vW_}OP(eӸK.dp4]wsmd\?Oh­wXo~WIѵmFOtJڅ7k)qkSmw* B00+=A(&ԬS169S܈n]dEaftdŌɳcP( &&dgx~Yuj`t&g7xcۈC9MQ68ňښQ>* Ba<:ne\M{60y[. BB_j;ԴMjF6MoZMzF>V oF0eC??|S^( mCT\ jѡ;.}eڧa֤of'j agl%ϗ!MoȾ6nzSٝnpww|<×x;[>L_{3iXP(&eG?)amsLMh[7v3$awo?6;/¶RKu5uQ;m5>g5zE#ovkt BaP)W*?q lJs MgċDHȽڪ39kw~"otƜQ_veF֯~ۑF .`ߏJr1'b6O|;^( Bٌ9)hΉ B0wc܆Ƭp3vuawW܅k43!(}:BP(qnkvum-kuָkrr˵].'e-9߸lx L6x;̡-zko\e3L8մ;, p_ BarP{ {޶Am>5c\xۺ+vcHg߆661611lcc8újvr/=uہnsqj[՟ BarP{ h;mԯ!O=Զl%he?g#ހem:٘O9唶s<4Boس>ی5lJTF 7#m#s;@F)P( É2N`}BP([(=I[-W6DҮ yB0s(=S~2bںQ.0B֖4mmMԻo;k7ٙn1܅htnFilfi8Zm@yO45S6kW|^b]tE4>LiHt+t$'gAx. y 2CpcL;k69d69Qa@:;wm7#Jovpi0X~YfH"-: _ v͐36Iǿ1 -PkCbo;\Nm8{T3zz7pC .hgh踤"o|n|r?Br:;Y/ .+B㑱p k$_(y}mSCgg#e4۳knF{o7c2uig g 22e.^`ؖYfMz %v6E0C@:Bg0Amy<1`]6xvMvdq33c\݆>ic|ƏLt8i:BV'nz9ZǷW#B0 0 4dQd$\ ŨQ\*lį ˍl5ޟ:Ch:h~I#}=yCW#S/Qxy?8/4]"y !| >2|y) ye BP"0jgl#O BPPP( !mT\P( e BP". Ba0nGNq9OF BPx%Q{ 8n=Pa!) BO?]{F``CCћ3 BP($;nlvKAkRGIaBP(n. Ba0nOOe BP\. BaPP( !p B0$ BP(Ly}}. Ba1n}9. BaQP( !BBP(HBP(&2?HBP( #ptIe BPdLp,BP(L.p B0D(](  wP( C2܅BP( p B0D(](  wP( C2܅BP( mO=2܅BP(L2mO;2܅BP(L2: wP( À2܅BP( p B0DXP( 5. Ba0n}g. Baps2܅BP(L>; wP( À2܅BP( p B0D(](  wP( C+]( 0`܆s)]( $駟.]( ° wP( C2܅BP( O3p B0(](  wP( C {n뷿ׯ~]h]/krv `|_^?f-]]h95\gt=cMޣ]>踯X4FsMvM hsVofV&zf-Ѯ9xVFhzeM+]0gS2UP#~ BP,G? ]7;= ?M^pOV( Bƿpn>F̥ש[p B0g/3e BP\ S1bmR~ӟ. Bap?d5~gBP(&wBP(v. < Çj5}GQ{jGu?>۞w>hs{Ǜޟ|v?CO?Ow{g /\On/gO#+ŃgxdK/sGǻ⊇pt>a7iმgυ.zd&OWܓ_<{v.O>G_:sxwpGH;]ɓ0>G_fxKrOzd'kaKz9yIO<?h%=x{h ]\7&>S"nI??:IE.tBR9+=iQܤ!tvoKŃ8/H: CivmqfmZ<4-<ƃ4Ж{gs.Oiq]) ',ܕAsx!wsW&)K䋟B1?t$YG]/hДq(> 4Q4ExmVDMƫ4 $2?2;~G}tW+a sǯ&H^;z{l߉?$/Fn޵"zYE'yGG8awG3x+tM)2J>LJ<;+?i]OX4ύ?>u,&j06hV edN#TPe g?Ƽ02*B?4yaL|*_ =t6lNh.q+STF,M4gʔ)ݥ"J7n44w \&Ӥvh 6ؠI,)MqГ 7ܰ+'aM2Oz^ >L7rS/|R"7܄Qo~d&;HM6٤Uf/ʏpz..]2Wa-yNN3~>mAO~-]]wV^’77qpI/6 =˯)Ya)?t䑬<= _xG^:ozM\2TH˥}pC'޼-%u%xR'/ܔĕP#Zz[.4/)wI\iI;Y<:I_JW~ϕ;z&~?ˆ@O].BGtMhKїDŽEC8iȣיO>~@^s+:>Vm C:9IqF&T8 `2#>a: d0sG#GG\ip/LB]hGxm鉓&?# /oxM#S~~*w< /?r!JMZi$¡Y&/=$gt֨$ OG>s|N9M|9yFC 'hhД0ɃLWhy&7>sI?]練'ţwyܹ)iF C6%Rr#䋿y&SENplI?y.x@?J@#yK&Ghn?o6y?υg);蒯&p>a-?iwI%\_xf% Nh˯g&2uWA",S4JK88(tE\(1"§pxL‰/œpɿ{#kH =Sx jܤ>ï 1n֊}BL?yJxGQDŽ_*Ks< ?s=~Fޕ7qM*}i /K,|)O|.r=W_O^\LБ>p&u%|![yJ^8aDkg5ǚ*8ŒJEP1}YQHV!Q2kZB IBr.UiJOE^ᯰ OE&!S.BG4-RWЌ>P%?@+.'YH2zoG?=T9cL&dڻĜwWdĕB/NKxE!(x@S:6( eH#v&^&wGxLݕpd/ qAg<-¡iȇKtCWQ4#ߴQ~CoxgBThrg4e^ʄ{xR]ڡהUƍ zO>x M{ww]Փ9r8 K.UK#])2΀ŗ2{Vt.OF^şwI;DY*§-']F+^g< Mܔ;'ԗ5ğ'wx)sF,%N&.0Ґwac呻<>KO]FKRV< /]a;ISzuOiEV tkRChp>ꞴA/N} n<#xr?wnwd蝿őGr/..Y1=V;4HqʐJA.@(4*0d]tR*gnT£OZ)`ѕ&.􅕖+0yq/-nJIzȉFq#Kq[xL:ޥd"T 724hx ^&"-}nx3Ґ-F]=Piѕot'S$Ƈ2a^E)MqГ7qSWG~ # fC#%_??OM+K^Tnd㎟A<} }*xNxi4@qOEG4fL"=钁w2º /=e .|d* -E%=2bī 6 MKKXa'uH;/waCdziRJC~ | .OUR£+4@_J? K+),wyk4ZTv=/٤~ o)O-wt 'GnH&.xޝ,. |K'Kj+C=r?"'ᤏ!gE8?z߻w}#Vt|0QQ0&è *d+H ?7%LzVK*l܅SAT|-7gB?h]Ai@'yVTPW%A>?(\2JG^^= FD\h>_pS*Y~,ʕ, | ]ZxeYwq| =~܄tOr''}-ti/ЎyVgΠޖpwSԓ<7K7E^ŕ0ʍ4KxG&lgt#T (dN%J%!żD.qe.܅W0⡟tRi';?Rw<'?aBҤ{-a\\RO]xƒK|ql7嘲7y&K׳.N7ڻ ]zxVΟ]gޤ+A^S&'>ȅOwi ϳpɧ4ѦBG< ' ?d/=V)M KJ0xNFӰ-J_\< wqȉt#cEy.xAgumqR3Gh{G'(#~!OpБ&ZKʈ /S\ ΣOI=xH\w"'WDU.Uho|'A/_z/_ãtk*!~Uᥙx&_hItM&io4׻hywEzɻ.(C z1S9pW ]:(ZyBC>ǻ4#L&wyqGG\?M)KiG^I]I_ #?x ;ųzO{!?|G6٘JO#'?C4^ZxT#]ծ{ʐ;7!A-aѣ`!ᆶ|YZʀ;< 'gaA7e]<-=wi*#qtK^/Z^BK,r } wwq. {8ږ0Ǜ4Gzp˷!;D=,VŠ']WF]q+F/$=7*;MxDž6.ntf@%Dt#x7Zޥ~,-~KrY]e!V4܄LI7C8q񒺁.Ym [.T 'Dgw˘ O(2O 8o nxF/h#?:\ܓ/ctGG3/‘ygxq珦;/ma#i +O1֡?:ߧ'w6"kホ͕.wuCx2P/r: M\^vhDCox-)G-nӮtE6vș7wiOgC|mBx)yGGK?y񌿔{O~F& 'L䏮\$K4I^RђfQ/Ω:=uN3*"7YVPڙ'?ps ϏT&:ѴCLwz~U7o~>]i - #_pg}vxNcVhyv .'h'\h+)VKꍰ_ '_)?a\;~D[x. e,KZx^: YMg|AzgyfS&MxO= 'qTnŸ0iW3#~M3?qO4{ꩧ6zS!ܕ:>_Ґ~4s+MҐE/rL񖸹6Ýo"%qBSVx=IIóxz#ZL}Ƴ8KV=G'˳g|CO I'y...ir|I#| :yH7m/Kz4U8\K3{ŋF{\ϓxNAGd*MyFU^t\vzEGAW8rBCz޹ zrBϻ,F"?鹄&mЈt, ,s. O>h=ʿ0^xGSXyxY_h)~&m4-E>q#[|i^бH٣+xƒ[hEғg|{?_.<72rE>.m12@]z܅Q'G0[ LL9襙0-j F oKL;g5aݴ=SLm+ :h&]aUaϙt ;^2n*0?ջC \I? -|sGSY$»s'Y w|IOdrsDS:$mq##n*nz? 4GzB_y*K]^2qF{& < wڞ<-rKÌgy-\;=^&\ܹ~d iڪw~ Wz7t/礛v-p.uVZ~'sË0܄I\wmf. B0gQP( !BBP(e BP"Lp?-]( $ᶙn].]( ܎2܅BP( p B0D(](  wP( Cv B0$(](  wP( C2܅BP( p B0D(](  (_~~QGunmBP(&eOv{wkʔ)/~2BPT|iu[neV[u{GwK3[ouO|WFBP(LpO?ަķbn=l{wvus\~ۮԧ>> BJc7>lcu' 7ܰmH!mڳ` {=BP(&^x_qf_z饑yK>gd|o~~]pݧ?nvjF{W3 +]zO?ݝzm {8{׿]kwկMt<3KZP(>hlI4}?|tAݟa4?z~뮻;[0?:oy;v_p J/CSC9dΤggyf4qΐ4yVyTdUb泯| _V_}? /lSGqD/~;cf3-Ǐ ,mjv]tQ{o~ӭj2؀ [ni{f 6۬ܙ).A뤓N}6~=䓻?+/׾tzkK![noO?9묳>Ũ{a֝wy#F@l0ӡCB?y͠{Mpgƒ=۳΃O8%\onumzMa^{[o|d~sifHgV.k4țn[~CD֞V HSNiҩlo?񏻫5,RES4CmR|5\*Ȭ@> K.^##Hk 6XmkPUj袋-{j|3P1<:twuW}ͪm6d7hfl]x'~WҌGyg6>鷛o[qdWYevg? g-Rݷ?n|zf/WZi5XLґM~MFVB_?魵Zp [-SAE l{e+kvA'í5k g җ*=o FRCQp;S\* >+MAWs 7E)!zzi@EUzmy4í,ҭ! ϏJӈׇB['_w8S¼FhUWmAd,vC=F?OZ7Z55Xh1~[d8elOw#folߎntcgTKё0p`27M-MGiS^l\|ōOǀd~7c$eh!{vhn4눮kuhȎ!Y]gI/<|_ny6W[NeT4#\p14-g띚Vn4G83аUt4\pփFPnو[ct4p5> ٔUGY=z H]aT깢Ay3ë'k!h =3YVqMʟ~ yM 3DӘ54H71 68=3=Cf NNi;^K#;Gff{ᡓ?3ÈpyeT,Y%nn~VTn=N:=eFET(\* h<w7xEt2c$íp3pf^׵Fһ]h2FFf1z\pn=gMxAk)i?#Ba^Bf?f2!)6=[M\?x -w*H;Cx[8wi$>#.]3j܅4H^1 !s z_8%oܼ]!NMzÆp3ޙ!mM;Y#al432pgUf,6{0v M^/Tz6LdW f4u0T&Aej*)Ǫmڜת~lfZq'051ܮᄏ!}C.2mL\Z:6[o_Zd`-:oJT͍^V^ l#Dm"Ў芉D, 1n)ێG#Eψ9S5FR:6r+b1iw.ɘ2>NpZy`Llam4'jҤǘ{i3h3~Em`h1H]ֺTF602jg)i'pXha ;hGi }+XH:a< yp3#lMf2 %?6o}z63dwk֗a9‰#]ui#Qk֊m1*6Z^|śaψTsp31܌tS^: %bZ#n]` 7Zt~{ +mvoFז  AU> gLgrC0Qթ7ӧ T::r gl4D3 H@{ i;ɭIzb5ѳ bLݍe$ɄXfP1BCӘ4laM?k0ix֪#8#S[)+&3#dZ1q^7Jga73q-?q2eJ!^{`no{gI ${Y w wIEG>)5h :h|m#f 9`F߳ҙDmQ6H c']N7W0ڤ ?3k7pCE񹩶g搾bCtHQ#u?Ѥݵ{ o)prMًypåR2zF qQT8&3 !#r3*'fT̈^׫DKRfM{wWU$EA;XAF >gJ aGF:3y8mc ڔtq0zכ7oz8SO8@&@'F'Eh¼mB;ba;|7 2 e9mc(Ɲ " 4@{qV矑rKht=ͤzz1f >ޞġ˜WaP{%xab4)W`SE*#2i*%c34F*ѷgWF._;eu4.i_ ;7]z3Z0Sl4h3#,~^cqy_ckm J1iqV?x[ =+5v'y-Etݣ3n:>CNm!]: :W t,ݤ1=>OBX{enz,S4Yоѐ<Ӂڸpg@C30K rg71,ʤh$*';=^ٻi(A/Wc̟s=BCčGӚen]hH׎qcoz^6ݑq0/qZNqftn#-dIOq7 L9a|c0]9if/i݇ k]tOŒ]m`=)ꍊcm*I8YPsl*[Oִv*@ÎuL;Ih2Mߙ֫5BP?&da5ܠG3 n7L0+f;zLna72gt{jxn2d]qOaWP(M016 vF6x'^6eCCϰCA7BOsM41l! M`@:+}2,eЛhMnlRf}mn0mz%<35vDfwS (IK6J8Yc7g5̗[R9C30kҎI|`4dm,8F Lc hX(rmHhȡ,S+gG.Ba^fD\b}me6Y *$V{Il =cjә d(JW=dk;v;9;nHXҩF j|Ӄ:ã) 6!s4F8=\JxjP4x< O 9NgT6Ł^-㫓ݙAg1\klF:yШmpfw~ӧ`/(^vui0;UL˛OG)}Dhj`p˷ BA.Ks i xyn?)v})vLaF:tO|a Op ;ӵg~WGж頼k zFFm2Ҭwq2\*TvMKg;DCԠ`w{gx 0>a`)w=iߐay@QHg)vS Gy aiĪ 0|:V@ը3j7:،4k;Fڵ8F`M$9oxGG. L$caCn, tykXUpҔ0#g.2*d f o01>8L9omSCexO[ fʛbyȢ.Հ}n(h\ ]jJA7[wYkej'c-#iٔS( ٬xf9^W7OQ :MU/̋`a֗5mڠ΂ix$ 4uB seG@ǀhi .wk$*y.3y3{hz#7#j:k_P?c3aq7]kNj36uZ@5t7k<1ns?gZΈ(cPoHZ]XbqntM0g B_7-tADaOz'?tKœc䘃W(2ovd[#0ex2FFզʌ~M]^M3~5h[rzFpGpI`mz[#Ǘ3ĥ7V{k^f;6- Ύlo5װiB1f_|6B) 3vF +?A+݃u;3-M3U0FOns0r`fGn6;]jt50ŤdcBȚ8AO\'YO5?ċw!kcm_dR( #֗H1BP(L&&du u#SikP( spObM[  B0(=XsS B07 `&BP(. Ba3 Lp B07F܅BP( p B0D(](  wP(a㓝1,~rh@qnpgY =4+1c&>g+?)r/A-p?s#>oCa7nq8^k?'^i79.. 9?Ys5`h õf57}s饗f>fW_}f^5~(n&poQ1/uoΗchhȿfv,_OHZx?=«;2f'KG>b@?vp)SQ?Ju]q!  3p Q5Ɉ~hK\DB5B}wfh1߿t[\pw衇6hKMoj_j252g &xk{}Í_07 cV[}?Q0&83~EpeRp +5ry3 pwѵ=w#W^yڈ[A]tіYYye Bae<д5X=m2˴`#Jl6υu5˸1F guEiSFF iS匂΃܍lu,_̀Y3F`dЇ}kmV~6ad e`ŗF:*K.ַN3܌;}kdnV;Qq fEfܚkɍ~Ƈ5je̬o3Oo#IFQ90*6ڵl}Z|qFigQGtj#f4ZowidHǨZ:p}MuwFh,L3Ԧ3I2#'Z7Un.;;j]( s1f4;ӾsTCb^&q $`Ny8 nBP?Lېf=s<7-nzrSp}E,.i#OͼF)l4L[K¼ nke Bab3ܺ/#3)k6LYu]گ O|eOl̲~ \֜m^f6=[_ɋ>... p Ov}&0&9 .qhا[vW۸e$Y>cm \ )rХet-aҴ0o wP(aXf4G)ln~vl|!+bS|.)s'"7].I'qL)-O8#< &l Ba0N)tgNk Z5kMܨѡY3cE}J[AO'\|ϰ Ï2܅B0/p B0D(]( aB&2܅BP(Lp B0D(](  wP( C{B+]( a†NN+ BaPP( !BBP(e BP"Lp;P( wP( C2܅BP( p B0D(](  wP( C2܅BP( p B0D(](  wP( C2܅BP( p B0D(](  wP( C2܅BP( p B0D(](  wP( C2܅BP( p B0D(](  wP( C 'x wP( w3G BPxQP( !BBP(e BP". BaPP( !. BaP{8ӻ;omo^z饑C]uUW_}{׿馛3<˺z.K/^xӟݤooݍ7}쮻}s/ ܅2s=-k1͠1t_| (d?2?`0.LZ{ۺE\rIwGwzk|8r?6hf/n뭷nt?5 ;xWU 7t;cwmuzho| BaBq .hc鮹w}/~n 7lj{fu=P^{uoZX{i!o?tuGudl,.Op g ]iۊ+w_׺+fm7xk._{P(.0ܵ9m[{G[nc0]guڳfeYa_-r-}ZkFp7CN~3hu 6~p} K/ݦn6eθR6` yCO~Mao /vvXMtկ~řthA0JS wᖯG}=ymP( spփMc:zYgզUVY+[r%56̸3kop3›J7Zw_s5#hv#߿̍ʭO6W]u~ni{cP(>L`6je]^A4lz|}{#lƙA;_b>566 /ǶO{m˰Zg(Y[Vzy]w5wqS种޾馛ĽP( spAdɨ[36r(hߦ|{q4x_A϶x`F7= LI Iv BaCԈN/u?OF|f/tFV( ye BP"-](  wP( C n뫅BP(&e BP". BaPP( !GWS؆۷e BP<. BaPP( !p B0$(]( aB۟p B0y(](  wP( C2܅BP( p B0D^ wP( q B0D(]( aBV( vi׿.9Q/K{t?q衇v- ܏2Ľۭnn~_4x{;H;N6xgZ￿mF\Gy[guo{级~c9-..}x_ݷ|wt?񏻋/?6nQ.x]wuw}wzP(~'f:ay睛rl;6N;una7Iv#:5-w}ͨn '5H/ZEb7oS{lKs9r||K_vۖ[u B0c†p3 W?isvuf؍`t¯6>餓;o-ƷFolϦ7xn86KZ::K/tBlڨN9` Z믿~py6jgȍ[o.?\( eg#+nk>;SM7ݴM3 5|ckֱ]gyf_wu'lk}|h1_f\s6`@/ 6p8m]<0F:w}OBP3zf0M+3_vkV[k5XV#Xpw{w[>sZ7c5o6je\ԭ]3ѿ袋E]M3Fp'vrSST3Fc⹙27x\r% BaFǀm][G#bֹd Qc0vxV7%mӘ#<US򦰍oF /:ꨖ /T `nanvǷ#G}~מT|q" {|>3~ {w~{+W/5P㏷v{= ]eM.܆2cn6dn=hfmc9)Jo4?Y1&נvX3*Qӝ}#_thꪍW^tPhs4C+'p#p ?׽k8 \pAK6>MTnxi#.~'>.W GydF+n_VG~6vm[nint[Vww[ou0aBۈo~37K/)phhjdLo_ #43``[Gb=|lZ믿{k^3],bfԢh7Q(ˆBbntwn ꫯnF=P})Hr02ߝyM A:<1FW]uUww7Οw]vYSI~S~ǖTQ٨g[mU//^3i|oxx[K +uԱ/_5Z[6ENNջN:SE&}oa׻5m_GK~uTxG+'0mɓsFf?M N seǀK 12HF9R5xf&%hDMS.{W{6Z_hx(k!* #sifN1(|#24|Έ%GSa6R ZPd6:CA190(ANSa>(w]_H}f4Q<2 Q0:oO OG6)3 ,gqM}d !@VX9ƞtn@=w묳[o;t~x[935)St{G10 Ba8Q{ \|m cm*?vi6*O?t1駟}Xc&qK_ji0\y啛Q>OeYnoHL۟tIW\: `z/:BPVLme|6Cm 7} 7t<@wGFF1 7އیQfm=#>)^{ǛN? ){5c ,#r3FBPwP{ XCԧ>voFm$lT ָvnuik6]wumd䍼Pσ0` ]FXaǠKg=6F6YG[.]]:kP(-\;¹IjnpkKxFf#L/BP( /p B0D(]( hBP(e BP". BaPP( !BBP(e BP". BaPP( !„ V. BaP Ba#O ~ᗙ߶,vm݋/8r@_~ D!$͘ȵ^ܾK/+?=/h~?|iiΗ$Gnj>4Z~q:yD:"xZ=ؽ Wm>+x饗o Wո%?fDpx {4zw/gol^v}[j._%\ʵD&c￿{G<~& tLGz?J&OR?2>=Wh˱O܏w?37߼; =.74.0wӖ(y 䔏e:eʔa me5J~j2ױ 1e+1 /o:rfH]O̜P1LĈ z)Ly?QmZ=PWAdBfkE=.O^(>+?1*oqe-mYbhc|Oe^Έ2 %Y*3&X|ji{ڀK9N;4ӆwq~pK>xfx|eD=ȂBGGýr˵zN.ڔ u]?ֱQE; #E~#Ն9~䓌ҡ+Le S15^1G>nP[F`H-M2(Mj^eꪫF!p3K4ĤGh`S7F?i|4Ϧ)iFF CO!Gb)X|JV>mmiyc]:3ɈŨ"`|]_>MfK(1 etEv)^ qe)ze,ɔe(QfЕ;Slk_ nи'z:DCYQ U9:90,청1,)k#5\@ψ Y)WiM⯎rJ-ȗ%?u1dʈ1S^ :jȃ 0Җi1p 9(^Y7ƌWd} ΦC/=lu- :(F*_F]C^_xW*] uUowѷ%Uxap}O:>Sq$&4p&44Є M MdD&("$(E (^w)XٿNs1{ժ5YsVժ3 5Ccd l^66yau4po3n4Έ,7c)4HGhv qh>Y3/ Aмֵ5fW ~ulJ䤌pu,mA\t8[0d9׫]j brʂ*nm9.yK8t, p όs̎n: \F ܂vӮ 2 l]pVf@ gL^t!m+YBB 3sُx4/AWtɲ>^]# *p3"wk^sֈl(/p* fb&`[-z'n|_]q~AP[LWKؾU(;=jm@frɭ=vB_uYN6kM6{>rioꘁ]~ئ~͈*p%pK㻴uV}an C_V7-Ԧڻ>?~(fJ C-鰜H2*l4lfpd: '0FP.{ˎ0ǒ#ũ3~gmk ЙsH88\0$ 9 nF@*BoMCڭ`AI=s&+t)[z5X6hh/Ӄ q(Ǚ!l99ps@M?-'>LnMوn:O z3S B @ u`Up= A9 ؕy4zNq\%#^ 6FU Tj7c`͔!#Y>?COCЃr>6J`deٌR?&#SP سlRe]Г`荾X0_lk[t138gMfS+;ԅ?z:$` [5Ό/^VvG>Ȫ>`ulf& =b{h"IEfF+ P>^`gfwA0:{fm[[c;~ iGmAfl3ؽ6!ct{M;i 9CS2eÜM 臽e )e67i&S ;"m(ٵ~B|d\e;x:K?$k {K(3lVYڼ܆90s1b;h.b0,@Y:,4 Տ?dym,qY:V9nKf$*X,6/ϣi Rc6oQ%jKX^ʜA!WAȬiq_P?ȿ|b` 6.,fYHBiV}7;~,ifh>Ll ˝ڹͼ dN>ѐ)c(}3ج\6 ٴcFGPܪ3fGMD6ZN!]{nUKns~k6KٌW=eWwf%cшnV|̀WEw:7lƦ`3>VnF/;VlFd@6ً2LVܯVvy2ydN[_~MW3ӷOul :! /.;f5 sՎǎro1]xthxnhvdpcC_fڜp›ß:~%h#ogII3( Nb34po#%iAbI̫=G*sx#Oxup-x뱎epp0 5*e&HxhYs2鈣r #( ͌KTNZ7=Z™{86 ÎTt$4[L<6XWdL <ߋ?LttD^*pp-t *ẁsit]ph͹{tGY_ |Ёsǃ@E@TUV]d$yWk/B |viKceʠɖc{1Է]l ܂Աu\UΟC 8 pVAgp^FA99a #g̮9OV0ٻUzҏF~ni&- zf`v1+^?[Te|ҽ^xB^R|X Qfw_28 >)xʢYsQX~2tF%>,O5[ҹm9p03gǹ~i4 02/2Ѧ(<`d~ D %^y/!?h7 2~viw4poNL 8S9unٌ1 3#͠z87@ FNS 'KdffN򜼠w\@ 1pg$@pdY9q5o &~fv?=̳L{qcOȈƮ]F9:<mr6/AB@ @(ۀ*|гMW'nmtk+zrnjج߂ځwx ] f\l>ؠ6BgKd؈P 1ẌgEHl`%ЦFn_'+RPK.;ȯO˧, !6xEm94X=}̟n!ytooVM4՟6r [ݸXhsLl9 :1cQ f'79<߬$۲ϏtlN\P 8{}Ai{5Yzk敩s}䜆`际z9oNAk^D&,@pfD3̇R83LKs8` cYmfxso܊yXѕEO9*EWҎffxנE΁[ >m_ֱځ'=v`VptAs\ ޜ=mࡍ-Gkhpc8.2jK@*;T,1WrKOv-(+2'O`?;liK/%2 t;9ٶ?CJ p ##Qn hC]Cۥ%{5[ lŻ: >؎vO߳#Kfub^) ܛlkQeA|#X :t@䚼fqfʲZ`?3'@=fEԸcOdz mTٓQ2(6 9WufX3(HP:!=~A~3<^+ppxn ;4.Z{%Nt91CS:~L  oবLtguh= A2GolY& (е|x`~{K;ݡzw0W K (gMᏞ=ʠTyA_wDR; EQEFh.(5BwQEQ(b(8rh.(5=rwQEQt4pEQ(( EQEFvc A^N1tGوžz 烉ftV_W,QGvePi=4pV|[g}f||[8_3*|Q1g?}m! _š]vI9|p`>n<^l*ϠL_iw+U3%}|tزOLb0u0!wykT C1@XESa_Ol[y*R,/i A',2 aTjM|>a/wLFjrݾޛϗl||+%7G?/e7Mz!&>"t4OC.; PXɱ:8#̧_h!'́N~;gX]|&7S'r7[StOFLe |L|Ε=ƀ|>kȢ=WQ s ҾRO=r' $9^;lO2OAҍ?^%]߫+oDr7}/@8N?/D;2:}/y ' y p# PNop_t9A d`7gwAS}ae(nu[ ]҃z f{'uvHwhj|W|̷c`£'uM__K?ו |N>A#~Qgz]3o:I?֖M\*YGvԋ__KO{iv~o4po׺ֵ."@}[;˷\c#ꘃ ۸mo;t_'8^ld >`*mxS]a ~ MVt&!}lU!w CgO|G>g p]m(d%@ 3Qr|3j.=uPmh6"e{MOt7>o ġm` .SS [ĥ.uȮ# #a(IvykN¸t+ g5//ıv3pZ6E4t}]ot?~A1Cӑ19Be4FQq sdbƹaڠCys,:#sXfhs9OtEO@9c3{3 fdH/ !(}ʹ7z9avE6SN_y3 4VR~7Y+( &Lׯzիy'XUl͙a-Gނ.JSǥ/}1p25/AfMxSw I'4zlA@:Q_Hvņvvk_{S4W)c<({mgH~"D+] 2vaO-mVSYp6!mdʙreaQ2P8J3EѶ| rA<#f#08c:0Hsc/ XӉeQry|VHr4gXDN椭lkdٱ!|-E', nv=;jfwy  ] ,fpڀʳ%q p }mٳ^hXҝ-#Tt3nG I  h7] #}dƪO@/Dw (i 9l]]GGп95[c;[?4m(&f7 8D|hjKfI`hpwtU,W:@ j1s:-sv:1cFq+x}43tN ,pF:@^q$n<nKptJ S/3 ن[`p9}RS4 G8sKgp U3n #΄Cg@Hz*K#@hGpHU2#@hΗ,%~t~|pټA 8˹qp3> p ̂r63c:m)=cPľ8o|Ud-3?`TK_!@d`" f 9 ҷMẀS_bY5#?-a[v%h}ݻ&Yn bawAA tNt^8v6A{ѣ_6fnȩ *gt|HTk p.G` eـkB7ڎnf@^{Jɦ678W1f;h"80 >G(' h'{7 hGc$. <3"E1{p̈tr}·cF[G!pX{mpxGyg @pBt53%?g\pqҁ*8~;yWN޳\YKr0xǃz9[F.1t(cCC7Bd N؎ ,ߒ?=jj橍1pb#ح4MA{<28fٓ-`NW7t=~B/)PmЯ:UvBoiofS??ouٰz!~leɒU)etomt-}/ tb@> J{l_=0@Ļ) [ @+DC]SǼ8uMw-}KyR/t&gՠ-`v(W]O߭ 4nDwUg˻FX!7C>z_/i_{Ys9 ].;Ӓo> -77*}Vi|X%U|̌ԹwU 竮L{rUu8_eވFPv#U򭢱Q}žmq([UъmL5Z>XFel/3,:2&%[Hz=X#FˡND;Fˬܗr;mZr NWn_\cj4pom@6 ?6$'ޕ<ہ{iy٦cC p^Mu-?ҳ]O{sN{㹷wA>pv 0q{kFADM_O=eݗnptO lbWpw2y ٣_n^`O&88h6dOpf'@H[(d3qѧszu]>G,xkJa><4e̐.lVQ%pλU`rMC+5!Άn}Qٸ@f+?G ԡ-]׽u }j @ģ1ڕlC?d-fa۳rkP20#d(<(z^iE*#Ljְ+}~؂pv_W-;9EeN슧{|cě-/v =8hq,oFy+I׶uvn|+HVC_y o|Cthkҙ:#~m#iox+]vYlٻɅVF=(K/Ϟl<B8i;5a]reF;:O`' &w)9;|]flşA>i6J{"Kv@ Oh3C@Td9nmDVw\.؇c뗻\)t7Ї 68>,=һ/|n1ö{NjvsLي4aU[M? ȋG&18(N3fK^Qg p 2z֙u 7= \8Ga!lـnF4NI~UvݨЁ@L-gZĿϘ7GCv<ӫIn Ny>ƿ@p/u/wY lرE! Jf6 e,޲^M>\׶xdڇ UuKZ5W߬-~-k:ӯ1e !ve%Pŷm>A]>2r&t>_`=sj& F={fY0|NJcЖtJAXǓ.+ M 8#X"oTB?gyfF݂E*g%]YK9|(9/͉hq$NlaǢr<y\A B\- w'궁r<!iO>Ǐrtg!I<]LC@nMphNhKf,#nLn .433UlK`7d'AVd59:Yx6JA&k[`0  9fȒelvɳ#yPLaKC ' :~[3_̯%|QPaS30~tf0 QZ)ax$T>ACuҭJ_VG~~.m2i*A)> Ɋw!vGF1'|l,=yK6#bdN{ 963s򵍐|[Ϳ](ݍ*~a&[ɳTeDž*[9Tt&Vy AAG+ 0l 3(¬*[E4ptсulAQ$n GQ~cvOwnܟPq׽f#_Yj;|v "?Ȧ!8ذo wi#mVWf羬{ڰ/=_6SrHܡy2 Imjs_z#ؚf_vo6p=ܿ'}ꍀGy|V`ơXw_[͵`g_m:fe{v?/q+fV{Ex;`?vlLvuu*yD{׮ZUAHD4l^.t(>h7ճe>bNkVOWq%:ْϣt&`'q$"Zʓ&2PNI=_k'SD:` /~2dqF-Ѱ%#|d ?: :']{zMNA3$ɧs^:<璥K]{nC3ܔtjz␳LGsQ sNoxpO% gySL"Е2Zx{KCnz8RMx_mvk\c ]Y _32HsNWֲ/8pN, Y^y H >x5cCkpDves:%K[v2rЩY8[0C̋Wf5AU6'O z̦/?{ٵA>ϻ]O=ZE`Tyu _6;I6+}3n%Sū4 ^OhF<Ә0H12 b2-1|38}a{=#7Q* #p`f+87P1*&@B>N% 6g"d&!Pѧ1ǔAD'6y;t8 @ l6Erv 8.Zӱ67`Ƽ?pԃ''[Q,9f :c(%et+8Y330rb&p1D#[3n\5Όb/n[&4,W F8@y7/CC ̀ h;R>#yV\ TeԜnn6f`cp@~3EtԧPs8я@tfK<3!RtbfL,r4F-mefKnvD3WK&sA6`M}Nhҭtl ҁ6I[q33.=7X>M޴ Ey8(бY4dѳLy>FD1~bȮfeoգW[`ef:7mȯ Jmw?[ @ˁ[ ;n6Ƈy[-)mo"ߠ~?O߬hcmľ.eS`ni-; -@#Ec2aT9*MSVpfa4iFI4'o&`o Z>T=q?3ԀsDo$l]5`8̾@=]hl=ǩkp'@Afxk9Y+ 3Sf+m#[N@yձ\t`F($:DWxF"țvYF:6kv] ;OZn㙍Q ˝MZp6m̘eK&)FlZrJy 6ª@ڲLlƚaUQfz6*zl&2MOK怆 u[ !C'<  {/G|3lv w5腟O{=tc֤9ȟ[HU`MI6:Dî~v_rӠ}@;\t2КO؈E$%e2yBK9i9OήkB{ot=U䚑庼hp8tht =!y]:`ǧvڌdG\0c3pݮ`N2H.Iy[f`Nvx<]<ᑖ50;=O,NRq6S0pUnd/K^ :pvF/esdrt!3R(gH73aQwS=;jnd5sy.B? xY!E;;tM[y[v<- :lW0كն6npǯԳQrChnl/ޙ ܛ~F0$p먜G3G#qC528t%98sB3 Q E݂@z됙qsˁlD 4L18\8O&uj C9+9'gE/H׀AE^1C964U%rږ,u͈9\7P&K֐M]rhA?YQжƦ>|iICrlEy ! T@ . VFVщ6V 4:7O`1! Jbv.e $Y\oO lcV~qofbҏ'y۠`bpy) Ϡ@ _ Km ` m% ˠB?jt@ .ml0ņ? Q؊*pW$KƏhS1;gElM?GG&Бt'~'.0[K!81#_.Mln_np s:\:XfpFCI#/q-npB 5:!~q 9 p̂'` 3+9|q',afm,,]902T.hZ gp.x"8<9Pzɣm~5|qx@OpAkֿH>=ҥ AGwD@Auz$$;1а)pʲU,gC;\qy8 ˭sKzm6e7l?am~ v0X4o'}NM;;崓fٝèЃ7"hj;IG;}ƠE?gQi 2>K/ON/7+ʋX``f[NOqTo3helM;́Ëvvd~ә&m6M`n2-M31 fD'rq'h*@c  FlFn˹ Aov+ JԯS'a; 1M]g cEvNn6X,EJL002y3ؓ!1å胣ováf ,>776Ķ t@6Bf_dǭ ~E?d̤3'dDlW 4 !"P؃A \ ic3n>C_g C&\-kqYfͦKGЁtjh`\pF/Ыv,f6k<$HU[D'x@x:jKC[S==8Rz)AY|h,B2|KRҏc[y3=G.\te@y6.ʩmx] ?ܖ7=g}~ߧ,~c/RW1860siO]ډ.ҟM_;]WSu#<-#2Я˶TwqhVuX`fsLb3pF2R~;8vLSGc[ D̈́80Pk8(Р{0YVU6JmY:Ff߸X< Ys `^[KGwԲ|~ w/qgh@nS%jw_rvQͭq{#p6ص@y@^ 6/t(]ÁL'pžf)ob@V)7 n6@aF3o;] hվQ6,3=XU}\oU>ZF?m(' /@MbΟtb}iejj #vAېf6'Qm ]%C<.徵tAЎ[`:6{h Z[icծNήrҖ<y~WnO0:=g@Tm1;[ѝaWݭv fv (fP`X(l0\fg:~l۳ǏGU]v`G>MK=Qz m74sng9]{LG06!]}FQ &v҉]`xrj~=e~+%MMg~gn|/4( [٤`)'Nπzn%bxSh|9p;R#7HK]R^W^`yA; -l_' f ܂ B4W/$C'3^ټ,uӿl@Ww:bjYɽ=<(ѹU>yQ; Yy׸Yn^Ùw@%pf[`ə 8u]n nY-9˙^;Ƌs.CΆ2x: -4͡%4[65[31<-[~uM8C@tm»mJF3XGxKV2%KeS̘|h0eBc^u10t >g)=sKMRY Mfژg/_LaЁ_"%{mHG 5hSV~  bȥ>3t6@w(}  Kf >9ebi񘽹n( fܥLfseє70SU?/CCg` #SɽzPkT󑒭kTq,ۇW,Jd8P>䘑lֱ z{чF& ]]MXJloߓOl:يȳU +F}eK2Sjڪ8_$WgK'>_Ӣ_zrǧe r6p>z}٧y}Ip'C[ 3S1|n3ЙOn>o-7w[j|ҷ}k;ll׿f;νiw?4# |R޶C$& (JT:.rlq4f2x}^7!iy&|TZ: h<sڬQ'}g}'5Oeg\]|ql#ӟH:k`E'AvOe(4a霜]'e*mFWk_gFL=2/~Cz׻Fݾl,B~C/O<״摶jpB?{1$3(c jO}j(CPFծv!]f9w>_Jfilp!}3yC;IuvIf|+ 0Ҟo⃭'Zg~ȪyԯPP&߀9<7]lA=󪟼ΣCy8zz& ]w}ZV~ )ݡvk੯+he]otɎ֖ibs4po▷0k^{3HA׸ⱏ}wo}3;OKwƌ3SNgw/ %ljdgy8>Y8G=j|NTg}7`sYnw׾G=L:8=N7<) +g*MƋM]Y7 FOw]}N;m V˿71ެ+v3Ե-O=ݚxr)cy\gm6"sڂl.ow ۡ3ћsŇ>%t 7Af50!DAUs@8;9 :Y|9NtVF7u]Wc΃#0]è#S\ gpkY@ ^fA6JY՛@Y&(]x#8Wz|&ıs ^xdF]DGAƕtHPƀg^צv)@3@p=9~_m # z2%kY&&/YɄwm!k@h7򑛭V @4[*t)[ [;C]??w fV;  ]Uſ^׾{(+_㿶=9X >btel(lBt49ɨO,ĘMĂK>:FD(+@džg8[_Dsٴ~V$^}`T@IGn7lJ{E"WVBi{_Mp2.6t k:a0 kbs4poml3 fdiik* H3sDH,,Y288g"<,1A:z#~#p(xeYN43J3ppq]ooY3NΌgpt)O^Nn%320=e l#4;m/AL0n 23?S[D+ #=̼p*$p=$hqژ ܖD9xmmn3de9oN\z?} << rjG2etiH?A5(0O+\=͂GT;%vaofQ0LP.*%Ǵ#ɶ$;fʇ_mpcR[[+z~A=`@fpУpO|Hl;Q}HnM&>l8WQvbfhk2ZISެ ܛ`9p/ϸ30*5JI ֜GɹAZ~cXY8 8Ns2WKJe/7O~YP6nW]|TQ@\pYf03 AӲgá3ˮ3ȞO9c thmg'Ft.9BA flGB ؚ6&{V FlS?d;A~u,o25xx 6Oh،I.Nw 3'_l@7h%>Gvm<[FSd\ڊ^=-bc4po#̐8z# \Q'#Q!ơp@Ɖ 8HIP:%wix̸|^-n6 A@όଲD:?zD$+yo}QP yr ~r 3lzmAnǴ4`hÖ Ȍ70Ktk`m@#x;Ÿ,7%bkVfZ>8魀j4ElWp4۔*HPi{ F&pV!cEQf~V'rHJDQw(4`yY f lU^%,sthe΂X4h@}|O,)#?ώa2ph^6ѥh|6^ԧ5ߐ Yb1IDATK4:u*c[An2ogLnbiYwE) :`WFY`i $)4ɰJ '+>3R]64-FBCm)_%E/Ztz`Gߑȏ_vHK_)eA slS=zb[Vvq۵L;6A[ُBDi=C}_y՗U6D uo^ȖӹY՟|4mlE?/T&*#/9><%>F;/316"5;`t/)`3#f3v@]{ch|t]6pFxă͉5*W9@>qv[-jwG7(ݯo7<52RZгc7MXjśو:Kfdo;ya>4l sm_褜 Bn:#G E1T/h\.G*v2fNFұ[WUFSYbS0 ,,O:cSVg넞% "7RPթ`#6"_8gPƉ/㍑  2@#ny ̂GiigBWKe!2lQd&HAN^v%P%~ct5C?dE#/蚝>rxpAwh옝w+&3?0b# =Ȧƞ'(Jg`m75M{8V/<=طt46R=dblI b@Ɔ ,Yltt:38FҬ[0ё,]3f]#v0qx:<:p!A[邍 qA7ӽgY93 Y Gm6.Pىql:tV@ܽ!8_xN$8TP'PDQA] L:Y98k+8 xG:W@8TZW^uo_@r@.!R=:ZY9!vN^яbw| arE0mi쇼KFOsm*} ]szն}/h^A 8 N߬1orPt/0SБ9 BF̩1tqkyާ.X㴌xNFל瀦r[C p6l@>C 9-ɮ ^9I<xГ:ufә9^e9'$ШCk<h NP۠Cp9t:g 9Y(gDV dPvkG03oC>[ծ Ș Upݱ 0لNd9=&yL lq3U*@ z/r!|ڒ>bst_N9AY.Э^ ,i+GeYW@/h " E0KVib>,]ɇW2Х }G}چ~:a;XEP^eSexC M Ioӧ >\Q~h F[jo .m2H,mnX qRBA';S MzBgYU׵evXUnN3l-rPr9/oBǁͺano32c[ H>`4)85YuFffHQšmkw\n.((X#4pEQaہ(( (b p{sw\n.((X#4pEQ(( EQEFVJ(8rh||w;;}P;}٩(({tosul: <><EQM`j>雽Uf { _җƷ}w}w.4ߪ}h߶-[}˹o({SyEQ7xŝt{mA׽u78{wڵ78Ƿ}tw?O :o|zc;>pw,-7|[q'uI+(=[~-/l?||'Z>Fඔ~w]:UrtyͰzիYg-nwۍ n 3Xz59f?IOZ<ߖ,n{./.ߢ(C&Dm Ҷ-s,SO{Qz7XF55w/nvr-9y _'0Cmo{_|#A{ދ?ԙCQEql{X>SvO}׿_]tI#pw>ރ+?n\3_=(Ȣ{-x#}k'|q8~>??A((w~,ofWjqm=o#OE/zўz߿]8s@(8h>0??f֧rW{Їw,P//| }F/eq/}iREQy4pf_W|+LjW~Fԧ>uwI\ҕ4%lqiԭN}EQ@a869G/g,n}[e,˿sqPƞB[xYvȥu]E}~'?cV^٬qOCwXsX_a7q'o6Y\xw5/^5yTKVwc,/mۮ\Eq}!X~#9ft&x%/_WX=G>xЃ4:zx&7ig|Y7H݌OO#m;Ҙ7cXzqgv/~q(@} f؏zԣFξo.'.p͸t;-w\ |+/ԧ.XW|ӟ@@o1۷T+xFYÀó#?ۿs耶08{ӛ4nm-3?s`3g6[cf f/^-~ww*\Eq(}/b,_X7]f^t]z`6c?cc/H , *@"׿>-nqcŇ?}W]^e`g4WWN:i}Go^,m]qg}ꐋlF@/8hO-{nyy90x}+&7 A^R瞻8?#?2~ ^b| }[Vc) oxx+f[>@]l7x N  G?q[,}{1~[:^'*}EQNl+p[mנ>vܗַ'[*eX>6{s/Ҷ b # ?s?7=[^5 {h'h `vYgߖ,Y0q[p6)gY`| _#MyGoou@;o@EQ 4poY%O|{R {fo l n0-o ,-l&ٵ=F6e104;s?]p˽]!s[~\*c#e{t-Q.Go3]͒$8adʻO:+ (osu  ]EQ]h" 6Ktw#=j Af7ٸ6: af1]ƒq7X^L?}LY6&A ֻoo͊_uқs2Y5.0p a]7ٞUw{zkMgЗ]ڂr X\ +˽#~گ'0#! ׽nmoD]W%L&]}ˇ(hC&06oZ굔;C\_![]3ʛږw?+g* ؖ6ә EQz{Ȗq3` wymÕ{6ӵm}&t/?v7g6)'kXoךwkYte<[nA lSEQ'7 <9 K6@ٱl@m'omӟY U:>i3:]3sm|>60P@=kuk@෤oE*^.(|q{7m[-O `lS jÚUvC{\F󙂼ߖmN[uL3_EQ[VණXǽ Q[v_9Kfvqg8PzxAI6wlL3(E=7EQEtn=_=7xӝ6o3iүqknܧ7(Mx4SYL;m~w5=c^޴nnmgMdcv7EQ[A6 {1$]9=k,ۜ||(8!v4po}-}{Ҹ۽}PEQ.4po?w_}h(8Th[3^~g=Wܯv{ * axR(bģ]??ҕ4q>?KmoË]z{ζ˰'1]/Xc4por]߿8JeG7y%slz9ˬ^}+L-cvoIC׼5#(v{9Mvҽ2(X/ K:w+Z׺֘I tmS 10zǻ ^peuYM u Ʀ/ ?~n/nAχKprܘMܦ/n8ϧDp]nif3OEQG;Ƚ\9^{ vu*k{zֳ,ߌ9\}jB]U;ǬlK_,_ǯʯHQE>h^) R&7Xz,]%s/Ś ꂷWzү|+nI'4.Z^bYl\-[ o8>Fb\xγVSO  b( K~p `׹u~hjs}lIf>8bv;osW[{YYeq=|/fU{UO-kD0/| cmx+ƽ˿ @( ܛ@>W>- oh ͣcK_0 .s*.nٹ;}ӟޛW7-nF7ac } @IF6^>(XtW@u\QE3!pۘ;.7pEQNG`X '9]s$2[L((M>׏~SO=u<}3S[~8&UoO xkɬ(`[ۮc-pS]㞕;Ƚ̣b6yF3^&wqQ13O96Mkvیf₽Cԕߎ4rs~7 O5>Q(X4poGfn. t|x#{/\p0x\>]xCHY 6(b} ]F`5K춷9>\|_w6/hܻs;%.1{;ewA}xQw{y{xũ(/ٶQH1S/v10(( ܛ`Ռg5F3/HbU0T[R稽dOͰo,nq[f^*'p?qyr<,'< #H{5פevn`ZU|_4CKXxƼ(X?4pon΂#=Wh@i,}{XB8gq{mwk,{Jf 2 #ފfFmi^],zk^굧pu{g?(M x>O̬7,mv앧~sZdPͬWmSa}<޼Wo{E%pqڮ>#8ےύUgVos]QE~h>JྶG,[6YaEQ}X s:f76Yjo;EQ{ XǙ+Gsnܱ|m8P](QEQGϱkTZv6z*x۷gBvOyg0Uٌv @= e܏3[6|a{^x-_@;5+8 ,Ixfۮr3U<E&kAo|D&M|3hh;S6.e0X(oO3k\#^j~l/mv3|)2x0 z\yV b3^򂮷YvM zN FˠY~j^@.ڳV,9clMXl37)8 g^f٪ٟ, Lf)+pghfmFc %_#kO-O[,I Aa 羲mR@6h} lU6AT\4SW%l`M4 !K7>O3qKnBʃ@^ xnɞ - = Ȇ^Nd2X0ü;(h͗ ܫ@AexŨ $p5{f "etztn8.uګRLl(0^p3oxS2>ӂoV+-S%0;Qxy\{s3=~iYA/ 23z[]~c4ZX2ӏAetɀ&wQG;NkAȌ|̈́t\^s_ʚݚ.Ji,1\G}e-ї3B IYfvL3s'iB :p \vr3EQG#(bmRwQEQ9l+p]EQG EQEFh.(5 EQE&(8h.(5BwQEQUEQCwQEQn(b{ 1o~{=(p{xCoiOpu*ԧ>'gQEQz4po8_M3~|EQEq k]Z|+Z| _nNk.(+7}]n,[*-ox=mwn.(+7Aʿo,{/2 Ї(8hus=)g,ַ㓟+EQEqh <җt"_ƹ瞻xx0~;=W(Р(( EQEFh.(5BwQEQ(b]EQk(X#l+p_n.(#(X#4pEQ(( EQEFh.(5BwQEQ(b]EQk(X#4pEQ(( HQEQY4pEQ(( EQEFh.(5BwQEQ(b]EQk(X#4pEQ{^wQEQ (b]EQk(X#4pEQ(( EQEF?6pEQ:nwQEQ (b]EQk(X#HwQEQ (b]EQk(X#4pEQ(( EQEF(X4pEQ(( _((((b]]EQk(X#4pEQa;/5pEQĶf EQEqd!psk.(u@wQEQ)ZEQ'' EQEh.(5BwQEQ(bi EQEq]EQk{ˏ5pEQőŶwqEQőŶwߜVEQG EQEFu(X4pEQ(( EQEFh.(5BwQEQ(b]EQk(X#4pEQ(( EQEFh.(5BwQEQ(b]EQk(X#4pEQ(( EQEFh.(5BwQEQ(b]EQk(X#4pEQ(( EQEFh.(5??5pEQź(( EQEFh.(5BwQEQ(b]EQk(X#4pEQoN+(5BwQEQ(b[]EQG EQEFh.(5BwQEQ(b pm.(u(8wwQEQ (b]EQkm((,(b]EQk(X#[~sZwQEQY4pEQa;R^y?tH׾77o{ﱪi,UWՕGʯo_Wb+w Umcnc 9Vc9V8VeczZ%FNt5m^uf*9GoGȲwG>8 .qnxs9{s=w/z9:}{#p_rabC}?>8qqWw7q:ӎdv&;>.݇8-^?>}\b˻wWѣG=zC=na3}{7~_}o =zѣGzx>e@v[ѣG=zCe"" =zѣG#w?4.(((((b_p/zn}qc;MiGmN;j=9c s& }xd6az֣Ǒ8j=vQӎdv&{vr%cd,d.!2іߝuY%EQEQEQEq'Hw~Ǘ{wsWLݗH s}OEQEQEQEq|+_3Ǐ>7pҝna (((8v}oyv&Ϲӝrw>|;.(((up_b񳻏}.w^vnǥ:.(((up_f󻏟}x{Kp_E'EQEQEQ1L?v]EQEQEQ ]EQEQEQp8Vp,Zź@Q*bp4;2/^{߼x+^xx+_x;ޱxްxы^4_.=Ż^93>[Ņ^8mo/;,/| zի/yKF9וE]z/}(׼f׿~}?-oy=y^q=usySVWՋ#Ȩבt(uyC4N]/@!MY=tQ}{52FO?K#A_Mo:M8/ox.~~zt_r^^<ӳgy={ |4B^6==|~G[GwNidc|G/~s|E%->!7ϧ>FdAE=ҡxJyilO{i/5r|T]HwOxD9[~i?ȃ/2eU6Şwn@hw<-M^;gvĶ^OWC2񕜹t>TNoJ7]Ïlؓ|^hD.u8ƴ-]Ms:~: bhO|b}C]MY7A=Yk"r]it@E>~c<(GE+"J9%?}uidû://Џ}i qmS_C Mb/YNKG z@W}yԧȉe^]5|bvCuUF}iOuJO_3p]9:ci _A`sku:K[H ۢ ~̷FVВyس~).A7ԫNI\C]G'xT߬O+>ixÜPN?Q#w'?yqq;yw_]<1Y<_X]<Xosi-N?AC~{G?z?x}xԣxC2h|ⱏ}_ŽuqMz#9\Cih6{yC_nwr#]=zЃCnwNw({;as;qu׻uMerr^'_#zѕFV:Fur[@? m.鳞iDgёp\ʹș2lLO}hm'/zDO^t!h|2@[d ;38cԉo|}Aʺ//{DK^m%ؾ_|I9##C#6}/!-o8KYxU4<O'@t4mDFd3U^\SΕo->^+e-'h/=)xמoՋuƗ˹XBcS|).7}35~|Їuoyh96HSN9etrئ=d'}9!?nxOʸg"]t!:\? ?|ǁF oҴ3ziu9PCY򨛞 lLUtCZڈ]S{/O񣌺N|PV_Hn˞I~"?ـ_|oG 16W*#MI>mF#c)|/~{wuA9թr z5D{A`;P^~뷆q"_Pmt<_؍|覍"kSY< ?ȏ.×)4CCol^io??9Vc'wǪ3[cЫ!)!i,13 pJ1N5k װphhd .|3 ΎNP ӉՉ0_>aLS? Ӈ2ExM9T^O9ȭ|CyU5i'u:z/t)Z+uk;nI?4;|:ԡ.S- Qb[F? |;Sqdr?OGK(_l"@#rAsDC3L\yu9E_&Md3e࡟G%?=ɋvJotY&x(+<7>mn:;[2%m9"gtE2+dRrhIvx:]2OntF/IҕGOȌ7Ň&kWknWʧ/"3^]t!thܯ9>CK/ɏ738/?,ZŹ_])[SW~rp=E葮G;U~ȓ6b_Ep?ȋE~J;,io?}2;+ȒʒAs xWAC^mw|tӏYs4!='yKCx%>_FiSE7m_kxBK]xq1. M0Ǔ\'t2cһteB3t#\SMhc֥Çzǃ2G#]V:)qD/-ryR6eơGfá><$6ppMAu=r;w(7v0iui,NG!~So!:hӃCu|=JVGw-i~ygnËh+ܵyx=GN]8W&;GśL~iuйsE^]LJ'<+Oꌮc)|1"]{bv-eßoE_;w L>Oy(mY'dB + :k_4BG>x|-\9ruRN"+:W7:p6` #I>| u,'_:;15OVt]OQ>Q#ˋ2m|_򫜼U_sMK\%_~Q^ȫk4whKpU}t\wM^eAOy6ЏY6ʺH_mUx!z>IT|{³_|[ ~-9Qt9Zh2JF: o'r߯#zuu=ɛsm4ݠ_yo{d_Y6>GWdH?+ YOtPsyC=@Jxa#ti[2MOSE=h9W&.Mag%#.-#o{ruMx]ғ_w]ҙm}NG?RȇZ }+^bҜO;tB[ߡ~oeO/C^t"+zEK>GLZbuʒ5,o*~2ū4W=^䗗^Г HsMi49ѕF^ЕOxQ|Зs8⟵KvUʪ+A}談cSȎnʓUrzڄ~!]ot#m;w(_ћeħ7ukiћ_tLȓ<›|v]uWՅgv2ҔKI9iЮm(W"CNt/hFxK9&]Y ~ȣCd /9*8bǤ2t,!ї4׽嘜pc,[)FAkp(r:P kc (^zN:z5g R9FWݡmCKW`d|cGl,t/M9i᙮љ4l_9K?rKNGڛ?K÷s2ҕz3:w]zt9~=eI<9a?tGh.F}jv/؀4NoGMn}=.ȏ7ɯ롋GyEá ?'6;~gq]VCV|aq+Цohmy6Y ne|t#?=Ml<]N|hFƇL//rMY\[+? Џn'v޹Ws.]{ :E籱n:\gi{uod 4szS45}9^@;C~zP9\~Wv`É%t>sh%t!O=dFx't7%_tz %vCG>LgmK×6pM_@b5GJdQ+i|&YuU:6In4vAy#z;56O!W~>9eoh;oцtz[څ]w%ҁeHm>2ˮM~(.Q&WXq~qHK9}z#?گ2җM~#_-ɦfd'rdC?Nwgox4n㜫6^^,0BVh}\C߁LO{ɇ4Gu|ʧ^|:?mNj6 ] OɊ2)Ogҵa;i?Ulu;g>ٿlI HQnGf@:}ikg_:Lh ]/'9)?Cǯ|ҕWSNS^#>:w]YGv]^CW^וKseՉ:idl+kK*Kh9Bk{ו ]ybkx-[;J^>+h)>zt/߁6ʤ]")[! PwN {r.)GFɀsޝ:m56ꋽtuN^tã~꓇Μ+]>ԍ:;U]G.4S.!]V4Q z''z>:"4C}WtuMyb3dr9zhMʻHې-}R];_]W_Cdq]]i |x'sC|e D쌽Lt^k#_QȣN{=UCN^GhKW^>GlG=O>HY':<#su/ԁM ^NY\HS~)4N.MälMt|BˡASCFbhiPG4tbء. F " Cƣ~ -u.:Ȩ<KS4?Gdk}Prh'lʥף{Ճu:HqNA:#e_=WƯR|хs\{WEFyɓ-sթz“:Muq]A>=&srOGڗ,ѕOLw|sbVYoB5Z^\yy~yGʓA9/QN]%OX!Z7<;W SʣG~GFȃ~%4␞N:Stԭs]:G :Ӷ E=ע?r]Zꖗdu2!%R?Iskʧ}Օ:ѐ,+_ot=~!?q(_54CWg"kʨ'rƻkh8䥏؊<(K/ѩ_5Bo=:W. /ot|6C'< GTơz_wrgOyr C^uEhF'hȋwy"ёW+؛zz/.xwN>&<˹2QKC>uY4ѩC= Pȭh e@CYzqDGw8'[xyB+dGx#z\Wίэ2hS>|Dse&;g vQ(PXF5(g h8L4@3]#:OnClLʤFѷsOۤ?˃ecx%e'i<Сzw]/i_>Q6+=v_m:%^44%W<:YçrSݮ)Ѯt{ʘLh܎:G[NEYit[xf˟Fلko$/_Cx#vˁo4՗k-CB>ЖOF_u:IdG&i u*C ]OBGNxIGg:RN~MExqhoK8P!sh[tG8|g' =y#_=y]OWF)=⁼G΁.&//r] e*W~y]*sӛt8 ~CO;/ k=zp:Х_iу%=mCʄY9W>\Y6?#rOb i34z_yt҇љA󋖼/Eio҇4t Ci.]&_vWʇWrHKl.sTt&  +W=qU).rȓ_9iВ?}@=ؠ<9|tO~><2Cf9I=/OxTt:qLhO;CzdN'GvL.2I_&3#>֯2-N=|(C\'Vdcl|ɟQG[2Z6FK9:=yHOE?dz9E'OpȮW|S4+i݆g+"t4"4:p)"rJS S:CW/ȧ݇V!\߹6EW~mԯtG5KZɦ;+oڃYKY5uH}oq!J]I\Ї41v/u$>]%]L[;3]C?u\@99?YE7x+ȋs}Е~72^y?wmidS?>Rmhjzv͡yEngrOWq]ܑ!}~#uӷ/iAoYq-3/:}u8W>mbqĶa0~y:.Fo_[m.QgIҥO^|Ozue9&/zx?MWιUE? zu-u~_gt*/=$/=juiɍi裓zt'?ɣ9LJst2x~vыoV?}C^:zm3-:!:D?|k]rҋz~@;tpiεzJC}F'~աkMdQ6+O:'+>PGW&oA=',=qQ6g%1:QmkN גWY&igoyhIo; RVzs-|8otcb/:C'>dJŷC}hɣ˔+~*n `~O]l9;qxp݅ eǗkэ:4M^4"UKwO2SG-+HQ$=uG_OI]}U?ge՘{yAtQwu)S>˧ 9r;tڏU~N@j[ynt&nVǶ|ץQw2K:-[ SVyd8'4tRO%ڳM/:fUYHste?8P^{UFw^/呗86Q;ېWg:JdtH?ȥ6Qғw衇v{D -؇%>lwG`Pu52\ ȎFkz3hT8j5HdJ(5iT C? 3u@g<|Np8\n:KU+>rO}FZ lp]jck 8.S2|w`еIڔ92E+=YF򱋼Pj+V?RGЏ\C:#)Iճڑb3\-U=EzW[W=랣ơ wȔA/u.|'!YtAN]>k߫W:T9Ȝ"+`g6GWOȫ SF;7}W^N/t۸&d_;BW6#ow_>WJKOՋUO,ij۹g!U2.?P>N>|I]S_6aN|w6TeU(NYҐ-L^eGߟW=Ձ3iK6[Sӳl;N^4'|}ضWc"^tיN)lPmʗ&W3)ӽ:}>&tUgD}< K麳2,2W_V*G>"]g\W),6vv>Kg|POe(Gz+OzGeQY~+lFNdU^JGvq嫇 XmG[C~>V[-tV>9ˎ'>+wJY>]2jӯ[&>\C6)gMzgVl uHB -ʠ<[?)tژAzљO+}ջ+-~,s٘?R>+]՗\6#W{}s&V;3Y5>M:K_}ʡ͔敆"rI*]]wW.? t*T(({'Qu,+ښ̺/icB6;ɯd;ݪ#Gґ!/]t9B՝,=yC=ȃOȄW^>,F1p 9s2SKaԫ]3,*,rdpep t^9=ʁ5ҔуlOSTcrRNlɕwUtyGH_(ס\r륳r!O9oJ/U~H.򨷴ה,EYq,\eйڐbKߝ"lv>]=![Җ:ߨGܓ _;ʠzR6){Pl:Ck|ܡL|Gˇ뺺WvrT;:tN,10נG&YȒ_!IJ݊ҕ|i%m٢^u=)]#_Ы|<5ڸokـ=Jr:[(Wzs,{|]|&S:Yle u'Kڑ ѓΥ+s.)A?Zgґ{cU~C:H#klB.=Qʮ>ekz_uP6}d٦PҸ E_IFvlٗ[:QMog^MU>ʖu]޾.t#O޲KLiI.gsgl>*ȯ2䗞:䡓%a[喭Ȫ?KEz]첑Uﮡ;_pTH#CGi3*Pw82 k֝wyt@9O rpbЕ#h0ɫYYT8A#(Sz6F9.)*\:|riԍq;$/YPF_y\tkrpT(]k2}|/V&|&lU;峴tTY:rldҵWS.ɯLY>QWi]ɂgg(YW}SE^3yli,Ojַ{W]JK&_M9U=|g#YeTV;V`Ru!f rvj.{&2\rktOyuvM]}\rS{*ek]'ݥcSPmPw6Lnٻ䓖 w_ڲ}2]{ƾK,gɑ\m6d2`_yWZץ׵ʤ{(sҁյ+S:˦d<ҕ ,_p_]t.m'P=ISktUCZ:/}ف6t_zeI \>>MNه bޥS2liɯqueW٘\$wvuvgis]J&_e+C>DT9ʕ"랺5eC>۸_&MW/(LngcMG~CD_ȵ/s]T!4iCܓ:V^dKKn}w+]ǵ]]ܯvr>렋4ʣYdms򹧬j:u&S:Ҫ2LZ׫ |o/=_ufK{'9XKZ,qN۹L7\lEߺNA6qwgiYzu頮ʒGu+?|HG}W~vuy>j{zl'[tb粑ǫWl Xݡum)k*o Is/B1R9z5F`\14cǠ^"]qYCFyK뚃.i/C9Ҹ,8{<b3yK~S'yK~~=grtzT=X&o_sqІ0(Sr)>K筓;j7*_zq=[սCCY)))@dpqvO嗮_嗟:Z]~Z&FyғU:8YJGWutPeJﺳr,̽{I|V2KڷW*!}قlgWOYqF^ו_Y&C9uvuutPV;W:C;u|}v!o[seݗu48|vt+[9+:Jߒ[v!\}I/٥Ks=|WUG%oɭ8_)}ʩtu:#O[# U~Mk5LrW+tuMgSv(l@j }M,Su靕5GiAP7((\OOSWz9MKCZTYiSG~eT{+lM,K{W}\qϵ~L_:o{}iCz$[+}OQJkUgYyCiKO]'W1O栃zS_p_::#[ݥ|WJNQyK6K(]='GS~q;Uұo*ZG_OyJJ/Ugrr]Qȑ4w]{|$ܯj# (G5V'+hҁݫ|pwQGDb\,2\w{d`49;7K dг.+3q]è裏nleva݁.~dKsաCyO=x4X:ȗ_t#%K~sOWהUSNi/qǶz_g:OT=ٵ*C]\o/;cZj.=GL؛+CұOّ,4{ٝޥzi*W~\W6OݕV!~IG{ْ6w^^NuґP/uR:Jo؎Օ:WW=aKܫrԡttH+_ٖu.miFetUyЍ,zO>P,|;:z #r|}iw5My?qS%][6di+|W4C%O/.䱏ez [sَ,״}S6߫}|]4q38}/}[+ ꧿Kdr߻GN~䚳z8Sz+^ޮG}/qC+{lBGuOoO'iKW]]~C:A6TjWr/KCqJ[S=+ ]nhGz)S6T6$t }Q>;L>h[*/,=׮|U!V;Z\F(KG؄j#gioSsn&Rka ;;K_uvHCwrHWc N']՗|/&tt&Kz-/J\v#{lA6S^#k|5$|.yU?/c#P璣\>lt_/oɓ=:)OsN[_|Y&5C͙)Tq>EP^餧=>{(;ӽ(ߑ(;˯\UV48ѣlLFٚ\nڃЇܺ.k>=*[Я|޹|ή#MڃDҿyO^tU'2PFFM?gr,#LݗNYy^xa{wBGGkVQA9M5cZp~C}grTGrv8qg#q3GՠY!=:,tV_:qruɫcp&Tg<ʣ]B*y>+WyttHO7YZLS~]g5[/3}v)L{/U7PV9;.X[TPOe|i婁K>G){U=H _S~KOeWT)w+-;:}K\rAvA2|LLҖl*KPGeԋl|V/׫]Mu!GZm y]<骞GtcG_սLv79ʯAfMʡK?gA_Nt!AG3td5rSSo_SEU[q5ՙMݝ壣ࠃo~+ٮ Nd-|tyȫ!^k;iݧ:d庲3СƍUd+j7ȕuS uY}td*>%w+Vy Um*|~+8CtYؤ{sVAzeJOfUd+^;/ew:-EҰe^?\WV]/[V;2;J|Ґl^ʮzTQrW䓧,K/{d-k!I:W9ʐOou[U7ZiK>]}d)Kҕ}!Cv>;+[5v"gzїMȐKҙn;!V2Wz>;AOijJ4զ5I/5h7|vl,>Zه :֜rJϲ*< Y,r;]}vH/Mɮ:'r-ܯ|lzH:u]>I2+EԉM|.)N6yPu.l,r#OYdz*cg`JSPtq2Q2޵jsm3W/iEEGtYyܲsTf/yJZ記pweYy~{, yL_9GhBPH;x#y g _[ kVȓWy4|:twi!u8eAvu@e)uqrJ[J>E+-+(g @3=8}tQsյoPc5tb嗮rUz@/tpGAQiKUѩ/SqI-;:WA7il[~]:*Ii}wLn,3]\w_'MrlTe$tWv$A6;*Od+Q52աʡ)T(_,k©4=-f_'vN򑣼z:w:)g2mIZ6VCӗ)|f?vWZzӇ^q򟪣﷉}wOddW6RzU)]_\ce+~كQ&tWȐNj#ٵ-[җ :4tWCJC/r}4횺Vɩ|ʬ6r]S*Aʓ\zN'R?z_yc6bttd{uRgRׅ2䥏z?TA^z( i,]qdT(G˗_*m_9屩{lVztV?rOYF>Gَ~ʮ||[y+ ϵ{C5@6ʬ{/ԩʫ:tAm(@,;W+|*VF]Nu^:һG*w1WK6қҗ}~_SNNE;+5窟)wb_t9oDm,ytvG_=Uo䧏{XTo2j' }QFacOgC}jt^KOKOVAZ(;;:>4IFwN}FiI:J>usrnl*li8liM2ȕg/pפeuO䥳ߗ?S&`exo=;||:?xKEndԵw}wl`Rhhze(rmBỵ/lg߃ QeFh}t.ʏ7/P0_jsƍ~qҸjCXRFh⃌Q:L H*΃熃|*Y:Y>}s?CY_}/dz+] }gg&5Y    1*K B   )}!AAAAQ1jۏC   )E    )pAAA(~'C   `$AAAQ%/BwAAA0E~ꩧF-!AAAQ!'tRwAAA0E#;   F!AAAA0    Q@wAAAB ›o=-ҝuYE]=o=6EAAA"Ϸ?j?Sm٦[n_[lź_WB -ԭZv{^{{wJ   2 _;[qE][fe^}_eUV[lAXovۭWJ   0h䃗^z⋻߾[aځL#׫z6bwoy[[ne5\#7鮻BAAS6{2ǿoFnneXcnM6iǦn:x{tgjζkmY#-݌3>_{AAA0E { Yvmw\sMs{;ӻۮN?0#H߈vn#V^yF]vuiy@P 2|UJ7)t \t>`c83ϴz/&' Vԭbg}vՉ q>#>h[o5dڄ^C>^pOAUW]wvin=vyk~y䑍sn /-Rqq#v^s9p m BO8VprvGuTw}M~ꫯ6?vq>o3watP+{cO,XKAmQ7w?O[l|"~ [1W{ /l7rOq]Ybңd3JaO{nw9Gڰ[ɣl.DΫޮˏx)u6Pvvi>HzSYq, 8#ZLNq *W^sT{V}Nt=ƔE g̓g6/xǶسU=x?F :!? f:AaBM@x`k޻M&޺ h.7|s{ko'_|#^_G5`{-=Y^{2M|ı.{[0P>nOja_<4Lm`5 Ss1G7Sw?OVZMN/>G}ػLO~w?_ݾApVbqXƼmQ[,dy.7"i<$Gqf bm14|Oqw;K,D#~'.B| dS\'wUb& aB112U/s?}[}Mwe9p Ȯ=[uUF́+ɣGOW\ѝ|݂ .Ҫ8I<EwfO1ۓH+lH8֖廍 OHj7M,j}٧)K锣Wq+?`o1){3GVim*F'-)2q"jGm#$C]`~W|>,D[YlmI;iwI+G惉 ADpyEg6khή\3M&&"-^Emҹ 1l`5M,^Q„X첏߳#&1cƴ{(600AmQA[L5T,E;"ŬB_mALJk EY=я~mqdckC,z#A8 %\!7%ԛ%iւhbe VRhqa!9ﴘ3G(Kb.=E'nCB^b#Hs'AVŃl"y.*rfW&r"G$MCȡ S" _؀ #Js93oכȂx[MzdVQYE'2-!C9u`D`B'ߚ>Co~mڎI~3%z/FЁ N?q;E:yBC6Vku@-VY`"LY  4aI1]Lj6/ZhlN0yy#O+i ͏bi}t|eV<|rO#'2k]Y\K,@ meV=G]pSkW>%)&06 5vtM=cڜ=̣l_ }W=g. H<=䔝;(@҃^ѿ6"NZvwIK]/TU7Yڡ/}2 1-MgiWeiKd-م̦ |.8Ў!ܟM!|G@= VUIڠ"Ĉ>Kh[ҦChܑtc亁@gY=^^V=IA7lG\4tuBȐ:ꪓc+V0$dkwiθ#>[F=nUXrLV<^24nJ(Aj[:(CBnvbctkYQ][]cDTY0x{|IH3ې{G,`xJ:2L^AEe}{k:[C:>Ұ* Ƭ7w5Y|'ؗ5P?ovDI1 @6%u\|H7Dv!BpW+ m2{X2]h⃀8g L! a"r9+'@(2hUv`auHV0eRv" J&+# FBNI,zT[ evl'OfH}m%RvpFU[$0Mvk|[~tzIxm-H ;LɽpkC>PJOre63&ix=bγ6[;cRHz1|b"}|~nBcc[C`_\~ZrvS_zjZ֖.[b   P 7>7<;+,f.2!v6lE<]"߈X$# dJ8P#%vݎ]?R99#@C(.uQ#b2U&'Ӣ@؏ $ZՎ/r&D,5 E"z$G=UrWNoJ=jOg?STFGأFtJG2pOC8ɷ#&u>k"Y[x?So\sd~>ϵ}3iٙdCB=^7W=Uq* v xdSVE [v Ac9Ǽ F {u7nks⮅ڑo~K裳Zy]l68wV|l#{2W!>-"ȰF vVٶiڎ]Rz \D H7"Yw]YȦkAI$:zdKkA@Y*L wuI#Q&& |)lAa!B<֌#t(=ԎIJpaDL{ڣ^sߤȞʷ(@GO4ةUX;g}Gr­}.G{r@Рl/AlIwcÓ٢zү -Ȱ ccLnuB>" Ү$!10 .H{>ۤEK3MHA o$n?7zA26PͿ9xnN2#4zo!(s@&҉iEZs*b?3?ϑxxڋ\ |QlP-;{!X$߼ga[,6ߚϼ[奏ynzxb>ͽ!#4 cbvˉԁ/)Ifm я,xj@z2m"4F-xdE -&EpO&@ |.C*` 8`Z58 v5[Y5yL(r nV zo'jR27 䘼LHIH:Ȝ|3Ajp&Ds$Y!^+}?M(I 8[;*/f2R/G1cƴ( >j] 3`"H=qmm 9DVM|&^;0"LUwkPV=RW*GE>lsnʴ(#i[ᗾ`1H=be |hpAMq{ Hj * |`A~b 4rj^GUm\ZUۇ_}2p#!'S\$x_$;TTBa~9\&1DnVtZ|c̍ȴ|exay}KB9[NXⲹW>6JĊvyyi,T;iyz 0r_!~F^yvɠ .&e2 T=#:V9 /66i8]Cj#& FDH V~C| \wD$eEQ7QH눯I͵րH/i& 'ӄlrj2Y-}@uϤ$U!vlÄjytzm#2 3 2{pA&Ky@G-3TN'QeYſ?戽:Cp,hLGd`A®6 &{͕bbzlSL-$.˃Z$E>N̊,mHd+s=-n3(__*(vsaCDn$N镫^!--ު"gy&b1o4XL9AMLiLj6lXPsvPM O↺Sl'ּ+c' 6/՜.ebM1tIrdc%`(;j0γ@#+G=$&&,y\ط݀D V FbrHv$,l`%vk2pMzrɥ?\פ' W?M8@XM&' TlڎrO*,Lg# Hn쒝 [mL H"'N2yې8qaCEb .,\e60WYFB3b-Duy_H&*s]m5-W=#$_}[ȫd!"2='m[Zu)O_d'[c-֛[aeC_zX&lGnڅY7NA0)B=àg18" V?) [Y2h0#6⋼".t[]s[D=t8]Of}rf(C:dm0W2Sz:x1je[{=f̘ȴG=qnlj)@-2x <8'AA$B?abh"qY+V%"v|"32'dn2BR!ή}(!V%*"v>IEgg9H[۽&ãIgZ & vlujaQ.5J'uV|]  Bpn;!/i`IFkvwZq~Xqb91\ '6t+d+<3AOAC/dZroybSbI-v) &bC vvpͣ6wȷ3p"hQ_"~\;2L$%7|\`B8KM0}G2I L'*tvT+X"|+^L1dCma6ᗾ[mֵ?Ԫr0;n^~4hG,~J_VOuء^^zG48:>!jQl߷|}Bɤo_g1cƴ@ɕ_^A0˜Hq?͙O=ȡTE>MMDO%HK.d}Z/=3HHzaa_L.<,fw`䉗ۼ[nw!ȴ>HV|D8z+msU'ӇlNX!9 >@$`5I鏤mX@ksܭne3~~#u 7;|Fhj<X[!EMV"MS\l Ą%hH$'Y'{yۼWދt'fwqw64ْoba3/O:m}A/EB%_ALo|[pd%Gµ[M cۤݵ{E"z|Wy念1V am6䝯#,r>&g ӧVo|g=vu:86(LN^G{ZnL6'[ \1$> P<(w-#vc9SzYBZ/i-Hz9O,~1oi\-gFFfZmdYFͭb 2JL)?bꀈig|C]O`b yBf^tE[: H8l`!/=kf'Qz[p2Wr`rG"%M&Kg0 p9l[1kEr,y; rr~i2AL0ךb'q #-D6ab>kn1 ȩ̝sβ9̼oNGgw\vYYq^k!Yl`t̥{r\,V7\ӡ_2+ 9}kAxMlö$` >*[yJ+C^ Eٶ [t;Bq0T"FbcE}6:`Mb& GM ;L*IsXNȤ O=h2hR#P&Y61ݘT+l2vկ~MR&aWH{ lr >ϵ2#vl%{(#H{IYl|Og+`e^YHb[ 2?Ȳtfi<~ Nȼz" Fhw$mf7tg2,8ȱD?Sk/>Y{]~AHCalAL0#vRD`@8 kלo;ٵ+0%l ڈ (욓GI:ݼc';Q.r"hzM(GX8V7eX7/͛_s{44V\n&.Z}͵ʢ-BrՓ>BʰK^"&y.;Ba0#b9#g&+upgd[>iR_nj(Xug& ;vrcgfwau>|OLF׎`'+t2;e׎ڄ^??v.z읝#_`D0ق >83s96!o4A0y ; a@#618;8 "n7};N$hR!DLp~Qf;}rjp"vYZmN{34S!e$VD@"vvfxFF=F\#lQ*!ɷ{ˣ f6x4 Lg+N6p9҄߇gDZz{LoaW76 7!tE=wVِ-<]e>f1A^g|U-'*'/RNWma1Ȏ{i<}`?ɠ-yeFEnAAwUsP? n;j!ܓ?&+W$6b%ѶC1ld t#G)Q}a:!HZ%$iaF>{ 5D!ɭom $vʫ{[|ENY;ғM[7uӇȯ˫ʠBp 2tgCr~uv]}O]/Un}9>K"^mO'CguAAOq@LD/k qs/h>!0AAA(-g'vl;^-DZhg0   p06l   ";` ~%]~AAA=B;   !AAAA0 p͟AAA   Q$oGwAAA|P   `ÿQyGŮ?ϭ~{Ց/W^yeVy|wGv<ث?^{|h_}ձwGdy /0MOQO<ѽcSL|SNi >y  &k sLB V \CYr>_Ҹu]\HkW\qE.tgqF+AKN8;UdI|nh$[om:=ܳʔAwϮ|z:+w0MٗQRKuM7]wE'}/n\rnM7\snE6xnjrAdk u*H[;fmoy\j7ge*[jOpϢfm׿znmV\qnV]u.k }YP. uur;C}Xx&lA*wy&l +Э:^rK|(}wpAAH<| kF#m]Zk52l";>tkv#3tP#*'xb7묳vԧݿk۱뷠9}ݻ1ct U^CgwqF{n73wgZ9~y7vG}t[t_~yˇTviM7uA6dVK/y!:o /"|yVjoL,L744}9nvukL3uQtkoـ~;CC5O?F՗L /|_lWzz:?;cG swnvcCucOޱvۭ& =餓Z!'|rKwzj[Fvt oy#+R ?|#8{[{jaт>N;m7\s5{v>?ObP֫2}s=wQ?B  3"c{}m$sш$"Un9l'Ͳ.#vhŰwFJ$ q}q1Eސܳ>W;HB`Q|#7AB}nvjD#cH't#obwe"dy@Y(`mK"+rwwx`K[l[nFD^lO^C ;硇vʙg|D6P&Q&3+_Jۙ$SO=w{kڜfaH}qǵvXRY-2'm^zVwǏ>[ʃ  ~H@XL!k%ڝckw"d'?A#G@iYn*rb @"Bv^BdH-GzM!|tF%W_ڵ?OMRvu[h l'nꫯ"Rm六s$nn9::*;Y89Bq{urǭ뮶3O6`т>mbª],رF>=a`q⬳j;;MG{A[ N׎V[إV?C.v"[{Ӎ]- #wW-6 E- ,XNӏ]#Nj"ܽoGwAA0y@@ةFҐd)Cvy~ΥV~?lWDİbdQE]C `DGLhroV>B"4<$сl$ yF- FD U>nG1f~ˋ%V[[2_RuET׫zCQE[ىG:>eIGS94YRA Dtnz",!ɮ!߷+m}EAn1[|"H#쮭}j'4l=ʏ@1PO 9WS]ًܑWѣl3ػ >Wwv  Fv#rv #-v: |ADp;V>Dڐ يqtϮ~,vkFʏҏ KHKNE`U'Nrսv9l"i>"W _"on.]+[ғ檇ѱB.нö~Yut`= T[bzgeGK+_տ*9dk /ӻ^̖G,}Ucթ g`wo;;  dO>IPOj݂  vB.A.]F;) h}qP#!A|:GY  `4qigݶ..-0y-{)Ű~~?뷲^];ZLMq{M6x5b/&w~Qb~L[ݗYe\v,Q#  `ᷴR/O$FT_/a3e]^T;R@/1/’Ed/SI4/B8;0/j5-+l۽ Fܕ/u/9C-o vUXr5/l/C҃ tAAL֨nd$۱qD:#۾UnoB#8&jXz[oo4CE'KojlN9"uDKƐgd#ܻkwAAAB   `0^   HpAAA(~ꩧB   `$1*N    hpAAA( ;   F!AAAA0    Q@wAAAB   `p?!AAAA08 ;   FJ   `Ĩ!AAA    pAAA( ;   FJ򗿄pAAAS$FpO    XꫣK|ͱEAAA    pAAA( ;   F}}pAAAH=3rC    hp#wrKcu;~?y_o>K/u8mSO!I+ҝvi"^-\7\suW]u{@wX}ջ 7ܰ[@z2>V6[vmc]Eck;~"ګj; Py睷;cۮmmvv{w4AAA(=/M ឲaE殾F`Ӈ]wF-2_픫{>暭],|   |$ lzh7ӶmC; 3ȷ[6B"t7tX)vU3h.B -(]+MZk[?ӛLe"i9F~k?y72l2I$.x~ی^q 'r!􄂭SN9=k-X`F ؁pӟ^@[o#ܗ_~ykG[bOU_y8  |hMJ+Hal؃:4~S,\0-EX#?OiGL?-?H]"e]֭j^{՜`go~Ln.mW-iUy晧[qp[j;~|NvBYu]:Q?;ȶt>,WTl΃`3e]H2˴(=iqd 6hmAAA0~p !j1 =kЮ/vl~%`SO=uE{ہ_n/b}y5bQu#hWvF#ȩ(]qgۣ?E[ezvulN~=#,8 ʈ72nI'喆m1rw{x -;<7w^6L3e[f';CSl'En ^^F7޸-T {AA\ ;`ةaqv}( gv=']|ō{ܮV$OۣHψroF2"v"W^ye#~'lln]<+En$s( V[2/p2AGSx~!yY>סD7*k e:"};>-  #;$1յHVe\G- oAA|p,K8q/=bi  `RGwAAA3;   FN)   4pAAA( ;   F!AAAA0 (?!;   F }'/t}w>hwAAA0";   F_Gpw    hpAAA(`#<AAAL   Q@pp!AAAA0   Q?9;   F!AAAA0 i-cwAAA0#;AAAA0 )-awAAAG%opwqݟ   `Ũ{'{キ;C[lͺwܱam~뭷駟nDXgqF;4bNOFKǧzmݶvک[{ -P77w_}w'w{Ww7]{wFmʒk;쉠:M2*Fpc  y28mkN駟q{w+Bwa5_ᄋ-X|uY_>#n-yꩧ#-\#;sLD׎jdw=즚jF#ݖofN987K&"^rKݣ{(`G# 9眳-" ?p#wZ}Yt'{k_qn4Lmc|AAA0a>4"`$7XKF 9_o 6VZincK\9?.ݴNvlkwy$Gۯ=st]ڪtM%vw[H}Sv|1q矿q;|^>;h7 /p7f̘&}衇]}խ Pج:y"L34L[lXve[ʳ=p]pm7ۣ%_jCOꫯGʃ  `'ܞ|_F`x 5n59/9pO#kgvn<#E=\@J1mN6FHUe 4Qm@/.G#6ksXPp/;꫍K3|b:"T oFgan"~qx:yqf'$ (vZ/]w{Wn#,!!~N>-|AAA02pg;x HRK--2m׿u Vm~#|smFđB;Ȝn,b@{nl61t#vf:ꨶr;^MH|v"CAYȣr?j}+~"v^ >Knr>#K7emrZ{"+Vu ^`Eh?wȏw~g?YkpAA!;H㋤AӋ٩s;ĜLb!Z;vlsơ~K̗Κ;^\f'Y* h#U]f$W9v?蛾em@v@hս|zНnZ$aqgGIqxg՟jPeE /kl\y晧!K vE{mw#\ˇ,#p饗v34Sm!GZy*_`Ⱦ7sh2L!O9nfk 1qȷ:裻[Օ]i{_ymW!̀(#vb1oCwsy=tu'tRAAA01Q &~08㌍c9ڮ{8۱Uv9-n֭K,-"/_ݬ?O.1cYy[wAA7B cγ=أ9QKw -PgCYf p/Q[kfaQGgy9L꫷rN?qAA fcw0A8""~0p;]tQ۵}-povgAȹO=nV[mnesC\vemw[9~RN;;V[myG   &6BuvsN ;7tSmtqXޣ:? .}꫇'t2{ :}   &&B   `0˱B   )}½{pAAAH~'C   `$1*[C   )E    )pAAA( ;   F!AAAA0    Q@wAAAB   `c?AAA0~'B [ou]!^{7sٱ~u'|rs_{O?i=c\>G}vgmy>.UW]՝yc=ֽ;?ܝq5\ӽ-?ӟ]|~V߾aw޹g}?K/ 7nno9#￿9yf~.neov.lzw_x嗻 .u(Hw饗69%c]w>[o^}ձFew^fku<@_W' lkpۊh[<裭~aÀiC=[G5}O<vqq}u_}wE{ȧ7xěu]w]wW'Op@fumQkkm}N|S;{ghWve6Wkyxwq 7N8ᄉ'-s9;c}ݷA`@3 @tErn,L7|uvZ#K/?nHx~{n 7~J+ԭ | 4;W6l&l҂%DRKuSM5U{{Ȕ~"?C?/w[mU#ӃooM%\-b7Ez@Ρ}M7th 믿~[l1,Cj/~+H>ַ^y啖O|FF,,I?=h igתo`Tov ,>3h7ߵ(j}/nUVi%]g(wWw;|bm_|_z%nlLz z՛}=\;`}zn뭷VrՓ SA;5;L3M%X~Ȩ?~ȷyPk 7g}MXaԍS~||ץe'rxG]wuۄhM!|J]ѫګ<:V]Jw҇mW+e_~weTY0X}QW_+E~uqǵ/>u(Лϐ>lL~{HCU=Swi'91i~@97v}toGia+ zA}g%k86A0F˿Ko|[guڄO- a+#ݪ^ҳ3_cC5CW_A8i &1^y啻SO=0y#30CFp)uYA `e_` &ty~\,H#jww oop DLU H׾F\w2|OFn7,fY~Ygu?ϻ|3r-nv[L;mA ʺ꫻9眳/忴nk}_~O1g @6vA|FoLoy7o2-z:3ws5WK+hJpkdYfi R7xcq&ˢWE,d5B<S|B Y]a| |f[m3sюt` ZcCl~njmǾ'tRƯj{ k{uC-o/"̒K.ȖBXXa#d[?GR lnb8jKL[;| _5!&i9җe9#k Ό3ŞG[r,y晧sC?|̘1͗]~J .__bkvʑBmd4?@"[mici!GO:sܸ=|b c"G?`8}ӟn L;fQ$݊T/}QF| ҈I |Pc^5?5Z>E&? ?c5m.l_zȱcH Fڍ"%c]`~7n(O[6 %LY`j+]F?>ϟﴱ Il /-ؚ͟X?٢'WAU-8 @!11 ~'L0f!&iA -A*Ȁ҃"ha`zՁ.Y 69od] B` gȡ [%@X#  -AS `vȈ}c=m;,XA7ނH#x% QGVHz >!_d\D@X`|T#E[[!')G-_O&r(۩^D)Y)R8xDވ~AA/kgAޮl@؉}3>njNIlr袋 $ =@OJ3Kǟ>}. ^=z['8?@",Zui",_}[$gb4gBz" t}NJBSP}-ZmqXg\A,"e/I;/\F_fcE{ll*~H =V5"#ߍkvO}<2S2&7}f\{o JK_d^ZYsvA65Fn}x__5rl|wmɜkaK Ӎԁy1nr6PmnlkF  Q!&O>jWd oA#( ,|=p vN:g3?) nT"egA/" ^F^Ld#"R`@Pڂ#$=H1Z "P60RX]Z)­pC$љWѲ{_m Z@dv 8Ifv̧ڈ%RWP?zk?ɘP@_ ~/(YT :GKz{[p "HjS_wAWPn/ E^Np7Ȑa"H_߶3E~??7vITCegR|)<eָ9)XZ џRv@aObcoGLguNu/}m=_v1VEcz"jl=\c[Z`K|y>Uvu=ԅd#_ {cဏvlXKߵD_vkCĔ-U9q,#f 6Dq=uW[67ݵP_ E_m?SU p򩃶1/p>ͅpk 6RV!V'Fv/,1gKOX2?>iqo a>2o b%?<Ȍ   v&i:n%p+,Xu =OOJ' 6SM% H 'P"]WWǾ:vD^Id!Ep50 *Xt8[zBvE䡇0;2mp#Ȓ])Pt| 7ra!@cd" !V?;ȞvՋŎT`VP*vD~bA\[!He,Nꀸ#HEjO-hh/և>Bď;? &Q⋈8?֡|'f?D1ta[! =^v+"Aͷ@v8"]څD,Op[ǢWnnW#>F81T:cm(­GncoE,,uTW>=HٝjG͞^i# CCp"2 Z"j"A]AZ#XpX8|# }(#@Ԡ#!Hz boF l` :ol&%CP.v_|ȴ|'('PG, .;1pR@ iB##t?Mwrl|aax#v(BԐk_G~!ڡE Ąv~`sV ~M~ y1`LU>wZtw2vvgKjш|^{|nINiڞ^d\= '2iN;~7U`E_[h[3\=Q䁱_ؘJgmL'>)1'5Ǫ?-ZY A#;Hy8X'!I! A 2S8]]H;!h3i|F0-X`gOǡ{v˖`]>I[/M~s{OkW@)GYzmRd۽Ѕ4?!zVW6<߇K_mWi}XõOFl|w]:ɤ}uzU>޽1}8}6w ׆Cշڎn{C> p}UPUնl\Pщ)St2kw\'Cz-[IJ3$#&Ox"ŮLϷ1]s?7Wv\"e#6?d?Amcl A}|vvɱ(" v{T0!=bO(XDz )!AAAA0 m6;   F!AAAA0    Q@wAAAFpO_AAA'!AAAA0 }GpAAAS4pu]{AAA#    pAAA( ;Hx{キ7Gz'Q_|wzo=7vRks=mlAA>>CCdSN{nVsnvin76`nUW]w}sI>`vK.dwuMnw-t.lZku;AAAL2wgyfKw'pBs&o{/R1Fsc׿6" 7s19SO=^xal ABN>N:W^y{s9M;?yW_[`(q2O>Voe1>/;餓%\=c=]|-;qqǵoV+\uUOǑG٭V[mli{Ƿ{zkAACyFXbFFjkj|Vkvء[dEwܱ>]c9N>  ^feɼ袋aRK5rwy3}VZihZ0ᶣFrxdZylI7f̘nM7my@nmy6Owzmzo O5\)y睭ދ-X:=!0Swkv#4]7[l   4|hFH=Z #^.Fn_[gu1]|Żizˋ\q) Ur-9կ~v{ =|5bCduO暖zчrHe|͛Hց,ŷ+]v#:묭lM#; -P#v-HXt8[2ڭ#nw=  I!bhg$Ȣ=$3;vv]o;>l۩p#:ヘp{FwFLcmYO6d/|7n/|Smgzj;n|fjEn 6uG|1r~?~NYЏcF<  6)$4;` >蠃=ۮ]mdcv=mg[͑jK"H5X[d֋4Jlw3\{DnjzǥuQmcMrgF"wqGsZ!hwAAA0";   F!;ӽk/ܽKj7|{W[o2xwӕ;oNӾxZ=;o1{l׿^|e3yuEYڡj@F`^>U_yh@*nh8O,hz86tDF^6t8NwƀzgZ_}??=#m϶ڃ̪1P#?=eOƶe~N>lqA)s?='{&|Xs4@I߂܀p9}1DŽp¡]onvVYenV]vnZhnWlV]un﮼knjN71@OeeN>!:%\mj;V^ynWouKd{ݒK.׿W:;*y=smt\qRK-Y &xy睻6ڨ;4O:nbLLe뭷n|~ꩧZY+BKGGFlIwi =1c-~7b6 AgmV_l|暭z/qeRj\:j}OZcq}=h}9ꦍO=1sj{'^{6+\V]w]1_;/&c8O~zƙ:qow}#7 g}v5!c6;;B{_p?-l }J?o6lfschA<歑G}tcmL>4IX;##&馛S`)e]wܱ{'IEO>dw6^82,_In;|wni;ajnvzO}P4L0!cO<>d-曯#΂U.9묳vp@W 4NrH]/H(WZHQomv&K{+GF W`( bҍGInPwz>l%Io,:^|>c`]}A>^GF؞r)W_=._z駻{ VmYĝ=zA]Nڀ94( aZǦXۚ[DG]~{*IDAT[ iۙJ_٬7ȩ> d)(ȣn)Bpjjs6@z}M&t"]mz~#1vX3yZguژ*g v7b67/ԡzXt7{-ЯŽY?7,"mtn?u>lϦl~$_#23}T{ЗSV燂Ґ%7{l]\~"m6Oeoy+ߘW',m¯ک6[EmAw}f˺.h袋t˃`;uoNѿQ9ꡝ\'tSYئ.dype't#ڀ[uule-:Y$q綂ѳUYkO sr8(S;hiuNJi̯گEACӛM2Fv 5_Q­pOyD}[jP΄]\3;8 v :;?|<J@ &ZIYc‡abDc2+D|{ka9v~ neTvϦ&6`/gMX pDhҩO?}mM)Z@Lg`TG$~_#]z,w} C,[uiCAՂ>Md#3O v3FO4`@0''|v Ogy{bXAaa@?vn-Y kk6C`G=4?ev}}iի(KmZ׎D@BJGl1峹{TmaCz|/ y6(?!Qk?i+^#,|vpaYfiz}B~>ƏMcƌiu5T}F*_+@Z|c(N`LDпsfSs՛~Ȫyڈݵ~aQP15'}̜V'/`ܢ3k;k˜l#kk&egSvQOOui[czA evt>wobb.=c|ܣf~ vf `Dq]5s|@cklO}{g* e3 2KlO)c\mS|X L.ֆdOc+(G>1eYsZ7h?]]dKqm9n,0>n>d#iȡďWUvU/`Oפn n8{ʂ`ưda6r G{,4h1L& .hh&;%N_0 #d$ > !`n_WZa7MvT&1X HXt5-ߑy:=t/ЯI!ȿIMR$dFoul-q+hkڄmRg&E[;LI]!+jKv7Bt(XҪ@5_j@=)V62sSW!Y b YL/ N8vЁ&HW }!?Ч:-OO;X@Gl]e$ B L> x(u`bB˾ Xqhc| 2yY(@t՗]\3ƖjK5?n؄lI_|}O;v7qRZwc"-k+>#9PjXO!}0i#c17ɡ5H|x/m 5xk+8f̘67' t1]*v`> ԟ>|=P}A_<1K^"\ˇ5|~~3zSC'7)_ B;{Cy}iC}a+K-͖aγљO֘݇zw'tB#c#s`hWW Yiڞ}}'?g|1ls~~X;~]vqبՃIL0_FC2\7WGl$]8!Nd;>/YO2&BΎI $LL&v@N%`H z ܂`gPDCcuLm7Qk55)a"4y LH&4A^szxM&&5|3A b5` $IG`ZG $y L L 8iX"L4 J d꧝z5Ao3 M~lѣ^l~ T)K'_&"^](Xzck,~te2g!EhBeB>AVpkC~d? ?0~D!$j#|N;_M/6:}_<ȏXh+vc6ڳ`;=/u>t~`6vv(!b㳠]'t_[ hQ'y9l"~{c bbRA^}uF6R?`iO|M_wm6G|xXCJ]j6[Koql=?buA­/X*;`\X=c"iV#_F?*vOCa~>lg̳U}6. Aksd"+,\ qbqj\CmV0t6jd_ӿ)b͑'}_tN;"R|4.+ OnѢ  c~bQٔi\3_j_3Z-_0l9Xeq_y"/{+΃mo0v$xTc|>6.t3oJZ|;ꨮ6ȨEy*, VN;|gc_ *V|~?`p#+nA'3 P%$ IE~9I$ PlAXpU#HA.&x'p=d (ǪIDL5vn '<ت&|rjGZi~yM &=Qn+@ gm8Mj#&=J?imp '1ZXюoMkх~zdP'|[]Ƃ|A`?ijyoJ+w,?_Jcщ*n[іvNkLeN[j<{^[pX[T,'9,C!_a"P8cq !SV(K_{łd"pu)|M7>HSWG$X6f_}_}=K+=}s>oX(6q!1w+iqx]ٌWM7&ž|?,$AP&g̸_ԅ?#X.|nPgo&\WًGt0u\pyoiSs d |YSeμm3 &ܤ `-­}]J~Ob{nq\Y4Ӎ5~Ƹ"! %ʂKcOȦ?|e(­/ӟ/"hL /!i3Q/LJ~gr0PL^|0@\b4`@ &0A ҙLʣ˄/3:L&[y WP%`H@z[y6Q &`2 H  jTgG( f  6њM|A")x Ѓl#`we;L&}:ITY 5`I 2!p)D/KmX>"|DO_kWϘ32Jc AvWں |3RtuFj7Bo9)[ x#HwwfKWے6,u3s\F(ʤ>-诅Bw"f;-XD wZVLG 4V@NL(Po}Iw ՅL:oԽӼY<Гmn-\c _23@Q͜%|957Ngc%\K?NCLv?C}C}a-V4Xic҃(/iOsVl/~?@tS}mA]ݣ>6t~J0"I&#Hm=G؍,r١쨎mlB1=q_9+1R?2>UZcv?gUߦ75tGY9X+|lm( K]zq5; =2E62t|@;)_ ̳dg %Ұa3cC&;]̵S(#&B `!؛TauX#@b x)跐a?M5!kR5Z9) E-9'j<`b!; s1;Fvڵ@=av .v=mQœ"vl`KFwA0780m5e! O|BOG Vhb{A7q~/H~497t~W6}A<%5fG w~[i~~kǭ^je%y]ֶI%؇{4Hߍ:O{=j7PL(②såC#5A+rf2% ]*,ݝMr*@-}esS&M^5 !No[/ #k0 `[6Kf>Qd3d|ҐW/A`ݪYZq*l,/dQmM o>ciͥ E|]EdziN& mHrHMW0ޞJz9 yz{}{3%<P7z+ &lڒ-=}2"I^ڰ||p{ E*߫O}9䯶/)RI9eH#k%= ƌI'[PA5M[n(^*|o5 %<$A{6/,Rr',FA[|w}ԉ~c3yٍzT9G3+ug _}T8|Y ծ%o[u'jSvQyysM㮶U~=CڳacyʦtsnWY+KAylJ&}g/6!JClDFi~WR~~B\;ݯ:*CZ'_U"Mx>H|_o3(ո@A=Kzץo[6nAQal4p _[*R&Klo0EH@vLM/!TZo+5+l2$ NQ^0)ۑ&9C|x㪷*|o|70tW ` v_.+=T0Pt)߅ر M2uboa+t0gA7kodm,_[0^@gmL:k# tDX yC**h ơo}[MAz*]eXP;l@-[;!oyG}/'t?ڎ/k+dN?(Hic} f}GhhW6gdk+~?鵩uGk1Ft'$7[ >G?f[>h↲R#}}wvl6|\eIdBOԂv/t.ytwG |4f̘Vo/eb{]v!߉tǢշN>:e }]|lz*_[͙G*8}rBaӘ"c'Yzi,@״6Eqɂ?3.4rX?pU} zʄ#_W[u.l&?3VH74@:u3_y\}LAϮV<ky[{'2}/ۛ{ڛgKWO+UGMߟ'<C*;+G|oϸnl(|Y4[5VcE+]`5 0v |V; 7i74OQO0E63޻H`T dT5 Bϯ/rf7$hDL&GFP-0 Бb ')C&4%O@I$*`{4 -vFnE+@W>Yx 9M*L0~*M;-(#vdX`>yԫIB|DpZ^;zH@ǟ>)@*,[>=s;\W6? _309A4>!R6x bGpa z |r`AEXPrA"@BPГm>-*hG}J` *zyWPQ\5ζ_~m,PGUt=02EKzH1@]p(HK~F0o1`_@&sk/u[|<uÑnj'iP;˃i[v/1O|__9Ч3OOj c|A'՝=> \[=-!ΖS)ǯj0OM~"O; 3&~[";)?d3O|H.1߲vb!]-#Չokc}-ޜM N3yt"yT[*s(p3Lٚo{5_ =x/W~6e;uP'R[3ْo1L؜F7&3)۱2ʾĂXâ-pjoC IpEM\p&;2*wTk8.)_Δ݊l2E@LCgX qnL%ʇ`P>i2?G l'.'@ad~p .vMp#XwA3`Y1H'҂p[PwT%hP \`,`CSyZ:ւ[>esŽ+vr (m'طl tA{Kĺ"Sp- H"KCA$շ rU_|@.?{TiC>r+дxlI_2$? N6{?o7X`'DEB7ӧ/A30C/KAoϤ6)"҆"j6g;99G\`ۯͮz;YخƲA(oJy|UFԕݐ>dj3&Xd@أ]FbH‰t]!Hg_g[mND*Rd!SM5UfDR}K+%q/?ߵ5KmĚ|21G#\cD|#cQgM E!ʱpU6U6R_Q6}[e7u/ "D<.ƟlOEQC5+]Ɩߘ׸Ï+|}Ekc Lܧ/R.]~88>Y*B I*L`vgMUA@ v&_@gA{%P'C 7RAry( dk[D=ȟ &buz A?0ݫyukRZӟt J7}S7m!XhAi_'@ bnvW0 NS_e@n2Y " "negKPMGtIS>($ӂ R(IЉX(.l.CRڐ'ܵí>n46T.yPPT*x@&AHoEu_GemѨ"3>C4RȎr6_UwmbaOowyȄVT t13ˇ1@v BS6`#vN>OO}oiB"bgFvɶb|d1 dH_)vWBE^xABpӛ 'q ?g- {hc>ap[]CȨnONO'e/~':(_#]|X{$6lb!O?0!څ'OR>`1/G;?7ׂ &!ϮD'ȅS@! &O Q:$v,rM&;i So\7ETpP0A -1A2Q;%&pHuSAl!БCAPB.=9d~N:kY:N6Ti ®="xAUpL~ G " lw ћe 7&ex%| ]#, ]ҫ_S3JgPG21A.!/>l Cin t#QeҏLÏ؈ ~ ='HԉOtO~ȋXYpc-Fo$D+oaO-X7 q t7mh}O.I>'ur~Q }RUXȣvcϮ7y];yd"#kM^d2 ~ˇ黾J7NNg6+ڊlVQ}[n^;e3uevd ޙ/hGaSua;~b*Л,0(oЯ H:UK.V䪿?9l%ӧӿz_)|],T}vq@=o,&R?Gczi':i7y~ѽڊͩڑ][Rt䬍de7lZ_Hzz@ς(_//=G^ql=gcz}t%kA~Չ -*! ?GZCٿV[Щr| ɤ:[ %Fe߆O}SYcoվCJA:Kҁ_&ľS~3wPՕ.t*1Fղ ah:+g4%KZe `d pv$k8KƠ/ WN43hoGyCA1bwLyUxv<99E`g0p!3؎NcmIH_qcW'Yp%M iO? !;   F}7ߎF=AAALp   `JGwAAAFp   `JEwAAAB   `P   BwAAAB   `0[TAAAL98 ;`xGy;ӺC=;C;;s}?cSO={{+.}M<']uU;Ӯ=cI'|z:>?:}F]VTy~ 8KFHMM΂$9J%'A3 P, (TPD1S9>vso];s\Ѧμnr~Ҿ\}sWW_ |'˼>Ϡ'?|s6=X~7~-'?Is=47^ZYPb~yN7ӯ|+|Nr7# ~w}?Xv~詧*cO}SE߇ߍ^yٟ&Yp'rw\q_nx̜9Yc5 .|E܊389Ka3LHMּ=0~ӛ 6ؠ9쳛.hsm>fwn駟n9眲5 Xln* ƂxڼًkaȆW\s(~|ž6tʃ6d Vn6u_v-iOD n' Ą`F@*K>v% ; $ 1]ńZ[BUw/_8GN*|sv&sE" "IH%sI>+(%};F7uYVو"=dg wqG]GE`>XoK`B-IS ^F!:] >ϖ%` xE nUxH}Hu/3A$=)}o,2g|8 Yvew}Mv\sW(;tXN/V[!#0b]kUK/}E}!{vh fmY{/cOl:"K/_)xcm;20ݡ~(,.?_ƾV4>D[BVh+y?mM>oux_ ;xiXi?@ϙgY,8Ut{/Pd|gt-~eB%B.RK-Uвj132|'6k|__G)}Ze /B>5fkfY`Us'K͟>!r&-Y0c>,&?2?ǝ\|3ފ mA]|E7b[g;;Zəl%l =s9vEkk)/*b[f١L?sr7r<#>ᗶ'tRy!2֎m閱CZؠŶ-%]gs;^r_N'_3ګuU-do/|9yZ sɉËޱ9*! :DF^5].k&by} Wm7'3|5kVw^r|cd5٣ mfUAȂ;1iగYfb%wV _yK B}}-V>;J2`RI*/ ܮ7fAHɵ%UvglIDV%3}.` ڒƵ^^)Vٝvک+!`9 '!dU",v $xW`2Kq`Zr%K -o%ӿѠ?+h,(K$ XI"=vEB7ʂ>;9L) HUr -% * 7r` ֏ ?O3x*pĈ~Y,ZoJ|vABb~ihs"}JB˸VdB؀X t6p'Hc">YJO%QK'}57:/)z%Ȓ͕VZ$HwзVn[䤝͔)SgUI|n˜> {%kv  &᫂AI)0G Qg >v32d #K}iteM[I~\f ja[,୤L{6*ka1ַ>BQ!__1'~ tŀa/>[? :s3E*%_@FlX<I+h!8106w͙qS@!]`O_dɋP4) >c3WP[<%k)!v #Tc! 1;u-3w46|Cl taF7?̘3;Y,ة"6>~3}B'9%͓ҏx\7;G961:uj_b.J2E;-Cfs/x?kXſ/<PG/4˭=O赠7;{V4[h'tYnf\\7t3}\'NLFSp y,XY]W+9t;Ɂr_ nΖ#8\ɄA2) ѩȳ)y+|Oc,^dLL xAaU+C@ٌy0r VfɊ$w`'8;*SH&q+bG|EtHP8A}f ,;v >$i տϽR($R20_OP%;AS4Ѥ? @+p+"*6Tu%*_%qGc!q+Nbb΄<\/57 s^JFM$+?km مĕ79Hb%T}$wa't+3 'o ;GlTB?g?/ ^vB` v4ѧ[Aw@v9J%~mlrs$vwYӼ>B_t2l;5_s"O8L!?|x@=䢅  ?_|~^t?]|O7v$|b>C.dNO"s.rP2nmt|h.}7|%WDs ;2Zxys#6ཎAto` m+}{ ٦OQ9!M̝*OG*A>c|,=ݸb:vyE߬o}yNN:U˯Fn,ꠅL.WB/SmkzBo/?:wg<$C6Z2TK1=5 nm~M,Gܣw~ ݣPox/LXFHtF[17.:G*:5o)bJ|AVP9?vCW] .D$dλ@'!xI$,I£  Ьwx2_>@ 0Nh$D Fd Ђ7d]~eSD(8# 4YJ.% - hdoIш^) Di/dIf+p6~yk+PTWb#u ֊47@KsN[shIn)IRܒ(Xr"(F(: aK/aovEgdD^'cňb.Idt†ف_1C. k5Gs^0 Tl|oI>.6dZ<Y3wdNǖ$Xb =IɴnstR.9|O$mHh.}7^dAּ +(6Qp#֯Z(͟*&I\тdϏ 8d/)8`WPc>kٓN̗ 5Pd ءw|36.}nO'yK%>DB7ٳqhSnI nKWȗ_E#Z5s27O> ¶yK> Hr3^@ntM /c ?p爣$k6<39#F {cC~7 h1>9zh>|; C<_ FEx͞`Am|vJ`NNjo'̑ n ~'X[ n _(&Nmޣb6Ў,V;rm~з>tK>@,X!?0߯_N̗e<͑藹DC<0RpJ-OE]t)9ӺH *8ހDDRV')&+g.Hs}Z-"K"+$F2#Y%tB x6<ྠj| O\r$V"ű )PFA&2 gU4."; do/)V|&!; xQқk%-G'$h%6Ot+P#Xw ٸ}M*&'/ `NY_tCg# Hdn]@{t ֒NH| ,H^%+#=U>ݢhv$A2H7ZurJFQC%j%N!}Җ'{T"˗CE=ǒ|%z_]q6b+7jDG= E 7MbN$q5:¾MdHtP_(-8‡ٙtXĦɀfwcrī.O>C^kYӟݏB]#S~MBX>삏'A1c3dB.W[_ɝog3Q\X"[Ɇ́w `ơ;?:L/,)`6Ei+[hHІ0but͵I7@>t#S~P 1V!_V 4# .¿♜mG^1_A.O/ԥSb}G|Ɔ?Q6b/7슍tA6Bo͜ؼПiG&Hόa&~ }gxv<6tӵ|t6+{K1ŵDQtr܉A.VI6/spNUБs]}!QKtʮ>ph4X$ 7Z06$Ih [؋ql>v[%1??z1bd7@H/}Oσޭw teB>]4AYݸ]Z`nXE +i5MoJ%}'A-]!56 5oF}"g5/㱅>>bNxj[r^Cqj}2Wz?G6n&Ћ>t B$A|{|jq=Y챞[uaAw򨁧6>O{FS̗>ܵv7WH6A_?%o|F9[揶]^/ gH$D"1AN-݉D"X00Q܉D"H$G$&DbB܉ 7m8~'.E tI~EĈ*y=۬n?#gxE+nr Їqkݟx][㶾n^8je.q\-xs V8s[xt˵G?"$n5t{@9-7G:+ lnMGت\K߀, Mxㅷ T~~~9 ~m36ڶn k׾=1z3:G/nxo3 _Cga7y u=eCj80* 'G9cQM;Az~=rNtJ*TC,p;Ng8LE;qUШ;EՁ/>rS/v"98EցE3g,c\:R3L(*YMlB,9xo2GWsHæ$bÃ3\`a;$r薃ƪk8@H.8lAT~!J c[/g_daF7vA6 tTb|'rDˡvYQ9PNqAh^ۋ9Ht! ĸ KJX@ !׾6ThDVCQ,D'pXPytkNt (Tjk'AN@ jӃb-x:}T4)zjk$9NM?[%}h4Gu"]p6" IK'=]v^ؕD㩃Rmq:_!򖷼) dNuD:v8^jn_AH^MnqiP Qp=45^`o|c9'iW;GH}sD$r{zz~%ľO޵"@_!i'6':q=ѷ.'=v"ca4,Ё6rs2BͼS2/Hn*>]w i+atN;4듞8l E2pR,v&'1{rG3)a|EI,vZ5g0']G3&]$tHН<읬TSw59`/k 9wXNeP&dvuQ?эA;ۡJ,0\}ՋA>>YB'O[drʔ)ŷkzU7n:w=~6 ~;N6GvEXc1 ߺ}p:>!mN2;͵|><sB|qgOSN->сgm]vThF_& > əL> -tk|4wU4>Fk/!nEm:–0s'grӨ}']ƦNk!{gfGx9c sCOm!M7xDZ?zh.l~6–o1F_to9Vv~=t%G,蔄̟y t%tSb. dIv?, !1k|sh<Iy(`]~J~է V));k] ӷFw9֑5 @?ShF㐅IFNQ/"2D.xn>//jc=;MؒxX`#@;vKd{jŞ$wƗ|V8? s[7 I1y+|Nɖt+|'ȡWƓ(,s\o_glr0gc>.Q>c3|"ߪ`t} FgƾP܉GL jQbY(Ж]t Gm;(=5%xCu㣋}][h2@,③CىbY)W>Nw?l\Ț/[ =PtIl3z:r 2X:ϜBcz|?uK5j:OoqYc7‡}_`,<0zn|$?7y'V+gdiqᅹ%>%ůx:{\y\% /G}3on^\9?!& (wbL [I%p*%G׽$zL&%7')#y\R(t8h;[jXu*Y # fN@ yG@LxgGEdn+R QPןT[@&EnH$RPpK1)!X\'Ip=[c>(TFe}\H`/pv#O]9~gQcPMVx,JX(hQKEdhBG_jCB29Kvɒm㑛b8E"7mP(J[y_jqCR.0;-@)[BB$ c_Q:==7+L?Le9I%a'`a Xb;)fc[h$co aI)-]@sy7syIFg{Ikƒ[EF iӦm|PB]/IL4%Cj!,Di I-ԶqCh^m>y 1-]&Iq耢^Xy< 6@٣@4&_}h_q7U(ض;[EB̍kR<7?}) <=}9+.>.qxڇ(g^S> kY] saK5!~tREhEB섟0~8d&;^mR?П$ pMQ \Nk_J'U>͋_ g 0]u> Aï>4/ OU@蜘=PwȘ]onCWȉ-!+<Ƌ]W>{6=(-~c//#BO~w:ļB܉qCUΑ n 9rZPK%tF|kzԆDis]p 2!F,HV@ВHJfd_ #F+eA% A$̂%yOp'ѷ(@ v$^$4mH$ R2  Z<["I|_%cC$ cK%x@q ĝ#>jDUp+z$dZ^1ߡS!y)HJ=I =?bJlv6C_^d]ڐnQ`uz1nc3f(zkv 8|=@vBn~G'X ږ@|vblG,^춯ƋvXWpz,(E t(7< 1ҜElRgB:)n%\C,Ae|b9[z/Eo,}SXL}B1vC3>u6J/4ϸڢmXCX1m̃</:V6l~v9"w3dd3vnnb9DaM|=y<.UpłH+d$Y"9_؀"A~* Z5 (!kA .`m\(>k`NZ.BD9lQER6vɈɬL E yt"X)8a3+o,JaGHlېIp*a7&%ZQP?6cJFND} )蓥[q-K6>H`$wAܻRЯ"NACfQp`-YCR$`+~$#CT蝤\`IAi. (6W<#PЩ_}$"=+r;גD㯶YzfIG"}M$Km9D!I'= n}X@+Q=.ȹ-`*?P_IIܥ+;a< +>c7K"X+^6| }óyvs-hG6|GW5W\/P'|&F ڇ|͉( ;G]&v4OW,ئۘ‾-*lX<-HONO??T<'_6H rt+-Jmqc(c>evHFdIG-Yء" 8AOY=~e㐓#xJ%]O:h.XPtS$&k񌯳$C>an>x:qؼ񑎋1ݮ5_אu,P/؊b.z N9cXg1]|_,!ȕΈۊm6E&:j~^tGC5oȼ;8<]zȍȉcQ~?BÏ=*WȂ;1!pCJpXC0P*~#YTI@1Jz׺ )%[{AVI_c Jf tV d1 R\&W5 $D,5}0ɞxi/N|k`՗Ga?x-r &:kSH\O=K1K RuPl8MI?~qЅfGK)At m#wz^"92.W[2;FG̑NL$HxsDf7xhWiCgxk<ҧ:Qð >*ލ(WЎ># 4Ak}k~^dExFfxmtniQ4Ջc1^0?vA|4GSxoOv6Zy hBڜ4O?:~ulsw\+\c\cNG'{|GޒQ6\CE|h2nت6'>8xB`NI}o,rp"R/A1|GؒB+Џx;m~:x@Њ6Ǿ>OE̷mA7~Ȉ 26Ovsov3hNf7/@<#d.Y]L$^p@4{I:/H>$HH, P)2m k!HXwbݲbY'D"H Q0;ܱaw.v1F2/ur9课Wn![ic-n)sD_ p >hsn-ns!5n]VFvI x-KæVy ~kߦo{o9ۡn{u{+BwV[rh~O?^[Ȇ?c}i7{KS 9Է0y?Y=HnEkn?׆6~o/Ty*i0>q?B콭~?sb1@& dh $_C/Fv,yNf ,4CQOơ9܂H#qP6Q.|O8oHzN"ux"F$]s_"9 m~K'B΂;늁jc4m';+Fٗ=rp~9Ĉ,}5drxG.73/my&K,Qлhנp`-`(hg 0"Gorh0;OrS]paW/qȗ܌@CI:PLY''A]✶6iρYht'caBr1 [ѶӱXqs}\`!5(,n:Ia,*lf鴟!zŒ-Uy `[yhkth|I}C 'Rp;0 E/|+R8CŐdw[b$R{Wrv4)m.KauRX/AѧG^ 6d%Q1:Nm}6u $@1709騃\m͇BkBfaKvѸqp9ᅢŁ1!+zP0 uA411D/򨓹Km%Sb>9_;|Cх ɤW? 1}b#:5;Q0_c **_H5<`tL_HG>Sx>E cבw/w+/m-)Ż_o̙3 =l̝=xotB:esx7e3Ew7vŇE=3,xl\O'qvuz'1l><,jБxrD8[C0mcGm/ mn< ^7—/}gLre4vIb/ۇ=;h{$7sa`L\+=U?l||22Ehf;9h~cun\ddO)#G2''Yq/֘߀C3@ ^loЇxˇ[ =}B[s;?>Y9U2ߋ1lސ'6=?X®: ĸQE" "10c x'؛1]еd>Z|6g%W:(i͍F9Ͳ:Еpdٹ)|ע Kwx K@ŊU(^,>7}J${7;lC!odH/3~K&9kw;)آE~_m%-Go"ik^hhw$j4y]hq#N㡗>ӑ!%SbC|kN]C ]K&_b޵> 3v{4fW}yJa_!OE|V2b>!E 4g NNy0w A Bc\+q7*Cx|TcE_|XF_(3ݦ哣@%gcyg]7m";;|9}u+,fo|HЋ=_僴|x@K1تCc\1G ~ r㚗9SaB,EUk-b' G9wxHVxA,9?[L`#֡nM!c6߈/tɝ͹S/ⁱvCTgni+E_| GЎ.φ#|1oqNs@3)gdr <[wr 6RpK^!3G. 6&#XjJ9nNdI cŕ#UrlrSR/N޵H$Μ\$ ҪD] n|If8>GUX*À %8\ߜ5RF38H[[ G/DRN|8ww炒$dd(c#(nHAM %৶t CU x%V0^ybg,oo!Q }I(~!Vt$d6x/ɑ%J'# WAw-h>z%l$t) `[xA؈$< ɋHD&:d'vf%-~lj*$tn3FH#  V:dA̽w<(O@ ɔ_2Z67o 9'`Eɞ[l[_;tȵx`0u19I+2n~E[ wIf$ɱx? =f;$OhEWߔK8Ґe-q+pol %gv $xMSÎ' xJ_,:uAObSWvC9m@ɵ WO.@3Cg/~tc饗.3胱a[hw+`ߵW?lAsF<,'k~+o\G(|a,pإ56Zg@f_u!`/1wvϳ[#ESc恷%>a1bk3y ,'2S#99x?]dfd>Gbqc?J,ؠ" Ę!Q#*X E1s nΔR0 LΆ*J j!J$$NЮ$\C‰qh<DHz'-h+VE &NX6uR ]PMpzmПBo[P% `EX $]q 89 0|EI]/E" 0bo$@2l7,Ha} MDLubG$׾gb,tJ:觤, n;9>)|$ oРPNp ]7OQ%P}C/E;uq(ޡӮ$O\C{" @o[E%/1'4tQpCtSIbwFa?6/zPˌ_"闈_ . v]vM&:nׇ}!@/ n OO_ɪ.ّ9;TY6z %QpO|(ĞTGhb޻?RXI%ӒHQ@T_Q01>%qG@B?׸= ߅nVPua $,قH-(㗘,vNjk>цvtų%Det/@!v0B%Z nc xxOfO}I $ʂ59Fsz+dIW[{g#ckk^RbuXk>xB7$9d3K:v$KQ0oō@xmtFaH_X2L>+?P͕Sqj 2AK_hnqz$*|wz%A+}reK,9ԧIoU$*8B>]*izl o.( ='g &e2C+~3C[w /x)%^ NC;X'J(A& 7<W1[jNMI%w__#etm`+@'$[sc/dvb/9)أ%ѮH}g 8S E Y@'~+12E} 6h5h?яO>GWB,5t%m,bJaRȍ|/H%C/[c_x/ֵ@vxAE3Z +l#fnс-g X'ŏ(t**u1q.y3:ĺxa; nƧ+l\c C =b 6$!OaW}\H*kY}7rc[/R8kb\r:ϊbr'g/Y7ǟv[ ~)2hv7 9?aׯ/o}O\sl6߇gٷXpAYp' s Ԝ)bNQ `q h} V%Α3d TprK̑7}Z9 *% >oJ*$~9coe8R B A}E) 2wADPA'GjwAz=`D6x]`s% h7-D$7m I0E>= y+{=Tt9@AC>gc楠P@)N$Rh w:n\>Ǽ <a{ktkCOa,m؈,:aLҋ ~%^6":{/r%thH_ыOxs ;Ȓn5 /GMֻ]py≅>WvUtɶM٥9|ǚs@Xk~|_/'^;Y,7Q{:xT!Gs|MߴW(؞vȑ_;;>97}o6`h IWT4'zɀMw)>zN1_c3Ђ={bn,"֠N{&6i 5o h mh EkLJA>E|HnhA؊v8de y3x6/sߙ9j.ٺ|%ZE\swckm"1O_/0peHL2JÎ؞{Yޭ,[;fV"$kvPl);w@I$#Co'0vջ |"M&Db0N$;QVwڕ A"1~;vdX$~6U]ц]*m-H$F~?Ajyoڰ۵>^KvļGV6 Àizkn󣷙w} `x7l(3O|Bh춸)v{]_{G]6A>6S8ہ ^~U mY;|5EyHr$Rdi7yTP9U!/ ~ rwEu2_81 ~ς6ﮩwl5'm̵>~ErOqmtȢ%k8A5x 23Z>+ڢ5CqSh>ܷ,X8(gXPK:zk97}o+4|2 <Nf,(gΜY":Z'>s?/A|%0ot|A]~zv|0㓟yk;At+Sk6` 'v7`A3VjL}YCCגĖ}OhcqN^NXx\3z|EЉ+!;O^ꓜZӨ/TG[k6Kg}r OtÓc<ڎM&(X^܉13jđ+"1(.N 2<&Aȡ Rv\vc$1-F'zYnbNx|c樝t[IG3X0NE<gu@y +PE-(#$nnSNeƗlM֯[X ;qzDs;sC; ݡ`%8GuX5$h_\/3(=sTp{~9H(<ڂG>o Xmr9tGEvH]T2Ǘ];3A}k%)T@>eLt[2z 7yI=$L#i07-KjyκNRhbSA{w!:cG?'4ポzFE"Kt(k*6d&mu76<ޛ'kb.tkHZǏy$s葹x|;k;mڴ)LVxƿ}djmwB3?@ :z?ƠXJ̑O2]tFt#(1@ L6a.hۮsytdzEC@[gE!B |99۵ ;4.3ؼ>ٓ19FqlofLk yzI0g sG9ONx+ׅ*]@Bx%6X'GUŸx6|;~k&|3(L;vF_"x#qzf.I>X%~9Y{t6DwʱI#|8߳Oty#C~;&c~I;$1وeK/ty~):sO<3K5}yE7=$7~y2|{:=l;C[mǻ1bhQC+>A[!KS?m %5G|sH>HWvYp'ƍ(8Gaq+LRH7XAs*3UB%#WV%]HP+PS#1 CuC23󣿂DAR'H7M%J6$ +#GAR"Wa) | cxI$#Ht7*X6ųqѮ`\$ Eɓ$DQphrf?{i KYbHr, icJ!wɠ/bnv|.kCNYXРWhtK"Gpioc1O7]Z >'| )3z,t%2I$ň6b4Hم+K$6]dvVea~(*M'J$?8"+͚5ZRh`3}_b`%B0b$1|hÜ;]Ou¯Htyk'3;IExaLYKZkzZ_88'W͇O:sUK-=9u 0$㺖=+^TwEE707'>}'qEm[.W j'{Cl3_#Vŷ3f#b~K"Pe WtqxsVL 3?f:~(boe^?{lV, ͑NQ9/7Gq S7:_0sb~*|3Ep3W,L π>%[Sd}GaNOQ l6b]׈=Y̕ 3~K<>ƥ{'7w m)z_c>S,j| _*l?caVъ~ÞC;Ɨ+x0y/~\b;?ܸ9c@q"wt7 "1>&wT~c>t p}I:e.xGKel6 ĸ!9p^j#H$g]ps)pD۠ohR|ر0%XrY]AgJ$u-*t$-h0%I cFQTJj0]R-y.Y+`cNRŞ$O&s_o\$ ^tL6EIBOƋAb"p+$ˊ{23z[҆Z-#X3K$y }+8dVQ)sc <%BRmy`W Ă{Pn;RJV$>H76#p;բb `GI] tܢ^aze'TMѡ Pv%`t~*"$|q 4vjWB".`w7,Z'&|!h䍦Xwl0;t*i-ozɎv)viln="'4BVT⋂_ H.(PSO3ݤloߵ@E`,:]H(UJaW05&jZPF-iXVS]p&EzjV& v@ņd-tv8}Cr&b-VZ& n ྷBQHJ%7_N9K̗{?. $A{c-)-#gɕbvtKtbDr H^zH.3X# (ɾhIc*d^̑YX -/t%xؓl`"Q"7d5*;%1$d#E.;S#!rȁm^ڵ@"JO@OQ[}EmW:Zz@rEk1_9*mA<#|r9RܒVMnlñ[p=I"ቤF?a (t_!ns3VȌNJAz͞${nyl\3K# Sh$#ȍ?9Zcc1xN{,Uƥ|-`qؑBteOڲa>k_ =1ؒ;k1قk2Do8>f qJWtkBh%_.Y>`})MF=q, 52ҧC'M~ ;,qut=Q(1}/˵|bu]pkNԖ>킛^-+ 6.(}d@[N_\?RqG ? m>3'm?٢ݜ~KN.dNgH)bh" ! ĄK%-bSR%xPRȡhK9{HE>%)׵, k%QRI p_2S}sh(HZ% nA9$4l%l8dB% x!0Q2;7K8,"Orh'aH H#! 3wAk\AT&wABAc1qM$v8 ^igIC@G3{rЏ: }0b.䶯ӿ muFO%;v贿nɄ3<4$?t[2@376$1?AydW2鏬 i-tD oEoaoxkNh #|$%dv$#wzϊxג{#4gsɉXߠ]_5w6z~9œC7k!> "ONgjچ~CHь|ľɄ yޡNmz1(+Cosax锿 lx TP_>,ᏸ]9Z`fx6:SCb?CQz t( at " '4OGY,À?m%3 tC'Ѝf#Y\¾Fc{s}-ScDlEYY'xe E`F8fxc읾A/C3WJBg)ovl}?`,~Q }0.~>्yn2MF!+4M{W̝!'wK/>/s3ב^S+d?#YCC9KgĂwbB9>ZC:qw>hO)P܆%(֫o7H$N{kEBF׵HtN&&ޱbИMod7Vvw1ƹ6Ա*BoQ( _@evnNLv^+ +nkbN9%FeJ$>vf|M$ ) Ԃ;nɂ;8gD"H$D"" n?Ȃ;1!P$r_on[d{kDwDaVvo;[6Kcmؕ{/< v0ߧiMqs[=[ =[ q[}_OYۇb^!D~6 ssP>1o~3>SD"H$NL rP3gS/%[@tS;/~KNHGڿ;KL;w[(SkScJշQ' L}am[3!@NuSI m9`6FCn^楨[`͉o.9% XON9GA0?-W'!+D1kslX8t˜ݪh1nڇ||^/ _9zBrv1%\6-$7';=3>x }?:vh0ZߍsF]36b%FTor tQ?A-3>Z铟8 YˑY cGFRN@s''+9}_}@֗w&|~YXS\ߘҏ9OPO ]f"4G66H$8 Ą S(6)I# ɝ$.m! n'gJr% /śkX!IԵMCZPP)jc'Z{46^Ql0}RYg5iWMw6(8k :;|g x.z|6XtҐ'V+8{Ĕ3g|]VϙC|h"#rh$k+O|>^g–:I!4)@}' 9O#S|kaNdî&B)vt$g6JW'W?ӸJ~K8[X1GvdLvh .tݰfv(:eы]jOcMH$DbȂ;1!(*$\ISboL*V<ĎAYí z~ՎE$R.AJ=LAВcō]_۳3 ^.!D+*$Ê5޼WLH1Ƒ쮸%JW+L؁2ʼnY?2!Snx) d;xϐ-H=bJm rBRQ14 K)HtJ(2\튁)|<.z nlIB h'Kŗ⅌ xO_Qp.X0 6g(vsɖ~+Uܢ5-'%E^'/vȾ,>ѽcj*D}I7 ݠO26[dl~~2.BWpE}x).t" )1x\.}. Jwhe+LwYl6vыWdm<:<&{r :zfl~a.zhutepݦxHG)]cd>Zjbxm*7sM$D"1\d7YGlS"yI|I%rEsUW-lE ZJV-)EZ K%X7;WY\Qh|HITBn\8+-,Dsɬ$n'EJ"Xe˧ ^ҮPUx8xƝ:uj)^*sGIȎDjWݮK/]vJdgQAa<yLvj n?,(,h3sgv}晤!3~HAwZbQ,o R(B+bWT (p͕>>W71%r>>ktlMag'< ;뱋;_U_M[t _qyлB]1?rt=iD"HLN >;AɜQaUîXQȑ*R;:"aOJ(aޙK;C|b{k|dvN'C,c?]r[6c+}S>l; l'soo鋻Bͫ+.?6`6s5'>dy[8]Э5mɁA7{ޡ_&l_h/ 'k_t͊z_5.gрW`O7l./H$Aޒwb̈X6(kWq]|.<}$߻kOP-U(d7UIkWGXug mT(t҅όu:E6cH >GsdM|G?@}e,Zoa]:Y<@x^}}mF3wW] njE_ЖYHv}׾y|6D"HL>Vp[ς;1LP^;vٙCFT HpOvļ)vg!H$DbȂ;H$D"H$! D"H$D"H$?˂;H$D"H$IP n'gH$D"H$Eu%N$D"H$DbJyYp'D"H$DbQ nBʂ;H$D"H$*N$D"H$DbȂ;H$D"H$! D"H$D"H$/R܋85_f7z.1oAR_g5s<:0̱=Z} G&ϹtϣċM.&F&hbAҖ! Ą/7_җ;yWg?|sk.si}Es~sUW5_WBܟxh~_tOt"3<\}ͧ?旿o~4zks6/O/+~Oo0o5?A/~WiSÀq4_}w2ëZRdR1}<͍7|[ߚtG?sʼn}O=Ts54wy8?&#|7wuWI}ٟ |3Ͼ7?x7~nߗw쫇vIrY>C5|p9'^N~`tel|^A 馛g?MlΎ^O;8qO;?'#v m&D͇-1#kwܱW>/fI'TX{p sS& $,H>9Ú{nムtw7m]s)ѧzNuAwYn7J[o,nAD!`0 nxǚ}%2.v2>-TYMO! ;b-LF>pO2z\pO-Xm[D\ow?_\lp4+1/o駟>g!gf+-W(Dw߽,LFh +GqDh0 6h3/2 '4{cݢ zA:;E0fKrfm\~`~BwgNZdX.q-LJ$z6{+,osǖ\]O}S>裏./Eu]<䓽Ik-|C*ŋ+s1eVNa5g}v7_i#+0N<SO-|I%z+08=åGY8ӊ! Zw(Ѩ~F{Z9߮SW*9c$ȱ[曛 7ܰc=|#endp衇~1Ir?/I>\x)O~v-F6[ne#gdjn+뮻6x;Jݗ0k]) I~ тK/eHrvUƶNhP@>aNq͝ޜuYoh 'wy؊ 3(тBxge ^z(v?;'GWЌ?>)({]R +2 ^NxW\.hGAdamxH$?; <"w~VIe+@*nyb)ZkWcc!? ]k[Μ9UM!ɞ.ԋn||A; dINo{ۚڪG)E=wٙٞW7s?ڰ\ \$V#bB?_wg} РD_:Gl}lIX$ia] %CzK7-Mx!ĝ>l FHq ~*N@^ƏX6ڰ7z_tе%dhC>1/~l qBq40=#Kv>} 􏖯}koZsd[hyؐvE۶-#G o,E>+er.;]1x?߅G#׋CW:qM%G,ʳ7_Owp^x>mE{|\k2oC\_/=^J%Vy99 Ckbs#ϰ~}%lsxv2'/3,B nNQ"K^V^yd%B%Z$Y>q$NQp ^ klW%WM6٤Z*;Ь暥oHʒNŦH,r%A"NRCp0WaL - .6vcsI#Z / @)@z? jΧ:JZ!T|"Z uY K@Do_hD g^Ё!B$il@.a7( \馛xGy'2%#r$O֧Aa%o/tv%Ʀdi,ɘ%^''k<%(x"XAtLrXq}hK"3ɗ# -HƂBZ2HMߎVIBͼ̟$Κ뮻n3CG,:;=ׇ͙Gi'lLI(56$>M%s ?I27^! 6;clo ;b_{!sG+./s5C#'dFG 6狌 _ ;as,E3%FÜt؄_/k}OGEP>H_|<+2>N 4[0q <`|>?y/ ;>mFlEe$'rT: 'ZḰkO˿ut;c|ɺ; g7>̙nXɎΠޑ11|#({sZ3g\ Y ;dgq~îO ٷk[a }5XW7%G:dzOt?'b??/3ȃa2ca?N&X裓#ge8b A ̘1> "Q/ 8H?$+sH=}8V9g8/YkJ;(b$5"p=Qp `NZ~2Hac'٘J$5v/`{I| S`C;^I=%A 7hY?NUYI_EUw?(XP^b,O%:%oBN[t-q%V]oxkh|+(WYe5 RxYޘď"͚5*zl*I]"<ɴq$$hVͰC1sID\eg;m䨖($˚5݊kED\龄I䱖ogQz->.$xi{7=J|V%QpKM>mstXAtojC_^KEH>o˸| ?TӊlD:w1J$z'ּ㧢P_F!c3)ZEisg/GV>ߢ`:`\Ӝ4lŧ!˸>g I;] 7vPS9}'mb?l_DnBMor pb$ov_ϷM}G|#]b[M웞Ot+27t1L)&xNv{ct<莅 @\/~)ȕ>:>MK2ɖn?Xd>?}R|y~JU18}:VO 2n芘GBjkΒ9w(2Ɉ@F)Sn $A ?=ϗ\,7d_Yky[3&b:~[|PxplmqB/ lA;1㉏dϯYf(ar.X8B7Z"׎q̗܊, L_ (E7G㍂[#%NQùk'x &hX>% 9ɉNW+qĒ%A`t$~xWdY67$! nr,7'`KR'hKx|0V`W$H6|IN$l]pC"107c XLr{ɅNb)Ɗ:@; +JY%QRi+9U xel1 n$dt-?3_ݰx?KșL$'QGbW2e,yg|N$$mA8A!i2b+ 2. yM/,1w>YsVr73uM~h2>=BE͎%xO s ]l o>g.,2|??Aߺcꋞ7?_ߡ?:Hanхxf|C }"v/K{*b "Ψ>_i#]GmE_1"tLJ>>:<>Яu9M 9U./'|47g x@rC!na>sLjL+߭99l@^kAĝ5Cظl`Pz< =}^w6%;箓k6 )bM@S:dQGBm&-D9AIIx.G3j'=fq=HD$Â|+[ {@cpI6F'ݸsB 3x5"A̒5FP'}m Ғ-Ʌ96,xJ1TA>˻1Rs0_Hx$ƍjtQq`(9( >׿D')G2\O^tN2fI%CNOƦ {( o8x$%$,$Vgh)HȅMiO}~{`U֎lHJ2-(ӫ0Ӈb/9E6.b' c|2ocyyc2OcO07vEctŮ; 29W7}x%W\hF9+}o#{g 7vwmtKnCVdxE:,Nj|RxißV4 7k&zC魅 m^/Kw4\K`Eu㝢SE'~zbiGn{x},IZ|h z}>N}at !#c}~iE:#kx7Y(!_І&3تg_BKhu-~ E.ǫ#hbt/g5h5SE+:tq%v?O&X(D؏gF+ Ʊ?׈O^(ev4/FC*N9쒝ɞU2"4'+.B?ّ :$v苍6}{gƦ3 =kCadG {#~,ӃDbȂ;1!H% ̱EBNR08@@!ډK2Hq؃ ɑEj|ɺkۉIU_B' m#XYH@=&6 HJ>X sɁ5 gծexZĜȷHJ~SXՉE\?׸}t∀=~ =.zs#(<0ߚm$}us`CJa]@=yig>@jlw%u xnuF'}ԅA| C|xu u6نjcP5bP{ֱ ]cXmhGg)%hQo/GOhl_L (lr,> 0MG;3o׮(Ur|XTtb }o~6Ч_͵I"?5\gnm1Pc,o!bomwؗJy чz ]_m\ds$c}[ KN̏|ZGUџ#A.rhg̡AlR,Ex (q^Vcr89G|P_1ctT|_1bxX44'+ZGu.WݠNwKI%K|s?^l3RYWm9#Q>>r Y XTW_>X棐vjz̝XfrxîQ9OqC s:25gcAbDkoϣHvmW<Յv u_^}chS] Dx|Ύc&D܉ A(;R %+z[`%INu5f+8?9T MWu:.-)2vSB9Tz;4꽶 N][ 8]Vv)9;-Չzo|IM _=sʹRhr Gsyڝ0*!wIQp^?x 0Iъ:1yNz=> /6tcJ43>{ zM~;o><!8#Fo>/r1 9N .9MhO a4G韞S鄂8k'/h zVCCDRUp+ЭP鬾gS|Ov )EKXpa2.; }D.Jx2%76fGAXH׼̟|Gى6ta@nlL|=>ӗ᩾鎃 wnxJNڠOhSdXg|M}z0$zjN;MQ~Ea dtaYr@3Z"I:'Yww]IJhx@7=}r4{L؅w42mG5{Up{Wp;NscsEhwo:vAAEkŹ͝?7/5G:Gr? ч@2п~-Ti'AbnN?ؙ!c}xLbLOɇޓ)^S[ Ga_ɐM7ݴ\AxD낛.GdWx! %8&KEٝ1"}3Os IqWFF袓ƕ@C_~b s dFˆ%,y <%!AV†ׯ2mO[61b]ȄXSX!^$3S(AQ_/An\}~؏Jo]d&0͹ K%z=c~}w6\>kyMq ]nWN_C'{L dV?x q-dShO7??zvƸV:1CwA`>dK'ٜ+PF4de|z c3zl;ZAÎ}tQ</\SqTvgΜ9gZEx/^k_o6B~.&C.g0|1[9C৹Y }' k闶c/l[|\?|?M+fL aw-Θx!{"7AxgӀYn1>[7w; rad<~y <}kW[mbڑ)?Ǿ Dbn ĸ pv1$*v8.ɛ)'()p  /%3Ph+qʂ`*ӏ>)8sn$uW.Sz@gKdv@"(pkmA!vb$ҒO6Wt_r,( E{ɿc~^+.P zuBleWД$w/GIbx#j+v% Ƒ ngׇwrTDfLEK ד$EbG66[ khx rB{%2'LdGDɅ }H$O/WBN$" [2,H@IoZ{A^p0g @3ZodE&F `|ױE2,SM hpm͙%Y VNfW_4K=dC(ft &xKEo]+f] 9θjݷÂv83Y,Fc2;$D#]K?t #E⫹HBl"tNB&l=^l`,2SOB ͂eb,5qrf|[! n~M|8%o<—L+xL7_9iþ|C' _l1Nz\to`lSH+؄>>Gmɝ'_]@dw\ (D魢#C>͕yZ͝:FC ·.>u:+ңZ'`kdv2/t^;$wEՅA7;3")vç{7dOW?w苿bZgk^bѓOW4Ab>d.C8c\5w1=|B#vV\1ɂhV19".Ʈ/$͏=K7>}@g;gl9 Q<>!~,I<{>SK \~@ G_H lV7O戲^8!8Hrc+8UQqJDJX@ Q!Ч14E"(I$I^v,Wdvw]ACI`!I^׿P#COANcނԁ-Y@fN(77:H,!Jnj;K{ LKɖG3|N_A6(Kƴh%ؓAĘ kHRY$voۜ̅"D+@Lr++|.ZԣೂNn3I4ITB $]ttTTZg${ {?^Ib|tNrKVRuކ>$^t,CtY"#E%hp ݒXAJZ,끷.W}&cvm7h3͟?0.ԎZBw+;V z`>^FrT I$g͚U#]g# #ԢUŒm~Pi^kyQ; } nmb~L H(La#͓Sz/|/= n'tv Gsؚ֜6F )Q0-EmbF\u(zD Qp1@d0>m`R 1_ѱgtK1I {C9G'%zxW2aG>c$>mo+w_?-2逶bdYģt1zd'|9rԖ'_/MF\H Or/żgm_t;6gSd.~'sn~L[?װy]-e(< rnˀ^]~0,pgpC( l@hV`sr5ɏMSN[")DrdK1ñr0.'[x8QAC6n$OaI[+)> .sڂ)-(Ц`.+ъ"O@SHE1Dk|.% DcJ* _H$5FɄyiOh'TW)a!ɾ_d`F }Q< |4KH$g^t?者'%i`s׿d_ctm; FNOС?iӦS ?EvB/_r9gZ4 ȅ.s$1dc K]l+wsTġATic>y$9.Y:ek+Fvx+(XbR,O}ǮE[lμЁ&E6,tHUGQ;Ctsr71^12h'@9?S0W8UaAMR`~ >I"ʇ=># 3r5aG֦ t[ǟ`//'ȁ@EM:Eftn m]K.,Dؔy„\]gAI[]NzAm |0Xc K4?7ٗPލC|d m($>XO>@QcB" '|Z0khEs.; JaSh\},Bo %Z 1-~A>/r+ |ַQp 6EfL'Ѩ/6l^xXB\_#zG,E`7r&+6"76[bsb=Eoﻖj睏&5oyE^&l9\ ? r ||A'b4~CC-puzقg٨=9[@"1ZYYp/gVe%6s8*4 ҕhcQ" A E#OŞ@P#66Ɇ>1\e$/+%@oERZbNq'^Wӧ}`enx>I`+Y6N%Ar >C4v9 .ZxQ'~tջc@O\N> xQg^՗quIԻE# d\iڒ9Yu|dN C^O/ڼ'&>Ăqшg [wgz:h,r>]>^beVɾ\h7}+;D)k x :CV0^^m=cWdF'+6lGlF_>k'd_e6{~6zO?dlxT_!7doOsaWh c燧<(Ocjdgls"藾QmI G|3c2_GG-m?< u/0=>^~m 7 sӗ'=iS/go0~OBW>(:}/j?߀~zۼ] +$t$`>HswGe\sGs|}- Z>fh_oCO?E"}ډZW :WczE7q ::GO1ryK~ %vGxyT-kҿ,0?~"l \gr܉с vbDH,ЭuVAq \]T._R'm6.LFHq%D"H,Ȱwb\Px+Z&&X9za[T,OoH;5 s^TH$DbE܉D"H$D"H Yp'D"H$D"1 [D"H$D"(" D"H$D"H$(~w"H$D"H$,D"H$D"N$D"H$DbȂ;H$D"H$! D"H$D"H$KN$D"H$Db20K/m~e/Ko~S?tꫳ?I$D"H$A܉ AC5gqFsQG5y{wAT /~Q׿nnOl|Z?,<檫* D"H$D"Ȃ;1!|;i;l'?I_y{9䓛m٦˛_~<gi?_xRS{<峿eO9Z<ӿh]߿Ke|^y啢Ys5O? TX+zUjF5]w])b/f 7lvefwokfkf͚lV_nvۭy׻Uv9f뭷nvac؜Y;?h6`}oO?ts衇63f(G'Ztٵ?ckVͷ`[om~SN) K?Ttڍ0no>H$D"H Fj,c*X.ŭ"x}mRuYWR*z+\݆mGk)E\PvEv+;R|{knfM6i?2U~-R}(_wyg{m;fumvu'(6?9;_[l\}եWRvO;fW/v>NqN'";\V'D"H$Yp' Ťa_ve7RPC֊|3дd+^{R*F(bw [?\yͪڜ}WVQ7[ne3s̲˭>W^v<梋.jy䑢~c~ 'k.q[o``[^ ~_q嶐/eWζ]vѽ{77xcYHk=^!7[}8SpvWYef7nܵ }kH$D"H,z *Qd;8{GUXۍҗT vmwvn1%h~1M+'tR)^~/t}PcMn[y饗JQNB|C*}k}ι 8po6l@ݶoI$D"H$ NL*͑n8 PQVօlsyW c0$ۙnwNg}~m}sO$D"H$ 6vm܉`޻5oo}rP;<rH$D"H,Ȃ;H$D"H$! D"H$D"H$GN$D"H$",D"H$D"^/gH$D"H$D'Yp'D"H$D"1Ȃ;H$D"H$! D"H$D"H$,D"H$D"N$D"H$Db /8 D"H$D"H$&C)/,D"H$D"H# D"1iP3<򗿜i"H$D"hC܉DbV?y|C9Y{ӧ7~"H$DbP wba_OS_|h}'h~5g\ꫯ6/Bsw7rJ뮻6K)YgfkR'D"H$*N$I+4:]zWwtMw߽l͚iӦ5'xbs;b_b>`sꩧ6[lE[7'tRsm5O?t/|y{[ pzeG[y76;Ssa5]Gi9fo: /lxo[ni<樣j>O6?f_H$D"H,Ȃ;"~??fmvء9Nkx\rN+8wݲk}Wk!>яBNx"H$D"dXd@_y~s@{4oq+6/|](L5\S ~9裛mݶ93 jn>[/~/~Qn`l[>nw?D"H$D nw^΂;CK/n梋.*;q>#_.l[6{n7/bU\wOmQZ!A/o&c-?6^>3˭fH$D"H$Pp)f܉ B|_-B\;"R|7y{o7nC~z)]4rŵ}v+>/`n{!elAy ;c7؞o]qwl8Ӽn=eźr;v?wz/}ج;wƌ{h@d0@p>.H$vòNi~Gۯ*{rW}X[qx%mE;NoCbn'o-\pA.4{)u@vEo_t5kV9x1\ 6Ywyen'OZqbۘb;(xꩧ-sOY檫u]WwO4犭ZPҗW"H$İwb~P@cs ?'KܻXeC)ŠTٷ 1ś]_>蠃YEeo6[7 Ϳ6Zmf O3wؙBo6'v!p [ܦ7~wSs@z9~=h?Sx>ES_s1'+^.脂l$F7>S:J 4]wUBCFg-nik٬>-D"H$t vU܉.H%l;]%AJ)e_DlWL,AStc)+9v# hP+RB9 ׼5yk_[nk-rEe]VkEB?P7v ݂m|ei_29;yE>Ź[ַ̑ _tеW{:s9eך|c@#ZsSǃx(0? 3gwqGXg9YIJaQȂ ["7wĎwc'D"H,*Z-ς;h;LRnˮᒜ+ S~;ivi *(@iE[Y(S8EUTN~' vw۔)Sn76kf9A\;{U9(NEs`oƥVs2wX iӦy"^r;솺uݝ l :={7vݎoEy kٝrg9y94ƭcQG& Ŷ(e,Ƌ12D"H$nZr܉Ɂ۾&6zJв6$^AhjŲbήB,:ϋVmVqɶoEmc- (TiUW]*\r2)v  ߗQ!hxucᡢ_y+7lb-cEO[=;v~ Nu]&-ڸ}dbWB]_ŬE*x߼]_ }"~,(wX7Վ2+wg(镻",?]vjnЁyN$D"|dt(.v+;fdɽe";QٙzK?t☾ۘv\r۹<ŷ۷;#! Ys iQ :+Fv_k+(bUlF?N ﷰsb,_ \SUX%؎ ;jV*'BwM6ifΜYvSۧM[gq hfCxPaX$ C<~l OSANwPpr~|Zk5K-T˖^䧀61^oc+; -@7&SD"H$F܉ CdGnBnXt@aUjJTٙSlzDBG R|=U(-( G[|*\Wظ=ڣ;}(tNfLvLghag)I]h} p_|q)6hRŋ:|u<36v/~2vCaxvkrs6æa-qq )/;گ8YLR-qxgq%^wN$D"XwbBk 0 uݶ L@ډԏknխvO|~@'=Rb.~7WT Yvۧg K<өfL ,\'YR`=X ]wu hSu~G*9%M$D"H$Vd #4=P nYQukߜF;nCb^8TN:跩՟ۑWϘ1Yc5-cj;vA]k++NJڮ1 }PY0\s vm-QP+`@[]"H$D"Ȃ;1&(8}nuV*l=~oIcnU0+Jݞׇq* Fىn׾馛ʭf;n׾ h;tU?ufW,f hbZU-8XvҷbX[bGZ~ns>s,;yI$D"H$s nE܉QAgsȥSXEڮh`wo[M]SP+& *n_ mzm׸kW۸N@`v0֛,'T/6/[6۔oY]4|o 7'EXtonS )'D"H$y(/Yp' ʦ;o;v2wBTQj'ة>s뵂S_ a; "cbfW-ۊ+Ͼm;R+lX~PtsH$D"H$`hf2%sp[ YAp'/rͱ[~_]$+La=2-viOֿomjsۮUh.oiO>v`6v-"إ<>9` zhN)jr=ˏnEݻsE''D"H$E܉N%?AMz7.ś[HV܆n+۱էۤ*" k#p+X]O<~˵vy>nr0z{؍nt*X ފK/MVL[,P(zŢ\ע{)Ϙ1-V &lRv-*إ߱_n"xf;zMWmx@,D"H$" D/*svO`ڮ۟?O(o'p+RVۯn/֭Yl;vNets;}-nv\{ky2ŷzk.q; gt?\ p촛wm]0qr^]mű"ܭ tϗE nw<^̭׉D"H$D"1 vt5 )۞- yڴiN:(W}G4o}9,s8V0r]6IDAT><aN!fUWmn9E}lfΜY753Gw㾏G-~&oۿYw1vÞڷݶC隮]k\jH$D"H$&Yp'& `( o c9;/şbaeN5zs;OX>4ngԇ8YfӝdZ5s=^˘N[7uJ8=v:"3'{kkz:]8-]cy;]8UzS=_4 o.c}хFF=1nkz[H$D"H Yp'&A-ܲRߟp eZ뮻bR!/2˔sy<"V[8VD}wGzxܗGbyS1aW^yey5ZqgxwV{GM2Kz{j\fvuŶgb+w߽<&N68馛~vG|ǥyN|=Y Ҧ}{"H$D"|dۻXzEw;tܘm!8Qc1Nh1X( 4FQ+b(8E(C8d"ۺUSI~9u{5bK;!(|+CoxzΓquSF]X-6_pz,,\~~'ak_Moz%v`r]njP(pD ú]0u sБozv+h[Q!K/BonۦYm}wݗNSe6nZz뭋SN9eg?{\(qÀAV{t ْ)·:u NH@YgznS>׽uTgp =u,ڵk>á].L{|!ئwa>QSj u ҭwϷmo M{/ Z=ܹs肏c uû] /\ k 4n~7[ N8ag Ma.ttlrYzV^5ź+^NtW7?P۪Y \u x3}vv|r h{L)} \׾iu[f!h ({sn0u[n}`\@8R[47q}v6 "4Հ÷MSﵛ_P͖Yn5>cg (8JuɾZ^߃]0-MQ\7wh M.ԎkmG^bN:g~|l=nSz\spq7%5ϢW=f\r[VY>mگG:7l{Syo:)wq_{`agN}ޤA?lT榑?V]W~+Z~S{i린fmjf1MCJ]}ozejV>#7]mwjOs'[z:/sBG2].|Uy. _.JI}8u{WwuBk[wa~r]|[wyCh>PWo+^bs{ {bl]mnޏ֡[Ƚ/xvr+Է _OW.TVu] 5P r.lL)C!p`cp;WGnb;.(w ](4 ʺv![~utOUV.9U۴5"k *t{rznAkСϻxYnt>݅Җz^(gunڞx<:]ح۞F붷}9^Boswz3deku;:GN;)x 0]kah];ΰicږ] ~m=z\6mߕ;;cC3ra,p*_җ:vGSuq])|uw݋jUX`u "~hxnyݏzV]pq/>_?CǷp4*ĵ=o[:u M-}]㻝ٙg9 "n %\8cNsj?׼f]ɼIϫ :M/caW& {ݽY!@mW![n1VP>Mk)^Ӷ]veO?}8&6r)m0]g>3쫞ӱluۏ-.D]`shߵ[fm3r t q+/oۖ?ñzbh@W}k u[ﶣuwu;Z5^j]خ}m -) s1>oW:WjtOnWWuhB8z@y kPVwuuA.b=׵- =SXnJp|RĚ֥,4BT.v-X/!0uh[o)  T^.}]~WpZoy s_Hk]G|߅:ث_afҗtݲ r 4Q-Uq{9 cv]mz޽{X 4QP,t֍-]g~x73c[:ujzu_Mo_xCn!ˇ =! ԥn[ƀqm}b*7cyXvnzJP?ޱo߶߮YѶYǴu:g;f $/@^8]uznl۟ 1.~;yg<8W*as[0[.Pl@ K uf\* C:u* `ˁ/f)ޣvQ<䓇PV'e׉,t,ԥgu^h,t.4]WׯS[;Z`<_P|+_9ֽ)mGVwSZ:amFAa/kPcǎaM/@wZ~kʎӟ;6: $tַ:m{y8,|#mwwܫBC.:`ڱ/8/eK!} Ic۹Q/ǯ\o`ݠQ],;wع~}x#m{ǣui0bI3 h7[;';^7[Rp-D cp((4m]'Y: qI!tU\ЬYթ#\״`RЫsXX+<>g^06͹ AV0*赼 וm*s\xu[ߖz:fcf\{lp6}/z^_^Po;ck:-7ڎֹuәq[߂eٶ@z 4B8;/~0Ѐ oy[@ǸskP7 [IC^< 0> 4庐6SG>2qH(AoЀAh 0 co(4wn]}oF!7i:=wiXj } cG1pd9luTp iںc]BV`Z(V u2 !c]0woӿ N̛> =Wsu [ ڴqoBdapq!?v<;ƶ}9?oҶ؎?OiP/uL Mn uӔ d탺-k,ZP\.-v]صZjӧǠ8{v۾>k0^Ь}1/D6QnDǯtֹ}~<yѱ\Ǹ TpyJ6 I-6̽~Gqlu[}tu#/ U Ywm37J0#p^\|7 3=p?_ և 3={nXf0K?-p/ñ馛_nX|_}nŷŽ;lo~3W3-yG^{_zꩋ /pO~rq饗_;N?wvZ׿^G?Z]_r-"p%WUK..vmN;mwkqw,~>餓w?|t <9c>Po|c}nqWs?[֡_bp5-x߼8`]]tEC?Onw~ O4?pٲB/~?9t󿪽{>Q]h&p n,B 3f p n 3(p?KY`] 0Y#<"p_,p*|AVi}55f0Kn֚ 3`7`}} < p* 0f0k~nrޱcje]&pn 35p?C7kI۷OU`7@0f p }]w *nX5f p n 3xnX5f p f ܻwXk7@{Ϟ=?5+Xk7@*p@ýw^%p 'p 0U pUwqnlS^5K+nŎ;nX/C{Y{7 3`{ -f p m|VD/c {YܹSU`Z` 0/p* 0f p nr޵k 0Kkn֚ 3`x@U`GyD`-|AVIZ&p n 3`߇[` 0Y?,pf ܻwXk7`9pܹsXK> &p n 3`/\` 0f/VA۷OU`O`m=cܻwXk7@01pu]7 3o }W,+pnrVJ6[{n֖ 3`7` {`Un97nU?mToԳ wg?{ZW?ܺ6רvq5|5M [Ś55unMW55uZSf5NS5u><~Dy睇TS۸>ٚZf|\2oZjj]j\U-竪[okjL1:XMmf5߆#]S;pkxXS\Spkx,j|k59QMv{g܍Q]q7ۨݨQk׮g}뢋.:ugnpsRwy[;vli+5u[u:묕9眳:[O|+?q'7wM9jدLCnVMnkPk퓩cxZ>V]S7gM9jJMڗۭ`5íe;zgΝ9?US:%s85c:Oéc}5uLܞj=7٨Qm nԿߨQQzFt^Q٨RJ)RJY[~FF=kN7lبt|݃ M-ՂiZs6wRQ9[9'v+nTOeu>^.F5#\UnJclT؇[H[`~+j$hJrNVI9[9'SYp7\^.7ћvt^Z%֔sRJ)Rj<\cf>}0cWJ)RJ)ֹ-s鏅fIENDB`}DyK _Toc478981714}DyK _Toc478981714}DyK _Toc478981715}DyK _Toc478981715}DyK _Toc478981716}DyK _Toc478981716}DyK _Toc478981717}DyK _Toc478981717}DyK _Toc478981718}DyK _Toc478981718}DyK _Toc478981719}DyK _Toc478981719}DyK _Toc478981720}DyK _Toc478981720}DyK _Toc478981721}DyK _Toc478981721}DyK _Toc478981722}DyK _Toc478981722}DyK _Toc478981723}DyK _Toc478981723}DyK _Toc478981724}DyK _Toc478981724}DyK _Toc478981725}DyK _Toc478981725}DyK _Toc478981726}DyK _Toc478981726}DyK _Toc478981737}DyK _Toc478981737}DyK _Toc478981738}DyK _Toc478981738$$Ifl!vh#v0:V l. t0 650alpyt*$$Ifl!vh#v0:V l t0 650alpyt*$$Ifl!vh#v0:V l t0 650alpyt*$$Ifl!vh#v0:V l t0 650alpyt*$$Ifl!vh#v0:V l t0 650alpyt*$$Ifl!vh#v0:V l t0 650alpyt*$$IfX!vh#v #v :V l. t065 5 aXpytv$$IfX!vh#v #v :V l2 t065 5 aXpytv$$IfX!vh#v #v :V l t065 5 aXpytv$$IfX!vh#v #v :V ll t065 5 aXpytv$$IfX!vh#v #v :V lZ t065 5 aXpytv$$IfX!vh#v #v :V l t065 5 aXpytv-sp00002 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH T`T ENormal$d`a$CJ_HaJmH sH tH j@j  Heading 1/$$$ & F 0@&^a$ 5;\^JTT  Heading 2!$ & F @&m$\]P!P  Heading 3$ & F @&a$;\P1P ~n' Heading 4 $ & F @&a$m$\NN [ Heading 5 <@&56CJ\]aJDA D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List @@@ jpTOC 1 $ `5;<O< . No indentd`PP / App Section$$ & Fa$5;HO2H /Appendix$$$ & Fa$FF Appendix Title$ & FZOBZ [Bibliography Entry0d^`06U`Q6 vt60 Hyperlink >*B*ph*O* /Heading4r4 vt6Header  !VV /App subsection$ & F^a$;FF #TOC 2$ $ `a$5;:: [TOC 3^`54 4 vt6Footer  !8"@8 'Caption5CJ\aJ:: [TOC 4^`5:O:  Preliminary  & Fxx ' Table Grid7:V0dh`<#@< $0Table of Figures B' B 3T^0Comment ReferenceCJaJd@"d #3T^0 Comment Text"$d`a$CJOJPJQJ^JaJF/1F "3T^0Comment Text Char OJPJQJ uvp Table Grid17:V$0$CJOJPJQJ^JaJ uvp Table Grid27:V%0%CJOJPJQJ^JaJBoaB uvapple-converted-spacet@rt uv List Paragraph%'$d^`a$m$CJOJPJQJ^JaJ2/2 uv bk_cite_availdj!"d *ZGComment Subject)$d`a$5OJPJQJ\R/R )ZGComment Subject Char5OJPJQJ\NN ,ZG Balloon Text+dCJOJQJ^JaJN/N +ZGBalloon Text CharCJOJQJ^JaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w<v f!!*)-f!XG (((+ SUpQ*Z)&^ پn*4z/ 4 Q&c?>?ɠʠ<=fh^iդl8| 1 B  IH& Q R r {  ) E G H J j }  : V Y Z \ | 5Uqtuw6RUVXx(?@`<X[\^&(BXZ*C} X%X%X%X%X%X%X%X%X%X%X%X%X%̕ X%X%̕  XX "%+!!l. .,b$~.7ߌ>k@ -|(    s *C"`? t  3 S"`? z  C S"`? z ! S !C"`?  ' Avd @V "Picture 4 'ImT'TSTTT`TR9TTI'I"0``?Z ) ^)?"Text Box 2c"`Ô?PK!8[Content_Types].xmlAN0EH%N@%邴K@`dOdlyLhoDX3'AL:*/@X*eRp208J妾)G,R}Q)=HiҺ0BL):T뢸WQDY;d]6O&8* VCLj"󃒝 yJ.;[wIC_ :{IOA !>Ø4 p;fɑ3׶Vc.ӵn(&poPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!l)Ndrs/e2oDoc.xmlTn0 }R'm8E.ÀZcaIJGIt0?H^ݎ$nЪ,+v}sCZ>sGoׯ_S\wZ6QLE;M$u7ӆ+tѴ0 z/zdooP`V;}V0kjE5kAr9,tbh*gה(Q'>zV$ ƕh0Џx:Zy#Jo:P;~g: 旅 z|^G}  := 0<̯ ] }Y<@ynITԢ·t<ל )awFZrlmb/¤"CE|>1W4~ǎ9;~ ǔ:Xc=F͊>nYǁMJl{A:ˬ(4D_#^zK(PLۍy3wVD~S&ǔi# SqiǨ_OPK!H['rdrs/downrev.xmlLAO0 HHXc*MmH\&)Mڕ9b3{'&;.BTQzAj6U g!sЦRƺ"rhL7۪acU>nݷַ7Ds??|FNa$$ ٚٽZpţR B^PK-!8[Content_Types].xmlPK-!8! /_rels/.relsPK-!l)N.drs/e2oDoc.xmlPK-!H['rdrs/downrev.xmlPK Z * ^*?"Text Box 2c"`Ô?PK!8[Content_Types].xmlAN0EH%N@%邴K@`dOdlyLhoDX3'AL:*/@X*eRp208J妾)G,R}Q)=HiҺ0BL):T뢸WQDY;d]6O&8* VCLj"󃒝 yJ.;[wIC_ :{IOA !>Ø4 p;fɑ3׶Vc.ӵn(&poPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!`c)Ndrs/e2oDoc.xmlTn0 }q1]  dYI&)%'Ym/ "uDCzu;hEy IN0iv}sC4L}ޮ_Zt_]2;-8n5UV"5߶mE [HKklb1I~LCIY`doPZr03h[E/y$3MO/Ȧ4$@@Oo}aÀǨs<1ى;k0i]\q|3l  ӑ< :|&Z+tqMglQ$2V[{ME+O!5J6[T2ܮ(G eT0eH_弘 "Oߟ JޜXy{gԏI51eeDFFPIIgd8殨gNP>Tg94$c6F*ԗf8BU4P2n7!MPޡ[rSƦM,Nť~?PK!H['rdrs/downrev.xmlLAO0 HHXc*MmH\&)Mڕ9b3{'&;.BTQzAj6U g!sЦRƺ"rhL7۪acU>nݷַ7Ds??|FNa$$ ٚٽZpţR B^PK-!8[Content_Types].xmlPK-!8! /_rels/.relsPK-!`c)N.drs/e2oDoc.xmlPK-!H['rdrs/downrev.xmlPK \ - # #" `? B S  ?450*\:J`0B +(#J!$1 D*d9( T)v:M T-N!t'(M7J@ _Toc106717784 _Toc478981714 _Toc106513527 _Toc106717785 _Toc478981715 _Toc478981716 _Toc478981717 _Toc478981718 _Toc478981719 _Toc478981737 _Toc478981738 _Toc478981720 _Toc478981721 _Toc478981722 _Toc478981723 _Toc478981724 _Toc478981725 _Toc478981726 _XXXH!Q{H <=M  fdddY!^{`_\y* + , - . eo9*urn:schemas-microsoft-com:office:smarttagsplace=*urn:schemas-microsoft-com:office:smarttags PlaceName=*urn:schemas-microsoft-com:office:smarttags PlaceType . 9 ^i`!`!&&w>>??||||(3 ǜEPLW1<OZٯfq/:ֿKV"al.9%!,W[_hltx$'FJ;?%5= "(OTly\_inw{W[\`z~  PYjnrx{6;"%~<AMPfi DIJOgjjops"*256;OZIO ! (E @GPgQ^GZ|HRz Z! "9"E"U%^%)))5*C*++,.000G22244 6(67w:P;b;;;>>??HBVBBB3CMHHHHCJKKMNeOnOP0PPPPQR3T,UAUTUbU(V4V1XLXXX__`)```AbPddffhllmnoo=pRppprrttuuEvXvLz[z|"|||u}})~6~ UgR\N`EɊiqky* IWǖuos%7Eiq'( q!68Ahy+6Ʊ(/Զ~AIO^n}7T>Pjv@M +9"{wcd~@C{$)PS49ehINz}^ctyp$'1;+/KN\_ku"%7;MPVZfiY[gj25GMOZ_eRT 33333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333 (_gS`!`!)IUDDKMN[e}}~jl{$%&&' q r   i j   { | 45wx(_`_gS`!`!)IUDDKMN[|j{%&&'|}L5~<rDgw8& Iv%V1 NVr<zQ` ȱ*6C<7f9FhuH-$g0hPO  Q `TVS HWDn5zX \{|ftw^`.^`.88^8`.^`. ^`OJQJo( ^`OJQJo( 88^8`OJQJo( ^`OJQJo(hh^h`. hh^h`OJQJo(00^0`56CJaJo(hH.0  ^`o(hH.^`56CJaJo(hH..^`56CJaJo(hH... ^`o(hH() pp^p`o(hH()   ^ `o(hH. @ @ ^@ `o(hH.   ^ `o(hH. 0^0`56;CJaJo(hH APPENDIX  `8^``o(hH Section . 0PP^0`Po(hH() p^`po(hH() ^`56;CJaJo(hH Appendix ^`56CJaJo(hH.^`56CJaJo(hH.. P^`Po(hH. p^`po(hH.^`o(.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.^`56CJaJo(hH.0  ^`o(hH.``^``56CJaJo(hH..``^``56CJaJo(hH... hh^h`o(hH() ^`o(hH() 88^8`o(hH. ^`o(hH. ^`o(hH.^`o(.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L. 0^0`56;CJaJo(hH APPENDIX  `8^``o(hH Section . 0PP^0`Po(hH() p^`po(hH() ^`56;CJaJo(hH Appendix ^`56CJaJo(hH.^`56CJaJo(hH.. P^`Po(hH. p^`po(hH. hh^h`hH) ^`hH) 88^8`hH) ^`hH() ^`hH() pp^p`hH()   ^ `hH. @ @ ^@ `hH.   ^ `hH. hh^h`hH) ^`hH) 88^8`hH) ^`hH() ^`hH() pp^p`hH()   ^ `hH. @ @ ^@ `hH.   ^ `hH. hh^h`hH) ^`hH) 88^8`hH) ^`hH() ^`hH() pp^p`hH()   ^ `hH. @ @ ^@ `hH.   ^ `hH. ^`56;CJaJo(hH APPENDIX  0^0`o(hH Section . P ^`Po(hH() p^`po(hH() ^`56;CJaJo(hH Appendix  P^`Po(hH) @@^@`o(hH) P^`Po(hH. `p`^``po(hH. hh^h`hH) ^`hH) 88^8`hH) ^`hH() ^`hH() pp^p`hH()   ^ `hH. @ @ ^@ `hH.   ^ `hH. ^`B*o(ph.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.0FhuHFhuH%V1 %V1 %V1 %V1 FhuHFhuHFhuH%V1 %V1 %V1 %V1 HWFhuHFhuHFhuH%V1 %V1 %V1 %V1 FhuHFhuHFhuH%V1 %V1 %V1 %V1 zX`TVS Q0hPOzQ` |}~7f9*\{|f7f9 Q*T''V'}                  jqNV        a Fi{#Bh*]0Ye_%bu :a; %]|[zs H p 4? )s "$ " I)j^ r| w-$@. ]L QO !"#Nk#8&''~n'/x(U )L)--n-q-:0d013|3s4vt6k7 m7C9b91:+;"1<>(?86?)FAJBU4DyvFI({KzMY;NOQ\R6Rc(SaS'T V/VRWY^PYqcY"Z ]Zn]^3T^V^_}_ `2ci`clc%d?9dWenengtgjjWj$k7?k UkmW6mOmCPmZnMn%,oF=o:koKpt&t3ujLvuvRw .xly;zH8{ }|P;v%wk'A E7=PMNAEUw~3`v,/015TT@m;v0ptShmCedu9?(iRZIs_i j,/R>hL 4Je*38$(I*l_Toc47898172438_Toc47898172332_Toc4789817223,_Toc4789817213&_Toc4789817203 _Toc4789817193_Toc4789817183_Toc4789817173_Toc4789817163_Toc4789817153_Toc478981714  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./02345678:;<=>?@IJMRoot Entry FP3L@Data 1TableWordDocument SummaryInformation(1DocumentSummaryInformation89MsoDataStore` 3P3AVEZ1U14OOB2==2` 3P3Item  2PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q